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Introduction: There is increasing evidence that the endothelium is able to 
transduce circulatory force into signals which influence angiogenic behaviour. 
The Von Hippel-Lindau homozygous mutant zebrafish (vhl-/-) has increased 
HIF-1α signalling and aberrant angiogenesis. In this study I therefore set out to 
characterise the angiogenic phenotype of the vhl-/- mutant and examine the 
effect of manipulating blood flow. Both nitric oxide (NO) and Notch regulated 
intracellular signalling have been shown to influence endothelial angiogenic 
behaviour in development and disease, so I studied the role of these on 
development of the angiogenic phenotype in the vhl-/- mutant. 
Hypothesis: Does angiogenesis stimulated by up-regulated hypoxic signalling 
require blood flow? 
Methods: vhl mutant zebrafish were crossed with endothelial reporter 
transgenics to assess and quantify the angiogenic phenotype. Blood flow was 
manipulated using genetic and pharmacological manipulation in developing 
zebrafish embryos. To study the effect of flow on endothelial notch signalling I 
utilised a novel transgenic line Tg(CSL:venus), which expresses a fluorescent 
reporter upon activation of a Notch regulated transcription factor. The role of 
individual notch signalling components was investigated using reverse 
transcription quantitative polymerase chain reaction (RT-qPCR) for various 
ligands in developing zebrafish tissue during development in the absence of 
flow and in control embryos 
Results: The vhl-/- mutant showed early vessel changes including enlargement 
and sprouting. These angiogenic vessel changes were dependent on the 
presence of circulatory flow and are lost in mutant embryos treated with 
troponin t2 morpholino or 2,3-Butanedione monoxime (BDM). Imaging of aortic 
endothelium showed a significant up regulation of notch signalling in the 
Tg(CSL:venus) line in the absence of flow, induced by troponin t2 knockdown or 
BDM treatment. This increase in endothelial notch signalling in the absence of 
flow was mediated by increased expression of the notch ligand dll4 in RT-qPCR 
and whole mount in-situ hybridisation experiments. 
 iii 
Conclusion: The aberrant angiogenesis stimulated by increased HIF-1α 
signalling in the vhl-/- mutant is dependent on blood flow. My data suggests a 
novel flow dependent regulation of notch signalling in the developing 
vasculature mediated by the suppression of dll4 by blood flow. 
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Chapter 1 General Introduction 
  
 2 
1.1 Hypoxic signalling 
The molecular apparatus of cellular hypoxia regulation was first identified using 
an immortalised hepatic cell line. In this study it was demonstrated that 
reduction of oxygen tension resulted in increased synthesis of erythropoietin 
(EPO) mRNA (Goldberg et al. 1991). A novel nuclear factor was isolated which 
increased the expression of the EPO gene, this being the signalling molecule 
HIF-1, which was up regulated by hypoxia (Semenza & Wang 1992). Upstream 
binding of HIF-1 to the EPO promoter resulted in a fifty-fold increase in EPO 
transcription (Semenza & Wang 1992). Many other genes were subsequently 
identified which are regulated by HIF-1 including vascular endothelial growth 
factor (VEGFA) (Goldberg & Schneider 1994) and a number of glycolytic 
enzymes (Firth et al. 1994; Semenza et al. 1994). These transcriptional 
adaptations in the cell act as a response to changes in environmental oxygen 
and permit multiple types of cellular survival modifications, which enable the cell 
to survive periods of hypoxia.  
1.1.1 Hypoxia inducible factor (HIF) 
The HIF transcription factor is composed of two complementary subunits of the 
basic helix loop helix protein family (Semenza & Wang 1992; Wang et al. 1995). 
The HIF-1β subunit is constitutively expressed and binds with the oxygen 
sensitive HIF-1α subunit within the nucleus to form a functional transcription 
factor (see Figure 1.1). The HIF-1α molecule is ubiquitously expressed and has 
a very short half-life of around five minutes in a normoxic environment. This 
rapid turnover and regulation is due to oxygen dependent enzymatic 
degradation by prolyl hydroxylase (PHD) and factor inhibiting HIF (FIH) 
enzymes and enables tight regulation of this signalling pathway (Figure 1.1 and 
1.2) (Huang et al. 1996) and its downstream transcriptional effects (Lando, 
Peet, Gorman, et al. 2002a).   
The binding domain for the HIF transcriptional complex is known as the HIF 
response element (HRE) and this region contains the five nucleotide binding 
sequence 5’-(A/G)CGTG-3’. Over seventy genes are under direct transcriptional 
control of this promoter (Wenger et al. 2005). In addition microarray data 
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suggests over 200 transcripts may be differentially regulated by HIF signalling 
via direct and indirect mechanisms (Elvidge et al. 2006; Lisy & Peet 2008). It 
has also been suggested that as much as 20% of the genome may show a 
transcriptional response to HIF binding (Mole et al. 2009) indicating the 
importance of this pathway in both cellular homeostasis and numerous disease 
states. 
1.1.2 Regulation of HIF signalling  
1.1.2.1 Prolyl hydroxylase enzymes (PHD) 
HIF prolyl hydroxylases or prolyl hydroxylase domain proteins (PHD) are highly 
conserved dioxygenases, of which there are four isoforms in human tissues 
with the PHD1-3 enzyme isoforms regulating hydroxylation of the HIF molecule 
(Fong 2008). These enzymes are the main mechanism of oxygen sensing and 
subsequent HIF-1α modification (Bruick & McKnight 2001). PHDs utilize oxygen 
and 2-oxoglutarate as substrates, with iron and ascorbic acid as co-factors to 
hydroxylate proline residues 402 and 564 of the HIF-1α molecule (Ivan et al. 
2001). The PHD enzyme has a very high affinity for oxygen but in the presence 
of all other co-factors, oxygen is the rate-limiting factor in its hydroxylation of the 
HIF-1α residue (Fong 2008). The hydroxylation step facilitates the binding of 
HIF-1α with the Von Hippel-Lindau protein (pVHL) thus targeting HIF for 
proteosomal degradation via the Ubiquitin E3 ligase system (Jaakkola et al. 
2001)  (see Figures 1.1 & 1.2 and section 1.1.2.3).  
The PHD2 and PHD3 genes have been shown to contain HRE sequences so 
that stabilization of HIF-1α due to hypoxia and the inactivation of the PHD3 
enzymes results in up-regulation of these regulatory enzymes. This may act to 
facilitate rapid removal of excess HIF-1α after re-oxygenation to avoid 
prolonged expression of target genes after hypoxia has resolved (Fong 2008). 
1.1.2.2 Factor inhibiting HIF (FIH) 
FIH functions in a similar manner to the PHD enzymes by hydroxylation of the 
HIF-1α molecule although the amino acid residue is different it is found in the 
oxygen sensitive c-terminus activation domain (CAD) of the HIF-1α protein 
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(Lando, Peet, Whelan, et al. 2002b). In normoxia FIH hydroxylates a highly 
conserved asparagine (851) residue in the HIF-α protein (Lando, Peet, Gorman, 
et al. 2002a; Fong 2009). Thus at normal oxygen tension transcription of HRE 
promoters is blocked due to failure of the HIF transcription factor to bind 
essential cofactors at the asparagine residue (Lisy & Peet 2008). Whereas the 
PHD3 enzymes regulate the availability of the HIF-1α residue to bind to the 
HIF-1β residue and activate transcription, the FIH hydroxylation blocks the 
binding of key transcriptional co-factors CBP/p300 (CREB binding protein) 
increasing target gene transcription. (Figure 1.3) 
Some in vitro experiments have shown that FIH has a higher affinity for oxygen 
than the PHD family of enzymes suggesting that they (PHD) would lose 
catalytic function at a higher oxygen tension. FIH therefore retains some 
regulation over HIF mediated transcription at very low oxygen tensions (Figure 
1.3) (Lisy & Peet 2008). As available molecular oxygen falls in the cell the PHD 
enzymes initially stabilise the HIF-1α molecule enabling formation of the 
transcription factor, then further reduction of the oxygen tension activated FIH to 
enable full transcriptional activation via the binding of CBP/p300 co-factors (Lisy 
& Peet 2008; Lando, Peet, Gorman, et al. 2002a). The different targets of these 
oxygen sensitive hydroxylation enzymes targeting the HIF signalling molecule 
enable subtle regulation over this process and it’s transcriptional output (Figure 
1.3). 
1.1.2.3 Von Hippel-Lindau protein (pVHL) and ubiquitin ligase 
degredation of HIF-1α  
The Von Hippel-Lindau tumour suppressor gene (VHL) binds hydroxylated 
HIF1-α and acts as a recognition component of a complex, which upon binding 
enables enzymatic ubiquitination and subsequent proteosomal degradation 
removing HIF-1α rapidly from the cytosol.  The proline residue hydroxylation by 
the PHD family of enzymes has been shown to block the binding of the pVHL 
which acts as an F-box like recognition element (Jaakkola et al. 2001). The 
ubiquitin ligase system involves several enzymatic steps which result in 
polyubiquitination of the substrate protein, in this case HIF-1α, enabling 
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degradation by the 26S proteasome (Iwai et al. 1999). Essential to the effective 
ubiquitination are the co-factors which bind to pVHL includes elongin B and 
elongin C, Rbx1 and Cul2 which enables ubiquitination of HIF-α (Pause et al. 
1997; Stebbins et al. 1999). Elongin B has been shown to be homologous to the 
ubiquitin molecule with in this complex, with elongin C, which has been shown 
to regulate some of the pVHL tumour suppressor activity (Stebbins et al. 1999). 
The complex formed by these co-factors and the VHL protein has homology to 
the SCF (Skp1-Cul1–F-box protein) which is known to target proteins for 
degradation (Stebbins et al. 1999).  
The ubiquitination process is catalysed by the by a series of enzyme steps, the 
first of these involves activiation of the ubiquitin by formation of a high energy 
bond with the E1 ubiquitin activating enzyme, utilising ATP. This is then 
transferred to a E2 ubiquitin conjugating enzyme, when this step occurs in the 
presence of an E3 substrate recognition complex the substrate protien is 
successfully ubiquitinated. The VHL protein has been shown to act as the 
critical recognition complex enabling specific ubiquitination of HIF-1α. Repeated 
activation of this process leads to polyubiquitination of HIF-α which is targeted 
to the 26S ribosome for proteosomal degradation, rapidly removing intracellular 
HIF in normoxic conditions (Maxwell et al. 1999) (Figure 1.1 & 1.2).  
Mutations in VHL lead to a number of tissue specific, highly vascularised 
tumours. These are as a result of HIF independent activity, including 
microtubule stability, cilia interaction, p53 transcription and cell survival 





Figure 1.1. HIF signalling in the presence of normal cellular oxygen 
tension showing the hydroxylation of intracellular HIF-1α and the 
proteosomal degradation  via the ubiquitin ligase system in the 
cytoplasm. 
Adapted from (Fong & Takeda 2010). In a normoxic environment the prolyl 
hydroxylase (PHD) and factor inhibiting HIF (FIH) enzymes hydroxylate specific 
prolyl and asparagine residues within the oxygen sensitive c-terminus of the 
HIF-1α residue. This hydroxylation results in binding of the HIF-1α to the Von 
Hippel-Lindau (pVHL) tumour suppressor protein, which acts as a recognition 
component of the Ubiquitin ligase proteasome degradation complex. This 
complex contains elongin B (elo B) and C (elo C) and the co-factor cullin 2 Cul 
2) and enables rapid degradation of HIF-1α in the presence of adequate cellular 





Figure 1.2. HIF signalling in the presence of cellular hypoxia and the effect 
on downstream response genes. 
Adapted from (Fong & Takeda 2010) In a hypoxic environment the prolyl 
hydroxylase (PHD) and factor inhibiting HIF (FIH) enzymes are inactivated 
which results in accumulation of HIF-1α in the nucleus. The absence of specific 
hydroxylated residues on the HIF-1α protein blocks interaction with the VHL/ 
Cul 2/Elo B/Elo C complex. Stabilised HIF-1α then translocates to the nucleus 
where it can associate with the constitutively active HIF-1β subunit to form an 
active transcription factor, which binds to the HIF response element of target 







Figure 1.3. Sequential regulation of HIF-1α by the PHD and FIH 
hydroxylation enzymes at reducing oxygen tensions. 
This hypothesised sequential regulation of hydroxylation sites of the HIF-1α 
residue enables a progressive activation and control over the activation of the 
HIF signalling system at different oxygen tensions. The N-terminal activation 
domain (NAD) is the specific site of PHD hydroxylation; the C-terminal 
activation domain (CAD) is the site for FIH hydroxylation essential for binding of 
the transcriptional co-factors CRB/p300 for full transcriptional activation. The 
differential regulation is based on the different affinities of the PHD and FIH 
enzymes for oxygen, only at the lowest oxygen tension is FIH blocked leading 
to full HIF transcriptional activation on binding to HIF-1β. Adapted from (Lisy & 
Peet 2008).  
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1.1.3 HIF signalling and angiogenic growth factors 
Hypoxia leads to the accumulation of the heterodimeric HIF1 transcription 
factor. This results in the expression of numerous genes, many implicated in 
angiogenesis (Rey & Semenza 2010). A number of angiogenic genes have 
been shown to contain a HIF response element (HRE), a DNA sequence motif 
that directly links the gene to the binding and activation by HIF 1α. This 
includes: VEGFA (Liu et al. 1995), VE-cadherin , ANG2 (Rey & Semenza 2010) 
and VEGFR1 (flt1), all key elements in the angiogenic process. There are also 
genes which have been shown to be up regulated by hypoxia or HIF 1α but lack 
a HRE motif, including VEGFR2 (flk1), PGDF-B, ANG1, MMP-9 and TIE2 (Fong 
2008). These genes may either be activated by transcription factors which are 
HIF dependent or may contain an unidentified HRE (Fong 2009). The activation 
of VEGFA and its receptor VEGFR1 (flt1) by HIF signalling is one of the earliest 
steps in activation of an endothelial adaptation to hypoxia in the form of 









Figure 1.4. Schematic of differences between developmental vascular 
development (vasculogenesis) and the formation of new vessels from 
endothelial cell of an established vessels. 
A. Mechanism for vasculogenic vessel formation from migrating angioblasts to 
form new vessels during embryonic development. B. New vessel formation by 
angiogenesis from established endothelial cells (Potente et al. 2011). 




1.2 Vascular development 
Vasculogenesis is the formation of the primitive vascular system by the 
recruitment and differentiation of pluripotent mesenchymal cells into 
angioblasts. The angioblasts migrate under the control of VEGF-A and VEGFR2 
to for  the undifferentiated primitive vessels before differentiation into arteries or 
veins in situ (see Figure 1.4) (Carmeliet 2000).  
1.2.1 Angiogenesis 
Angiogenesis is the formation of a new vessel from the endothelium of a pre-
existing vessel (Carmeliet & Jain 2011). This enlarges and builds upon the 
initial vascular network formed by vasculogenesis during embryonic 
development of the organism (Swift & Weinstein 2009) and aids formation of 
new organs and tissue by neovascularisation (Adams & Alitalo 2007). It is the 
plasticity of the endothelial cell which permits this effective reorganisation 
(Potente et al. 2011). 
Given the critical role of blood vessels in maintaining oxygenation and nutrient 
supply, perturbation of vessel structure or function can lead to a number of 
diseases. Vessel overgrowth by angiogenesis is a key step in tumour 
development and retinal diseases, whereas vessel degeneration and occlusion 
can lead to strokes and heart disease (Carmeliet & Jain 2011). 
1.2.2 Vascular endothelial growth factor 
VEGF was identified as vascular permeability factor as early as 1983 (Senger et 
al. 1983) but subsequently renamed VEGF. There are now five isoforms 
characterised (VEGF-A,B,C and D and Placental growth factor) The ligands 
binds with the tyrosine kinase receptors (VEGFR1 / 2 and 3). In the mature 
vessel endothelial cells are maintained in a quiescent phase by the autochrine 
production of VEGF-A and other ligands including notch ligands, fibroblast 
growth factors (FGF) and angiopoietin-1 (ANG1) (Carmeliet & Jain 2011) The 
absence of this local VEGF-A production has been shown to lead to increased 
levels of endothelial apoptosis and dysregulation (Warren & Iruela-Arispe 
2010).  
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Paracrine secretion of VEGF due to increased HIF production leads to 
activation of endothelial cells. This activation results initially in increased 
permeability of the endothelium and enlargement of the vessel. At the same 
time there is digestion of the basement membrane to enable endothelial cell 
migration by matrix metalloproteinases (MMP). This digestion of the basement 
membrane and removal of mural cells liberates angiogenic factors, which 
facilitate the differentiation of a tip cell (Arroyo & Iruela-Arispe 2010). This tip 
cell acts as the central focus of the angiogenic process, stimulated by local 
gradients of VEGF and co-ordinated at a cellular level by notch signalling 
(Potente et al. 2011).  
1.2.2.1 Ligands and receptors in the zebrafish 
In the zebrafish there are the same three VEGF ligands as described in the 
mammalian systems VEGF-A, B and C. However the tyrosine kinase receptor 
population contains an additional gene. The three receptors with orthologous 
mammalian genes are flt1 (VEGFR1), kdr (FLK1 or VEGFR2) and flt4 
(VEGFR3), the kdr-l gene is thought to have existed prior to the teleost gene 
duplication. However it is thought that this fourth receptor was lost in 
mammalian (human and mouse) lineages (Bussmann et al. 2008). 
1.2.3 Tip and stalk cell formation 
VEGF-A gradients lead to the stimulation of a differentiated endothelial cell, 
known as the tip cell, by activation of the VEGFR2 receptor. The tip cell shows 
a number of behaviours which facilitate the modification of vascular networks. 
Tip cells are polarised and produce filopodia which respond to local guidance 
signals such as semaphorins, which act via the plexin receptors and the family 
of ephrin signalling molecules (Carmeliet & Jain 2011), to facilitate migration. 
These signals act to direct the mobile tip cell by repulsion or attraction to 
produce a vascular network (Childs et al. 2002; Torres-Vázquez et al. 2004) 
(Figure 1.5). 
Stalk cells, also modified endothelial cells, form behind the tip cell by a process 
of lateral inhibition stimulated by Notch signalling (Jakobsson et al. 2010).  Stalk 
cells proliferate to maintain contact with the motile tip cell and produce less 
 13 
filopodia. The differentiation into a tip or stalk cell in the angiogenic sprout is not 
a fixed cell fate and alters continuously depending on levels of notch signalling 
and other local factors. It has been suggested that Notch signalling is the 
mechanism by which continuous branching and sprout elongation is regulated 
via the expression of Notch-regulated ankyrin repeat protein (Nrarp) and 
induction of local Wnt signalling (Phng & Gerhardt 2009). The stalk cell must 
also form the vascular lumen to enable blood flow and undergo complex 
reorganisation to form an effective vessel (Herwig et al. 2011; Blum et al. 2008). 
In addition these cells must form tight junctions with surrounding cells and 
produce a basement membrane to form a stable and effective vessel (Jain 






Figure 1.5 Endothelial differentiation into tip and stalk cells during 
angiogenesis and its molecular regulation. 
A. Initial endothelial activation from mature quiescent vessel in the presence of 
VEGFA. B. Selection of a tip cell and the lateral inhibition of adjacent cells to 
stalk cell fate by notch signalling. C. Maintenance and guidance signals for 
elongation and activation of the angiogenic sprout. (Potente et al. 2011) 
Reproduced with kind permission from Elsevier publishing.  
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1.2.4 Haemodynamic flow and the regulation of angiogenesis 
There is a large body of literature on the importance of haemodynamic flow 
signals and particularly shear stress in endothelial maintenance and pathology 
(Reneman et al. 2006; Davies 2008). The majority of this data is derived from 
endothelial cell culture experiments using flow chambers to look at migration, 
polarity, growth and endothelial gene expression in different, “flow” 
environments. Although this data provides numerous insights into the effect of 
shear stress on the endothelial cell it doesn’t address the role of associated 
vessel cell types like pericytes and smooth muscle on endothelial behaviour in 
the more complex in vivo environment (Egginton 2011). In addition it is only 
possible to study the effects of shear stress in isolation on the endothelium 
where clearly in the in vivo situation other physical forces and physiological 
signals are constantly modifying the endothelial response (Hoefer et al. 2013). 
In the field of arteriogenesis research there is data demonstrating the increases 
in endothelial cell numbers in response to increased axial force or radial 
distension as an initiating factor for sudden recruitment of primitive arterial 
channels (Hoefer et al. 2013).  
There remains very little data on the role of haemodynamic flow on 
angiogenesis despite the increasing amounts of data on its effects on 
endothelial expression, behaviour and phenotype. Research using the chick 
embryo as a developmental model has shown the role of flow on arterial and 
venous specification during developmental angiogenesis (le Noble et al. 2008). 
In these experiments the authors were able to show that circulatory flow in an in 
vivo model is able to regulate various aspects of angiogenic remodelling 
including fusion of primitive vessels and shear stress directed guidance of 
developmental angiogenesis (le Noble et al. 2008).  
Using the zebrafish model it has also been shown that flow in the developing 
intersegmental vessels regulates the arterial of venous specification after 
vasculogenesis and onset of cardiac contraction with subsequent flow (Isogai 
2003). Their data indicates that flow is important in the production of a balanced 
complement of arterial and venous intersegmental vessels. More recent data 
has shown that haemodynamic flow and intact VEGF signalling is required for 
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effective formation of the dorsal longitudinal plexus which forms by a process of 
angiogenic sprouting and endothelial regression to form effective circulatory 
loops from the intersegmental vessels (Zygmunt et al. 2012). 
Additional data utilising the zebrafish to study in vivo angiogenesis have shown 
that flow has a role in the angiogenic behaviour of developing vessels in the 
hindbrain of the developing zebrafish. This particular vascular territory utilises 
the chemokine receptor CXCR4a as an endothelial signal to switch off the 
angiogenic programme in these vessels (Bussmann et al. 2011). This study 
showed that this flow dependent signalling pathway is not present in the trunk 
vessels of the same embryos indicating different regulatory pathways in the 
development of different vascular beds. 
Despite these studies and those describing the effects of flow on endothelial 
cells to date only one paper has described a regulatory signalling pathway by 
which developmental angiogenesis is regulated in the zebrafish embryo. There 
is no available data on the role of flow on pathological or hypoxic driven 
angiogenesis in the in vivo environment. The paper by (Nicoli et al. 2010) using 
the zebrafish identifies a flow dependent aortic arch vessel which requires flow 
to form by a process of angiogenesis after the onset of circulation. They 
identified a microRNA (miRNA-126), which regulates the response of the 
endothelium to localised VEGF-A gradients in the presence of flow. There 
experiments showed that the endothelium of this specific developmental vessel 
in the presence of flow increase the zinc finger transcription factor kruppel like 
factor 2a (klf2a). This transcription factor has been shown to regulate 
endothelial expression in response to flow in other in vivo and in vitro models 
(Lee et al. 2006). The upregulation of klf2a in response to flow increases levels 
of miRNA-126 supresses expression of spred1 which inhibits angiogenesis 
(Nicoli et al. 2010). 
The available data on flow dependent angiogenesis in the in vivo environment 
indicates that there is likely to be different regulatory pathways at work in 
endothelial cells in response to the physiological stimuli to regulate 
physiological angiogenesis (Bussmann et al. 2011). It therefore doesn’t seem 
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unreasonable to suspect that different processes of spatial and temporal 
regulation of angiogenesis might be further altered by transduction of physical 
forces by the endothelial cell in pathological angiogenesis. 
1.3 Notch signalling 
The Notch signalling system is a pathway by which cells interact with external 
signals and integrate them into a coordinated developmental response by 
regulation of differentiation, proliferation and apoptosis. Components of this 
pathway have been conserved from nematodes to humans indicating its 
importance in development. This signalling pathway was originally identified in 
Drosophila over eighty years ago when it was noted that haploinsufficiency of 
the Notch gene leads to a notched appearance of the developing wing 
(Artavanis-Tsakonas et al. 1999).   
1.3.1 Canonical notch signalling 
On the surface of “signalling” cells a transmembrane Notch ligand is expressed. 
In mammals there are five ligands (Delta-like 1,3 & 4, Jagged 1 & 2) of the 
delta/serrate/LAG-2 family. These ligands binds to a Notch receptor expressed 
on the membrane of an adjacent or “receiving” cell (Bray 2006). Activation of 
the notch receptor leads to sequential cleavage by the ADAM and γ–secretase 
enzymes at the cell membrane. This yields an extracellular domain fragment 
(NECD), which is targeted by the ligand-expressing cell for internalisation and 
lysosomal degradation. The Notch intracellular domain (NICD) translocates to 
the nucleus of the receiving cell where it associates with the CBF1/Suppressor 
of Hairless/LAG-1 (CSL) protein in the presence of the Mastermind-like (MAML) 
protein to form a transcription factor complex which drives expression of the 
Notch immediate target genes (Andersson et al. 2011). In the absence of NICD 
the CSL complex inhibits transcription due to binding of a repressor, which is 
displaced by NICD (Pursglove & Mackay 2005; Phng & Gerhardt 2009).  
This relatively simple Notch core-signalling pathway has no amplification step or 
phosphorylation in its signalling pathway, which means that the level of ligand 
signal determines the output in the receiving cell. This is unusual in the highly 
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conserved intracellular signalling pathways like Wnt, JAK/STAT, PI3K/AKT, and 
Hedgehog, all of which contain amplification steps (Andersson et al. 2011). 
Despite the relatively simple components of the core-signalling pathway 
extensive research has identified numerous auxiliary proteins, which modulate 
this signalling pathway but are dependent on the timing and cell type in which 
the pathway is active. This complex modulation system enables the diverse 
effects and spatial responses of Notch signalling (Andersson et al. 2011; 
Artavanis-Tsakonas et al. 1999). 
1.3.2 Non-canonical Notch signalling  
In addition to the modification of the canonical Notch signalling pathway by 
accessory proteins there is also additional evidence that non-canonical 
pathways exist which are capable of activating notch target genes but not by 
the traditional activation of the Notch receptor and cleavage of the NICD 
(Martinez Arias et al. 2002). These non-canonical pathways may facilitate 
cross-talk of other developmental intracellular signalling pathways, like 
hedgehog and Wnt to integrate environmental cues into organised cellular 
responses (D'Souza et al. 2010).  
1.4 Effects of Notch signalling on endothelium and 
vascular development 
Endothelial cells express the Notch ligands Dll1, Dll4, Jagged-1 and Jagged-2 
along with the Notch receptors Notch-1 and Notch-4. Notch signalling has been 
shown to influence a variety of endothelial behaviours and cell fate decisions 
(Iso 2003). 
1.4.1 Vasculogenesis 
One of the earliest developmental effects of Notch signalling, in concert with 
VEGF-A during early development is the migration and maturation of 
angioblasts (Flamme et al. 1995) to form the primitive vascular system, a 
process known as vasculogenesis (Roca & Adams 2007). After migration of 
pluripotent angioblasts there is early differentiation into arterial and venous 
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fates even before onset of circulation. During zebrafish development, changes 
in notch (Lawson et al. 2001) or the ligand dll4 (Leslie et al. 2007; Siekmann & 
Lawson 2007a) result in abnormal arterial and venous cell fate (Phng & 
Gerhardt 2009). Further evidence for the role of notch signalling in arterio-
venous fate are found in two zebrafish mutant lines: In the mindbomb mutant 
there is a mutation in the delta ubiquitin ligase which inhibits Notch signalling 
leading to arterio-venous abnormalities (Lawson et al. 2001). This is replicated 
in the gridlock mutant which has a mutation in the downstream Notch 
transcription factor ortholog of HEY2 which results in a loss of arterial cell fate of 
the developing aorta with characteristic arterio-venous malformations (Zhong et 
al. 2001).  
1.4.2 Angiogenesis 
Suppression of Notch signalling by treatment of zebrafish embryos with N-[N-
(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), a γ–
secretase inhibitor, results in inhibition of Notch signalling and increased 
number of filopodia due to blockade of dll4 (Leslie et al. 2007). Whereas binding 
of the alternative Notch ligand Jagged1 in the mouse retinal endothelial model 
blocks filopodia production due to competition with the Dll4-Notch1 ligand-
receptor complex (Benedito et al. 2009). The Notch pathway also influences 
proliferation of endothelium to facilitate angiogenesis, vessel migration and 
lumenisation. Activation of the Notch signalling pathway leads to inhibition of 
endothelial cell division in mouse, zebrafish and cell culture (Phng & Gerhardt 
2009).  
Studies by (Siekmann & Lawson 2007b) in the developing zebrafish showed 
that knockdown of both dll4 and the recombining binding protein suppressor of 
hairless (Rbpsuh, ortholog of CSL) resulted in an increased tip cell phenotype in 
the developing intersegmental vessels of the embryos. Endothelial cells with 
over-expression of notch show reduced migration of cells into a tip cell position. 
An excess angiogenesis was also seen in the zebrafish embryo after 
knockdown of the Notch receptor notch1b (Leslie et al. 2007). Transplant 
experiments in the zebrafish vasculature demonstrated cells with induced over 
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expression of the NICD are less likely to migrate to a tip cell position (Siekmann 
& Lawson 2007b). 
Increased notch signalling acts on endothelial cells to supress the angiogenic 
phenotype by reducing motility, and the production of filopodia characteristics of 
a tip cell, specified by reduced levels of notch signalling (Phng & Gerhardt 
2009). 
1.4.2.1 Tip and stalk cell selection and notch signalling 
An increase in dll4 expression is seen in tip cells, with increases in Notch 
expression a feature of stalk cells in the ISV and DLAV of the developing 
zebrafish vasculature (Leslie et al. 2007). Genetic knockdown of Dll4 has been 
shown to increase number of tip cells, filopodia and genes expressed in tip 
cells; FLT4, VEGFR2 and PDGF in endothelial cell culture and mouse retinal 
studies (Hellström et al. 2007). The key regulator of tip cell behaviour has been 
shown to be the ligand Dll4 (figure 1.5 and 1.6); this ligand drives many of the 
adaptations and expression patterns which define a tip cell. Dll4 also induces 
lateral inhibition which determines the behaviour and fate of the trailing stalk 
cells (Phng et al. 2009). In the developing zebrafish vasculature defective dll4 
signalling results in aberrant angiogenesis in the presence of a functional 
vegfaa gene. Although initial sprouting angiogenesis is preserved there appears 
to be no off switch when the stereotyped vascular circuits are completed (Childs 
et al. 2002; Leslie et al. 2007). 
1.4.2.1.1 MicroRNA regulation of the DLL4 notch ligand 
Although the role of DLL4 has been extensively studied in relation to 
angiogenesis and its regulation of tip cell selection little was known until 
recently about how the levels of DLL4 are regulated in endothelium. Studies by 
(Bridge et al. 2012) using cultured lymphatic endothelial cells and transgenic 
zebrafish embryos have shown a role for the microRNA-30 family in the 
regulation of DLL4. Increased levels of mirRNA-30b and c in the developing 
zebrafish embryo phenocopied the effect of dll4 MO knockdown on the ISV and 
DLAV, resulting in increased sprouting and migratory activity. This mirRNA-30 
effect was partially rescued by co-injection of a target protector blocking the 
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Figure 1.6 Endothelial notch signalling determines tip and stalk cell fate. 
The figure shows an current scheme for the mechanism by which endothelial tip 
and stalk cell fate is determined based on data from cell culture, zebrafish and 
murine retinal angiogenic models. A. Simplified 2D diagram of endothelium 
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forming a quiescent vessel, with stimulating factors for angioigenesis in terms of 
hypoxia and the production of local gradients of VEGF-A. B. The cell – cell 
Notch signalling in the quiescent vessel isn’t activated, the key signalling factors 
are indicated in this schematic but with no activation. (Activation of a signal is 
shown in bold text and arrows inhibition is shown with red termination lines)  C 
& D. The increase in local VEGF-A activates the KDR receptor on the 
endothelial cell which in turn leads to the transcription and expression of the 
notch ligand on the membrane of the activated tip cell (green endothelial cell). 
This ligand binds to the notch receptor on adjacent endothelial cells activating 
the expression of soluble FLT1 on the stalk cells (purple endothelial cells), this 
results in binding of the VEGF-A ligand without activation of downstream 
transcriptional targets reducing the sensitivity of these stalk cells to the VEGF-A 
gradient. This process allows for the selection of tip cells and the subsequent 
suppression of additional tip cells with the activation of a stalk cell fate. D. The 
levels of expression of Dll4, Notch1, VEGF ligands and receptors determine tip 
cell fate. G & H. In experiments where notch signalling is inhibited either by 
chemical treatment or my genetic knockdown of the notch ligand DLL4 this 
leads to all endothelial cells becoming tip cells, in the presence of a VEGF-A 
gradient. Adapted from (Phng & Gerhardt 2009) reproduced with kind 
permission from Elsevier.  
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1.5 Nitric Oxide (NO) signalling 
Nitric oxide is a key signalling molecule in vascular biology. Since its 
identification there has been extensive study of this molecule and its role in all 
aspects of vessel biology and disease (Sessa 2009). NO was initially identified 
as endothelial derived relaxation factor, released by endothelial cells in 
response to acetylcholine and shear stress in preparations of rabbit aorta 
(Furchgott & Zawadzki 1980; Palmer et al. 1987).  
1.5.1 NO and vessel biology 
NO is synthesised from L-arginine by the highly conserved nitric oxide synthase 
family of enzymes. The NO produced by endothelial NOS (eNOS) diffuses into 
the adjacent smooth muscle in the artery where it activates guanylate cyclase to 
synthesise cGMP resulting in arterial dilatation via modification of calcium flux 
and potassium channels (Yu et al. 2002). In addition to the regulation of arterial 
tone eNOS and NO have been shown to be critical to the correct embryonic 
development of cardiac valves, structures and arteries (Liu & Feng 2012). In 
addition to a role in correct developmental cardiac patterning NO has been 
shown to be a critical factor in vasculogenesis and angiogenesis.  
Recent data has shown that VEGF-A signalling in the developing mouse 
embryo modifies NO signalling which alters proliferation of angioblasts, 
influencing vasculogenesis (Gentile et al. 2013). It is suggested that VEGF 
receptor activation in the developing mouse embryo results in the 
phosphorylation of of a serine residue in expressed eNOS. This occurs in 
populations of primitive angioblasts and embryonic endothelial cells altering 
levels of proliferation in cells which produce primitive vessels (Gentile et al. 
2013). 
There is also a role of NO on vascular permeability, which has been studied as 
a co-factor to early VEGF-A induced permeabilisation of endothelial cells during 
the initiation of angiogenesis. It has been suggested that endothelial NOS may 
be a key early regulator of the VEGF-A induced vascular permeability which is a 
hallmark of early angiogenesis (Sessa 2009). In addition to modulation of flow 
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NO maintains stability and health of the endothelium of the vessel wall (Sluimer 
& Daemen 2009). 
The role of NO as a signalling molecule in vascular development is a huge area 
of research but it is becoming increasingly apparent that the regulation of flow 
has indirect effects on other embryonic developing systems. Recent studies in 
the zebrafish showed that blood flow and vessel regulation by NO and other 
signalling factors is key to the migration of haemopoietic stem cells (North et al. 
2009). These cells are also involved in the correct patterning of the angiogenic 
blood vessels of the somites and arterial and venous fate decisions in concert 
with VEGF, Hedgehog and Notch signalling (Wilkinson et al. 2012).  
1.6 Zebrafish as a model of vessel development and 
vascular disease 
The zebrafish (Danio rerio) is a small freshwater fish that originates from 
Southern Asia and the Indian sub-continent. The adult can grow to 4cm in 
length and lives between three and five years. The zebrafish was initially used 
in the 1930’s as a classical embryonic and developmental model. However this 
model has become a powerful tool with which to study vessel development and 
behaviour (Chico et al. 2008).  
In terms of cardiovascular development, the zebrafish forms a rudimentary 
circulation by twenty-four hours (Isogai 2003); aorta, cardinal vein and 
erythrocytes can be easily visualised using microscopy at this stage and then 
the continuing vascular development (Isogai et al. 2001). Another unique 
advantage of the embryonic vasculature of this model is that the embryo does 
not require circulation for oxygen delivery (Pelster & Burggren 1996) 
(maintained by oxygen diffusion), which means lethal cardiovascular 
abnormalities in other organisms can be tolerated and the effects assessed 
using zebrafish.  
A number of non-invasive techniques have developed, which take advantage of 
the optical clarity of the embryo to obtain detailed information about the 
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developing circulation (Chico et al. 2008). The vascular system demonstrates 
similar molecular signals and functional conservation with the human circulatory 
system (Lieschke & Currie 2007) despite differences such as a lack of 
pulmonary circulation. 
1.6.1 Advantages of the zebrafish for vascular research  
Female zebrafish produce eggs from three months of age and lay up to three 
hundred eggs a week. The combination of this fecundity and the low costs of 
maintenance compared to other animal models makes it an attractive organism 
for biomedical research (Chico et al. 2008; Lieschke & Currie 2007). 
1.6.1.1 Optical clarity and imaging  
The large lays of eggs develop externally after fertilisation, enable non-invasive 
study of embryonic development. The developing embryo is transparent which 
enables visualisation of numerous developmental processes including: 
Organogenesis, vasculogenesis, cardiac contraction, angiogenesis and 
inflammation by microscopy (Lieschke & Currie 2007). When combined with 
transgenic zebrafish lines this enables the study of these processes in vivo and 
over time in the same individual. This repetitive observation is a particular 
advantage in the study of vascular development and adaptation. A particularly 
striking example of these unique advantages is the real time in vivo interactions 
and behaviours of individual endothelial cells during angiogenesis (Jakobsson 
et al. 2010). 
1.6.1.2 Genetic tractability and manipulation 
Over the last twenty years there has been massive development in genetic 
manipulation techniques and sequencing of the zebrafish genome making the 
organism highly genetically tractable (Sprague et al. 2006). 
1.6.1.2.1 Transgenesis 
Non-homologous modification allows generation of transgenic zebrafish. Recent 
techniques using the Tol2 transposon, a genetic sequences which can relocate 
within an organisms genetic code, have enhanced the generation of transgenic 
lines. Using this specific transposons and the transposase enzyme techniques 
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have been developed to insert multiple copies of the flanked genes and reporter 
constructs into the host genome (Kawakami 2004). These modifications have 
made it simpler and quicker to produce transgenic lines and as a result, 
enormous numbers of different reporter lines now exist. 
With relevance to the study of vessel biology, transgenic lines exist which 
specifically label endothelial cells (Lawson & Weinstein 2002) with green 
fluorescent protein (GFP). The Friend leaukaemia integration 1 transcription 
factor (Fli1) a proto-oncogene has been shown in the embryonic zebrafish and 
mouse to be expressed in predominately endothelial cells resulting in its use as 
an endothelial promoter to produce a vascular reporter transgenic (Mélet et al. 
1996; Lawson & Weinstein 2002). More recently lines which label only a 
specific endothelial cell region (such as membrane or nucleus) or subset of 
endothelium such as arterial or venous cells can be generated and combined in 
the same organism to provide useful insights into the dynamic process of vessel 
formation within the model organism (Herwig et al. 2011; Zygmunt et al. 2012).  
1.6.1.2.2 Forward genetic manipulation of the zebrafish 
Forward genetic techniques have provided large numbers of mutant lines with 
identified genetic mutations and developmental phenotypes which have been 
used for the study of many human genetic conditions (Wienholds et al. 2003). 
These screens produce groups of phenotypically similar mutants and the ease 
of observation of the developing embryo using simple optical microscopy and 
identification of mutations by targeting induced local lesions in genomes 
(TILLING) has increased the number of stable mutants with characterised gene 
defects (Lieschke & Currie 2007). 
1.6.1.2.3 Reverse genetic techniques in the zebrafish 
Several techniques for production of stable mutant lines now exist using a 
reverse genetic approach including zinc finger (Sander et al. 2010) or TALEN 
targeted mutagenesis (Bedell et al. 2012). These techniques enable the 
relatively rapid mutation of a gene of interest.  
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1.6.1.2.3.1 Morpholino antisense oligonucleotide 
Transient genetic knockdown in the developing zebrafish embryo can be 
achieved using injection of these modified RNA sequences (Bill et al. 2009). 
The modification of the MO nucleotide backbone stabilises the construct 
protecting it from degradation. The MO is injected into the 1-4 cell fertilised 
embryo and results in a transient translational block of an mRNA target. There 
are no endogenous enzymes to degrade MO residues and it is thought that the 
effect is diluted by cellular division, by 3 dpf in the zebrafish embryo, although 
some reports have shown effects as late as 5 dpf (Bill et al. 2009). The MO can 
be designed against either an ATG start site or various splicing sites. Despite 
the low cost and relatively easy targeting of morpholinos for gene knockdown 
the technique is not without its limitations: Certain morpholinos have been 
shown to induce cell death by a process of p53 activation, which can lead to off 
target effects in the embryo. Due to difficulties with the zebrafish and the 
production of antibodies for Western blotting this makes it difficult to 
demonstrate that genetic knockdown results in protein loss. It is possible in 
some situations incomplete knockdown by MO may still result in biologically 
relevant amounts of protein, which are then impossible to quantify. Accepting 
these limitation this technique still provides an effective screening tool of 
targeted reverse genetics in a short time period and at relatively low cost (Eisen 
& Smith 2008; Lieschke & Currie 2007). 
1.7 The vhl homozygous (vhl-/-) mutant zebrafish 
The vhl-/- mutant zebrafish was identified from an ethyl-N-nitrosourea (ENU) 
mutation library which was screened in silico for targeted mutations using the 
Hubrecht TILLING protocol (Wienholds et al. 2003). This mutant has nonsense 
mutation within the HIF-1α binding domain; the vhlhu2117 line has an inactivating 
germline mutation as a result of a C/T substitution on chromosome 6 at position  
Q23X within the zebrafish vhl orthologue. Given that the mouse knockout of vhl 
results in embryonic lethality and limited homology to the human disease 
(Haase 2005; van Royen et al. 2009), this mutant line has provided a useful tool 
with which to study function of this gene. 
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Two lines were identified from this screen carrying mutations in the zebrafish 
ortholog vhl, both being nonsense mutations in the HIF binding domain. These 
alleles are loss of function mutations as no VHL protein can be detected on 
western blots of homozygous mutants (vhl-/-) (Van Rooijen et al. 2009). The 
zebrafish ortholog vhl encodes a single transcript for a 175 amino acid protein, 
which is 52% identical and 70% similar to human VHL. The key binding 
domains of this protein are highly conserved compared to human including the 
Elongin C and HIF-1α domains essential for hypoxic signalling (Van Rooijen et 
al. 2009).  
The vhl-/- zebrafish mutants demonstrate numerous features of up regulated 
hypoxic signaling induced by HIF. Whole mount in situ hybridization 
experiments indicate up-regulation of phd3, lactate dehydrogenase (ldh), epo 
and vegf mRNA; all classical HIF target genes (Weidemann & Johnson 2008; 
Van Rooijen et al. 2009). The mutants also demonstrate changes in behaviour 
consistent with increased hypoxia signaling including hyperventilation. 
In addition to behavioural and molecular adaptations the mutant embryo has 
developmental adaptations of the cardiovascular system. They have similar 
heart rates to wild type siblings (wt sib) at 4 dpf although after 7 dpf the mutant 
heart rate is higher until 10dpf (Van Rooijen et al. 2009). Zebrafish cardiac 
output would be expected to fall during early development in a wild type embryo 
(Schwerte et al. 2003); in the mutant there is a 3.2-fold increase in cardiac 
output at 4 dpf and 15-fold increase at 10 dpf. This results in cardiomegaly, 
oedema and high output cardiac failure leading to death of the homozygous 
embryo at between 8 and 11 dpf (Van Rooijen et al. 2009). 
1.7.1 Vascular phenotype of the vhl-/- mutant zebrafish 
Vascular endothelial growth factor is a key initiator and regulator of all forms of 
angiogenesis (Yancopoulos et al. 2000), however many other signaling 
molecules are able to influence the developing vessel. The vhl-/- mutant shows 
increased expression of vegfaa (ortholog of mammalian VEGFA), due to the up 
regulation of HIF signaling. The mutant also demonstrates up regulation of 
receptors for vegfaa (Van Rooijen et al. 2010) including kdr and kdrl in the liver, 
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kidney, glomerulus and kdr in developing blood vessels, indicating potentially 
higher sensitivity to vegfa (Van Rooijen et al. 2009).  
Initial patterning of the vasculature in the vhl-/- mutant is normal, but an increase 
in cranial vessels is present as early as 58 hpf. By 4 dpf there are clear 
differences in numerous vascular territories. Increased angiogenic sprouting 
from Intersegmental vessels (ISV) is detectible at 3.5 dpf and 5.75 dpf but 
although a qualitative description of these differences has been described only 
a detailed description of the retinal vessels has been published (Van Rooijen et 
al. 2010). 
This vascular phenotype seen after 58 hours in the vhl-/- mutant has been 
shown to be vegfa (aa/ab) dependent and the areas of greatest angiogenesis 
correlate with the highest levels of vegfa. By administering a kdr tyrosine kinase 
inhibitor from 58 hpf for 3 days formation of new vessels was blocked in the 
mutant. This demonstrates that up-regulation of the vegfaa pathway is likely to 
be the dominant signal in activating the pro-angiogenic phenotype in this mutant 
(Van Rooijen et al. 2010). This model of pathological angiogenesis is consistent 
with the established literature which shows that VEGF-A is essential for 
paracrine activation of endothelial tissue and also stimulation of the 




1.8 Aim of my research 
My aim is to characterise the aberrant angiogenesis and mechanisms 
underlying the initiation and maintenance of these vessels in the vhl 
homozygous mutant zebrafish. 
1.9 Hypotheses 
The aberrant vasculature seen in the vhl-/- mutant zebrafish is initiated by tip 
and stalk cell differentiation with classical features of angiogenesis. 
The aberrant vessels of the mutant vhl-/- zebrafish are dependent on 
haemodynamic force for initiation. 
The aberrant vessels of the mutant vhl-/- zebrafish are a result of reduced notch 
signalling which produces increased levels of angiogenesis in the presence of 
vegfaa/ab. 
The aberrant vessels of the mutant vhl-/- zebrafish are dependent on 
haemodynamic force for initiation. 
The aberrant vessels of the mutant vhl-/- zebrafish are dependent on the 
presence of nitric oxide for initiation and maintenance and that this molecule 
mediates endothelial flow detection in the mutant. 
1.10 Objectives 
I am to test these hypotheses by completeing the folowing experimental  
objectives: 
• Characterise and quantify differences in the vessels and the angiogenic 
phenotype of the vhl-/- mutant. 
• Identify differences in endothelial cell number in the vhl-/- mutant and wild 
type siblings. 
• Identify if the differences in endothelial number is due to increases in 
proliferation or apoptosis.  
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• Assess the effect of changes in circulating volume and red cell density in 
the vhl-/- mutant on the angiogenic phenotype. 
• Manipulate haemodynamic flow in the angiogenic vessels of the vhl-/- 
mutant to assess its effect on angiogenic sprouting and endothelial 
number. 
• Identify if the aberrant angiogenesis of the vhl-/- mutant is lumenised 
early in development. 
• Assess the role of NO signalling in the transduction of flow in the 
endothelium of the developing zebrafish. 
• Identifiy differential regulation of notch signalling components in 
endothelial cells in response to changes in circulatory flow. 
• Manipulate notch signalling in an attempt to regulate flow sensitive 






Chapter 2 Materials and Methods 
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2.1 Zebrafish husbandry 
2.1.1 Adult zebrafish maintenance 
Adult zebrafish were maintained in accordance with UK Home office 
regulations, under project licences 40/3434 and 40/3082 issued to Dr T. J. 
Chico and Dr F. van Eeden. All experiments were performed under these 
project licences and my personal licence 40/9855. The adult fish were 
maintained as per standard protocols (Nüsslein-Volhard & Dahm 2002). Adult 
fish were housed in a recirculating aquarium system with a water temperature of 
28±1°C, and a 14:10 hour light/dark cycle. Adults were fed Artemia nauplia 
larvae and maintained at a maximum density of five fish per litre of aquarium 
water.  
2.1.2 Zebrafish strains 
Experiments utilising wild type zebrafish were performed with AB or London wild 
type (LWT) strains. 
2.1.2.1 Mutant zebrafish lines 
The vhl mutant zebrafish line was obtained from the Hubrecht institute 
(Netherlands) and all experiments were performed with the vhlhu2117 (C/T Q23X) 
mutant allele (Van Rooijen et al. 2009).  
2.1.2.2 Transgenic vascular reporter lines 
The vhlhu2117 line was crossed to the following vascular reporter lines to study 
the vascular phenotype in detail: Tg(fli1:eGFP) (Lawson & Weinstein 2002) 
which labels endothelial cytoplasm,  Tg(flk1:EGFP-NLS) (Blum et al. 2008) 
which labels endothelial nuclei, Tg(kdrl:HRAS-mCherry)s916 (Hogan, Bos, et al. 
2009a) which labels the endothelial cellular membrane with red fluorescence. A 
dual reporter line was also raised with both Tg(kdrl:HRAS-mCherry)s916 and 
Tg(flk1:EGFP-NLS) in the vhlhu2117 mutant background, enabling endothelial 
behaviour and quantification to be assessed in the same line. The Tg(fli1:eGFP) 
line was crossed with a fluorescent erythrocyte reporter Tg(gata1a:dsRed)sd2 
(Traver et al. 2003) to give dual fluorescence of vessels and circulating blood 
 34 
cells to study vascular lumenisation and effects of increased erythrocyte 
number in the vhl mutant.  
To maintain adult populations carriers of the fluorescent reporters were 
identified at embryonic stage (3dpf) with fluorescence microscopy, and embryos 
expressing fluorescence were raised as adults. To identify vhl-/+ (heterozygous) 
carriers in the adult population, fin clipping was performed to provide genetic 
material to identify carriers of the mutated vhl allele from their wild type siblings 
by PCR and enzyme digest.  
The zebrafish cytoplasmic endothelial reporter line Tg(fli1;eGFP) was obtained 
from the Zebrafish International Resource Centre (University of Oregon, USA). 
The endothelial nuclear transgenic reporter line Tg(flk1:eGFP-NLS) and the 
photo-convertible endothelial reporter Tg(fli1:Gal4(GFF);UAS:kaede) were a 
kind gift from Marcus Affolter (University of Basel, Switzerland). The erythrocyte 
fluorescence transgenic Tg(gata1a:dsRed)sd2 was a kind gift from Leonard Zon 
(Harvard University, USA).  
2.1.2.3 Transgenic endothelial hypoxia and vascular reporter lines 
To investigate the role of endothelial cell hypoxia, in contrast to the global up 
regulation of hypoxic signalling induced by the vhl-/- mutation, I used a 
transgenic line utilising the Tg(fli1:GFF) promoter (Asakawa et al. 2008). This 
reporter uses a modified Gal4 promoter (GFF), and a yeast transcriptional 
activator that binds a recognition sequence, the upstream activating sequence 
(UAS) (Scheer & Campos-Ortega 1999) this in turn drives expression of the 
KAEDE gene as a fluorescent reporter. This line enables endothelial specific 
expression of the photo-convertible stony coral protein KAEDE. This line was 
used as it was already established in our department with the appropriate 
molecular machinery to utilise the GAL4:UAS system. The KAEDE protein can 
be used as a traditional green fluorescence reporter without photo conversion 
and as it had already been crossed into the Tg(fli1:GFF) line. I was able to use 
this as a specific endothelial fluorescent reporter without the requirement to 
produce a new construct and establish a stable zebrafish line. Colleagues in our 
department have developed a dominant active form of the zebrafish hif-1α gene 
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by site-directed mutagenesis, this has generated hif-1α which lacks a PHD3 
recognition site, thus rendering the HIF-1α protein stable to bind hif-1β and 
generate a transcriptional response, despite normal cellular PHD3 and oxygen-
dependent hydroxylation (Elks et al. 2011). Their group subsequently generated 
a stable line expressing the dominant active hif-1α downstream of the UAS 
sequence: Tg(UAS:da-hif-1αb-IRES-GFP)i218 (Elks et al. 2011). This was 
crossed into a Tg(fli1:Gal4(GFF);UAS:kaede) line with the aim to produce an 
endothelial specific up-regulation of the hypoxic response and enable imaging 
of in vivo, endothelial and vessel development with the fluorescent reporter 
KAEDE to identify any phenotypic changes in the vasculature.   
The UAS dominant active hif-1α line was a kind gift from Stephen Renshaw 
(Centre for Developmental Biology and Genetics, University of Sheffield, UK). 
2.1.2.4 Transgenic Notch reporter line 
The notch reporter line Tg(CSL-venus)qmc61 was a kind gift from M. Gering 
(Nottingham, UK), this line acts as an intracellular notch-signaling reporter. The 
line is produced using the Tol2 transposase system (Kawakami 2004). A 12x 
repeat of the CBF1/suppressor of hairless/Lag-1 (CSL) binding site sequence 
with a downstream sequence for venus (a modified yellow fluorescent protein) 
flanked by the Tol2 repeats is co-injected into single cell zebrafish embryos with 
transposase mRNA. The resulting embryos expressing the fluorophore are 
raised and there progeny identified for carriage of the construct. 
The carriers of this construct express the fluorescence reporter on binding of 
the CSL transcription factor activated by NICD signalling which can be observed 
in vivo by fluorescence microscopy.  
2.1.2.5 Maintenance of adult reporter lines 
All fluorescent reporter stocks were maintained by outcrossing to wildtype 
stocks to maintain a normal genetic background and fluorescence carriers 
raised for adult breeding stocks. 
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2.1.3 Zebrafish anaesthesia 
MS222 or Tricaine (PharmaQ, Hampshire, UK) was obtained via the University 
of Sheffield veterinary services department. Stock solution contains 400 mg of 
powder in 97.9 ml milliQH2O, distilled deionized and ultra-filtered water 
(mQH20) (Millipore MA, USA) to give a final concentration of 4mg/ml, this pH 
adjusted to 7.0 with 1M Tris. This stock solution is diluted in a ratio of 4.2 ml to 
100 ml of aquarium water (final concentration 0.168 mg/ml) for adult fish 
anaesthesia, (fin clipping or other procedures). For embryo manipulation and 
sedation 420 µl of stock solution is added to 10 ml of E3 media. This final 
concentration can be adjusted depending on the duration and depth of sedation 
required, lower concentrations have been used for embryo manipulation and 
mounting for imaging. In cases where an alternative doses of anaesthesia was 
used the reason is specified, dosing is consistent across both treatment and 
control groups. 
2.1.4 Embryo collection & storage 
Embryos were obtained from pair mating an individual male and female adult 
fish over an embryo trap, enabling control over the genetic pedigree of a lay of 
embryos. Alternatively to obtain large numbers of embryos from a tank of 
identified mutants or wild type fish, marble tanks can be placed into the adult 
stock tank of up to forty fish, facilitating multiple egg lays from different females 
and fertilisation by different males (Nüsslein-Volhard & Dahm 2002). Collected 
embryos are maintained in E3 media (see section 2.1.4.1) at 28±1°C 
supplemented with methylene blue as a fungicide and antibacterial agent.  
Embryos stored in 90 mm petri dishes (Sterilin, Newport, UK) in E3 media at a 
density of 40-60 embryos to maintain adequate aeration. Unfertilised, dead or 
empty chorions were removed every 24 hr after fertilisation and the E3 
refreshed to minimise any detrimental effect on embryo growth and 
development. In all experiments embryos were maintained for up to 5.2 dpf 
prior to protected status unless being raised as adults, all embryos not raised 
for adult stocks were destroyed in bleach solution prior to 5.2 dpf. 
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2.1.4.1 E3 media 
Used as incubation media for all zebrafish embryo until 5.2 dpf. Made as a 10x 
stock and diluted with distilled H2O (dH20), contains the following at final 
concentrations and stored at 28°C: 
NaCl    5 mM 
KCl    0.17 mM 
CaCl   0.33 mM 
MgSO4   190.33 mM 
Methylene Blue 0.00005% (w/v) 
 
2.2 Identification of a zebrafish vhl hu2117 mutant allele 
2.2.1 Phenotypic identification of vhl homozygous mutants 
To obtain homozygous vhl-/- mutants requires an incross of identified 
heterozygous adult carriers by fin clipping and PCR, as vhl-/+ heterozygous 
carriers lack a vascular phenotype. Homozygous vhl-/- mutants can be sorted 
from their wild type siblings (a mixture of wild type and heterozygous carriers) 
from 3 dpf based primarily on a number of phenotypic features. 
From 3 dpf angiogenic changes can be used to identify homozygous vhl-/- 
mutants. Homozygous vhl-/- mutants showed loops of blood vessels emerging 
from the DLAV above the pigment line when embryos are imaged in a lateral 
position using a dissection microscope, enabling them to be sorted from wild 
type embryos (Figure 2.1 C & D). At 2 dpf there was some looping of the 
primitive DLAV as it begins to remodel to form the mature plexus (Zygmunt et 
al. 2012) in the wild type however these loops rarely extend above the pigment 
line. By 3 dpf in the vhl-/- mutant there are numerous loops running the length of 
the DLAV, again this phenotype can be identified with dissection microscopy 
(Figure 2.1 D arrow). In addition the vhl-/- mutant shows expansion of the 
primitive blood island, expanding the potential space between the caudal artery 
and primary caudal vein, leading to increased tortuosity of the venous system 
(Fig 2.1 D arrowhead). The final defining phenotypic feature, which identifies 
homozygous vhl mutants at this development stage, is extensive pericardial 
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oedema, shown in the homozygous mutants (Figure 2.1B arrow) and is not 
seen in the wild type siblings (Figure 2.1A arrow).  
Live imaging of these vessels and of the movement of red cells within vessels 
during cardiac contraction highlights some of these features, which may not be 




Figure 2.1 Phenotypic differences between a 5 dpf vhl-/- mutant embryo 
and a wildtype sibling. A. Bright field microscopy of the head of a 5dpf wt 
embryo arrow indicates normal pericardial sac. B. Bright field microscopy of the 
head of the vhl-/- mutant at 5 dpf, arrow indicates pericardial oedema (scale bar 
100µm). C. Mid trunk of 5 dpf wt embryo, overlay of bright field and 
Tg(kdrl;HRAS-mCherry), arrow shows normal DLAV plexus formation, 
arrowhead shows normal venous plexus size. D. Mid trunk of 5 dpf vhl-/- embryo 
with bright field and Tg(kdrl;HRAS-mCherry) overlaid, arrow shows looping of 
DLAV above the pigment line arrowhead shows expansion of venous plexus in 
the mutant embryo (scale bar 100 µm).  
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2.2.2 Genetic identification of vhlhu2117 mutation 
2.2.2.1 Gel electrophoresis 
PCR product was loaded onto a 1.5% molecular grade agarose gel (Bioline, 
London, UK) and run at 100V for 30 minutes dependent on product size. 
Hyperladder IV (Bioline, London, UK) DNA ladder was loaded (5 µl) for size 
comparison of products of 100-1000bp. Larger PCR products and visualisation 
of plasmids were run against Hyperladder I 200- 10,000 bp (Bioline, London, 
UK). Gels and PCR product were imaged using UVdoc imager (UVItec 
Cambridge, UK). 
2.2.2.2 Genomic DNA extraction 
2.2.2.2.1 Genomic DNA extraction from Fin clip 
All genomic DNA (gDNA) isolation from zebrafish fin clip samples were 
performed using a REDExtract-N-Amp Tissue PCR kit (Sigma-Aldrich, 
Gillingham, UK). To extract genomic DNA from the resected fin tissue residual 
methanol was evaporated off the sample at 80°C for 10 min. Tissue was then 
resuspended in 25 µl Extraction solution and 6.25 µl of Tissue solution and 
vortexed. This mixture was subsequently incubated at room temp for 15 min to 
complete the digestion. This mixture was then heated at 95°C for 3 min to 
denature the digestion enzyme and 25 µl of neutralisation solution added. This 
neutralised and digested tissue sample can be stored at 4°C for up to 6 months 
without degradation of genomic DNA and this buffered mixture can be added 
directly to a standard PCR mixture containing Taqman and nucleotides (Biomix 
Red). 
2.2.2.2.2 Genomic DNA extraction from individual embryos 
Isolation of gDNA from embryos less than 5.2 dpf was performed using a 
Proteinase K digest. Embryos were anaesthetised with tricaine as per protocols 
or placed on ice for fifteen minutes E3 media was removed and 25 µl of 
Phosphate Buffered Saline (PBS) (Sigma-Aldrich, Gillingham, UK) was added, 
5 µl of 10 mg/ml Proteinase K was added to the embryo and PBS then 
incubated over night at 55˚C. The enzyme was denatured at 95˚C for 15 min 
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then vortexed to mix the digested embryonic tissue and a further 25 µl of PBS 
was added. This was used directly into the PCR mixture to amplify the vhlhu2117 
allele. 
2.2.2.2.3 PCR amplification of the vhlhu2117 mutant allele 
A polymerase chain reaction is performed on the isolated gDNA extract using 
specific primers to amplify the mutated region of the vhl ortholog gene in the 
zebrafish. All PCR primers (Invitrogen, Paisley, UK) used from a 10 mM stock 
and at a final master mix concentration 0.5mM  
2.2.2.2.4 Primers for vhlhu2117 mutation amplification 
Forward 5’ TAAGGGCTTAGCGCATGTTC 3’  
Reverse 5’ CGAGTTAAACGCGTAGATAG 3’  
2.2.2.2.5 PCR mastermix for vhlhu2117 amplification 
Table 2.1 PCR mastermix components for vhlhu2117 amplification from 
genomic DNA 
Biomix Red (Bioline UK)  10 µl 
F primer 0.5 µl 
R primer 0.5 µl 
mQ H2O 5 µl 
gDNA 4 µl 




2.2.2.2.6 PCR protocol for amplification of the vhlhu2117 allele 
Table 2.2 Thermal cycler parameters for PCR amplification of a 414 bp segment 
of the mutated vhlhu2117 region (Figure 2.2 A). 
Step  Temp Time 
1 Initial denaturing 94°C 4 min 
2 Denaturing 92°C 1 min 
3 Annealing 56°C 30 sec 
4 Extension 72°C 40 sec 
5 Cycle to step 2 x39  
6 Final elongation 72°C 10 min 
7 Hold 4°C ∞ 
 
2.2.2.2.7 Restriction enzyme digest of the vhlhu2117  PCR product to identify 
mutated alleles 
The amplified vhl PCR product is incubated with the restriction enzyme BciVI 
(New England Biolabs, Ipswich, USA) to identify wildtype, heterozygous and 
homozygous vhlhu2117 mutants. The enzyme recognition site is located in the wild 
type PCR product. Figure 2.2 C shows the restriction site, the red highlighted 
cytosine is mutated in the vhlhu2117 (C/T) and thus the mutant lacks the 
recognition site for BciVI. In the heterozygous carriers there is a partial DNA 
digestion and no digestion in the homozygous mutant. (Figure 2.2 B) 
Table 2.3 Restriction enzyme mixture for digest of the wildtype vhl gene. 
vhl PCR product 5 µl 
NEB buffer 4 1.8 µl 
BciVI enzyme 0.2 µl 
mQH2O 13 µl 
Total 20 µl 
 
Incubated overnight at 37°C, the complete digestion mixture is run, 20 µl on a 




Figure 2.2 PCR amplification and restriction enzyme digest of the mutated 
region of the vhl allele in the vhlhu2117 mutant zebrafish.  
A. PCR amplification product 414bp of 3 adult fin clips (lanes 1-3) and a 
genomic DNA extraction blank (lane 4) 1.5% agrose gel run at 100 V for 30 min. 
B. Restriction enzyme digest of the vhl PCR product with BciVI restriction 
enzyme. Restriction site is preserved in the wt but not the vhlhu2117 mutant. 1.5% 
agrose gel products run for 30 min at 100 V. C. Restriction enzyme site for 
BciVI enzyme, which contains the vhlhu2117 mutation (C/T) highlighted in red.  
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2.3 In vivo imaging of embryonic zebrafish 
2.3.1 Preparation of Embryos  
2.3.1.1 Dechorionation 
Wild type embryos spontaneously dechorionate at 2.5 dpf at 28°C, however in 
mutants and transgenics this may be delayed (Nüsslein-Volhard & Dahm 2002). 
Embryos were manually dechorionated under a dissecting microscope using a 
pair of Dumont #5 tweezers (WPI, Florida, USA) to mechanically remove the 
chorions to aid normal development. 
2.3.1.2 Inhibiting embryo pigment development with 
phenylthiourea 
To enhance transparency for vascular imaging, the addition of 1-phenyl 2-
thiourea (PTU) (Sigma-Aldrich, Gillingham, UK) after shield stage (6-8 hpf) 
inhibits development of melanin in the melanophores in the skin of the embryo. 
PTU 80mg was dissolved in 25 mls of Phosphate Buffered Saline (3.2 mg/ml), 
400µl is added to 10ml E3 0.00128% (w/v). In mutant or injected embryos to 
reduce toxicity a 1:2 dilution of the PTU every 24 hr reduced pigment without 
developmental toxicity. 
2.3.1.3 Mounting of live embryos  
Embryos were mounted on glass cover slips (22x50 mm, Thermo scientific, 
New Hampshire, USA). After Tricaine anaesthesia to manipulate and sort 
embryos, they were mounted in 1% (w/v) low melting point agarose (Sigma-
Aldrich, Gillingham, UK) with 0.0168 mg/ml Tricaine. The embryos were 
positioned in the agarose during cooling in a lateral position for optimal 
visualisation of the trunk vasculature. 
2.3.1.4 Microscopy 
Fluorescence microscopy was performed using an IX81 inverted motorised 
microscope (Olympus, Southend-on-sea, UK), Ultraview VOX confocal spinning 
disc imaging system (Perkin Elmer, Massachusetts, USA). Images were 
acquired using Volocity software v5.3.2 (Perkin Elmer, Massachusetts, USA). 
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This microscope and software package was used as it enabled multiple 
embryos to be imaged with using motorised stage control, which enabled me to 
image large numbers of embryos in a single experiment. This was an important 
experimental consideration as from an incross of vhl-/+ carriers only 1:4 embryos 
will be vhl-/- so significant numbers of embryos need to be imaged in order to 
ensure the numbers of mutants in an experiment required for statistical 
significance.  
Z stack images were acquired in 2 µm slices using sequential laser scanning of 
the region of interest (ROI). All analysis and quantification of vessel parameters 
was performed using ImageJ software (v1.44 public domain software 
http://rsbweb.nih.gov/ij/). Image analysis performed on extended focus images 
of the Z-stack unless specified. 
Whole mount in situ hybridisation images were taken using a Leica M165 FC 
dissection scope and Leica DFC310 FX camera (Leica microsystems, Milton 
Keynes, UK) with sample immobilized in 100% Glycerol and illuminated with a 
Zeiss KL1500 LCD light source (Ziess microscopy, Cambridge, UK). 
2.4 Vascular quantification and measurements  
2.4.1 Calibration of images 
All measurements were calibrated to an image of a graticule (10 mm/ 0.1 mm 
division graticule, (Pyser SGI, Edenbridge, UK) taken on the same microscope 
at the same magnification. This image is then used to calibrate images taken 
using imageJ and quantify measurements. 
2.4.2 Endothelial morphology  
All measurements were taken from the mid vessel, unless specified. Aortic 
diameter was measured at a point corresponding to the adjacent mid somite 
point and calliper markings for measurement taken as the outer leading edge to 
outer leading edge of fluorescence. ISV measurements were taken above and 
below the parachordal vessel (Isogai et al. 2001) and averaged. If difficulty 
arose over overlying vessels in an extended focus image the Z stack was 
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analysed to isolate the measurement in a single vessel. Total vessel length was 
taken over two somites at the level of the cloacae for consistency, all vessels 
including sprouts were measured using the segmented line function in Image J 
software and the total obtained.  
2.4.3 Endothelial nuclei quantification 
Quantification of the number of endothelial cells using the Tg(flk1;GFP-NLS) 
reporter line were manually counted using an extended focus image of the 
vasculature of two somites at the level of the cloacae. Individual Z stack images 
were used to identify overlying endothelial nuclei and counts made of all nuclei 
of the ISV and DLAV above the level of the dorsal aorta (Isogai et al. 2001) but 
not including aortic nuclei. 
2.5 In vivo intravascular fluorescence angiograms 
Embryos were mounted as per previous method (section 2.3.2) and Quantum 
nanoparticles were injected into the circulation (Qdots) (Sigma-Aldrich, 
Gillingham, UK) to produce intravascular angiograms. Qdot 205nm non-
targeted quantum dots were injected into 4 dpf embryos at 2 µM and 200 nM 
concentration. Non-capillary 1.0mm diameter boroscillate needles (WPI Florida, 
USA) were pulled using a micropipette puller (Sutter instruments California, 
USA) and loaded with 1µl of the Qdot solution. Using a PV820 pneumatic 
picopump (WPI) and micromanipulator (WPI) the Qdots were injected into the 
Duct of Cuvier, the venous confluence overlying the yolk, at 2 and 3 dpf. This 
structure is a flat venous confluence of about 50-100 µm at the widest point. In 
older 4 dpf embryos these venous structures are less accessible for injection so 
the distal common cardinal vein or directly into the region just proximal to the 
atrium of the heart is used as the site of injection (Isogai et al. 2001). For all 
injections the embryo was immobilised in 1% agarose in a lateral position and 
the micropipette is introduced from the dorsum of the embryo over the yolk and 
into the venous circulation of the embryo.  
Using a gated injection which delivers a fixed volume using a time gated 
pressure release of compressed gas (PV820 pneumatic picopump, WPI), small 
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volumes of the working Qdot solution, were injected into the circulation. The 
delivery of the injection was observed entering the circulation by light 
microscopy due to distortion of adjacent tissues and subsequent fluorescent 
microscopy using a 488 nm laser and GFP filter to image the vascular 
opacification. The volume injected varied depending on the needle position as 
loss of the Qdot solution back along the needle track and into the subcutaneous 
tissues occurs to varying degrees, but adequate intravascular contrast can be 
assessed with fluorescent microscopy. Repeated small volume injections are 
required to avoid compromising the circulation leading to cessation of cardiac 
contraction, small volume injection also allows for intermittent visual 
assessment of the intravascular opacification. 
2.6 Morpholino antisense oligonucleotides 
2.6.1 Morpholino synthesis, reconstitution and storage 
All Morpholino (MO) were designed and synthesised by Gene Tools (Oregon, 
USA). All morpholino are made up to 1 mM stock in mQH2O and frozen -20°C. 
Prior to use aliquots of the stock solution were defrosted and heated to 70°C for 
5min to reduce secondary structure and dissolve any precipitated morpholino 
(Bill et al. 2009). The working solution is then vortexed then placed directly onto 
ice. Equal volume of Phenol red (Sigma-Aldrich, Gillingham, UK) was added to 
give a final injection concentration of 0.5 mM. To manipulate the final 
concentration of morpholino alternative dilution ratios of morpholino stock to 
Phenol red are used (specified if not 0.5 mM). 
2.6.2 Morpholino sequences 
Troponin t2 (ATG/start) blocking morpholino (Sehnert et al. 2002): 
5’ CATGTTTGCTCTGACTTGACACGCA 3’ 
Control morpholino:5’ CCTCTTACCTCAGTTACAATTTATA 3’ 
dll4 ATG morpholino (Geudens et al. 2010): 
5’ GAGAAAGGTGAGCCAAGCTGCCATG 3’ 
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2.6.3 Morpholino oligonucleotide injection into single cell 
embryos 
Single cell stage embryos were injected as per standard published methods (H 
William Detrich et al. 2011). 1.0 mm diameter borosilicate glass capillary 
needles (WPI Florida, USA) were pulled using micropipette puller (Sutter 
instruments California, USA), after filling with MO, these are mounted on a 
PV820 pneumatic picopump (World Precision Instruments Florida, USA). Using 
a dissection microscope S6E (Leica) the tip of the capillary needle is removed 
and the volume of MO injection quantified using a 10 mm/0.1 mm division 
graticule (Pyser SGI, Edenbridge, UK) and immersion oil. A sphere of MO is 
injected into the oil the diameter of the sphere can be manipulated by 
alterations in delivery pressure and duration through the Picopump. Thus a 
sphere of 100 µm has a volume of 0.52 nl (4/3πr3) after calibration a total 
volume of 1.04 nl is injected into each single celled embryo, at a stock 
concentration of 0.5mM this delivers 4.205ng of troponin t2 morpholino. Further 
alterations in MO dose were achieved through manipulation of the 1 mM stock 
by dilution with Phenol red as specified. 
2.7 Whole mount in situ hybridization 
2.7.1 Embryo fixation in paraformaldehyde 
4% (w/v) Paraformaldehyde (PFA) made in Phosphate buffered saline (PBS) 
stored at -20°C in 10ml aliquots. Embryos fixed in defrosted solution for 2 hr at 
room temperature or at 4°C overnight. Fixed embryos are dehydrated in stages 
into 25%, 50%, 75% and finally 100% Methanol (v/v) (Fisher, Paisley, UK) and 
then stored at -20°C  
2.7.2 Reagents & Buffers 
All reagents obtained from Sigma-Aldrich, Gillingham, UK unless otherwise 
specified. 
• Phosphate buffered saline: 1 (PBS) tablet dissolved in 200 ml of mQH2O. 
• PBS-tween (PBT): 1x PBS + 0.1% (w/v) Tween 20.  
 49 
• Proteinase K 10 µg/ml in PBT  
• 20x SSC buffer: 3 M NaCL, Citric acid trisodium salt 300 mM 
• Hybridisation solution: 50% (v/v) formamide, 5xSSC, 0.1% (v/v) Tween 
20, 50 µg/ml of heparin, 500 mg/ml of RNase-free tRNA, 5% dextran 
sulphate, solution adjusted to pH 6.0 with citric acid (460 ml of 1M citric 
acid solution for 50 ml of hybridisation solution).  
• Maleic acid buffer (MABTw): 0.1 M Maleic acid, 0.15 M NaCl, pH  to 7.5 
with NaOH (1 M), Tween20 0.1% 
• BCL III buffer: 0.1 M Tris HCl (pH 9.5), 50 mM MgCl2, 0.1 M NaCl, 0.1% 
(v/v) Tween20 
• Staining solution: 1:1 of BCLIII and BM Purple (Roche diagnostics 
Germany). 
• Blocking solution 2% (v/v) Blocking reagent (Boehringer Ingelheim, UK) 
in MABTw  
• anti- DIG antibody (1:5000 dilution) (Roche, UK) 
• Glycerol 25%-100% (v/v) for mounting  
 
2.7.3 Outline of method for whole mount in situ hybridisation 
2.7.3.1 Embryo permeabilisation 
Proteinase K 10 µg/ml was used to enable RNA probe penetration for whole 
mount in situ hybridisation; duration of incubation was dependent on the age of 
the embryo. 
Table 2.4 Duration of proteinase K digestion to permeabilise embryonic 
tissue for WISH 
Embryo age Incubation proteinase K (10µg/ml) 
24 hpf 15 min 
48 hpf 35 min 
72 hpf 45 min 
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2.7.3.2 Method for WISH 
We used a modification of the published method, (C. Thisse & B. Thisse 2008) 
embryos are rehydrated by successive washes in increasing PBT/methanol 
mixture. The tissues are then permeabilised with proteinase K (Sigma-Aldrich, 
Gillingham, UK) as per section 2.7.3. The embryos are then re- fixed in 4% PFA 
(w/v) solution, after a series of washes they are then pre- hybridised at 68°C for 
2-5 hr before adding the probe in hybridisation mixture with dextran 5% (w/v) 
(Lauter et al. 2011) overnight at 68°C at a dilution of 1:200. The probe is then 
recovered and a series of washes in increasing concentrations of 2x SSC and 
then MABTw. Blocking buffer is then added for 3 hours to minimise the effect of 
non-specific probe binding, the embryos are then incubated overnight at 4°C 
with secondary anti-Digoxigenin (DIG) antibody (1:5000 dilution) (Roche, Wellyn 
Garden City, UK). After a series of washes to remove any residual antibody, the 
embryos are transferred to staining solution until adequate staining is observed, 
the duration of staining is specific to each probe.  
2.7.3.3 Methanol clearing 
A methanol clearing step can be used to remove any excess background 
staining after which the embryos are then fixed in 4% PFA (w/v) for 20min at 
room temperature, prior to imaging. 
2.7.3.4 Imaging and mounting of WISH stained embryos 
Embryos are incubated in successively increasing concentrations of glycerol 
(Sigma-Aldrich, Gillingham, UK) and mounted on coverslips. Imaging of whole 
mounts was with a Leica M165 FC dissection scope and DFC310 FX digital 
camera, using a Zeiss KL1500LCD external light source. 
2.7.4 RNA antisense probe synthesis for in situ hybridisation 
2.7.4.1 Outline of RNA antisense probe synthesis for whole mount 
in situ 
Antisense RNA probes are generated against known mRNA sequences this 
enables complimentary binding to the mRNA and subsequent labelling to 
localise the expression of the target mRNA within the embryo. This means that 
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the spatial distribution of a specific gene and the timing of it’s expression can be 
demonstrated in the whole organism in a qualitative manner. The antisense 
probes are synthesised using digoxigenin labelled bases, which are 
synthesised from a DNA sense strand using an RNA polymerase specific to the 
gene fragment of interest. Once purified this enables the probe to be used to 
hybridise to the mRNA of interest and then using an anti-DIG antibody labelled 
for visualisation. 
2.7.4.2 RNA antisense probes for WISH 
Table 2.5 List of RNA antisense probes used for WISH with the 
restriction site, RNA polymerase and original reference. 
A/S Probe RNA polymerase Restriction site Reference 
fli1 T3 XbaI (Brown et al. 
2000)  
kaede Sp6 NotI unpublished 
dll4 T7 SpeI R.Patient 
cxcr4a T7 Not 1 (Knaut et al. 
2003) 
kdr-l T7 EcoRI (Fouquet et al. 
1997) 
her12 T3 (primer) EST clone unpublished 
flt4 T7 EcoRI (Thompson et al. 
1998) 
vegfc T7 EcoR1 (Hogan, Herpers, 
et al. 2009b) 
 
Many of the antisense RNA in situ probes used in this project have been 
synthesised from plasmids kindly provided by the original groups and linearised 
based on restriction enzyme sites and sequences as published. The kaede 
antisense probe was synthesised de novo, and the her12 probe was 
synthesised from an EST clone by a project student our lab (Freek van Eeden 
Sheffield, UK). The dll4 probe was a kind gift from Roger patients lab (Oxford, 
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UK) The restriction site and RNA polymerase in conjunction with the plasmid 
provides the DNA template for RNA antisense probe synthesis as per standard 
methods (C. Thisse & B. Thisse 2008). 
2.7.4.3 Extraction of plasmid from blotting paper 
Blotting paper containing a purified plasmid is placed in 100 µl of mQH2O to 
dissolve the plasmid. This is then mixed for 5 min using a pipette tip and then 
incubated at 37°C for 2hrs to ensure adequate plasmid goes into solution. This 
solution of purified plasmid is then used to transform competent cells directly or 
can be stored at -20°C for later use. 
2.7.4.4 Transformation of Competent cells for plasmid synthesis 
2.7.4.4.1 Reagents 
• LB broth (Sigma-Aldrich, Gillingham, UK) 20g / 1l mQH2O + ampicillin 
(amp) 50 µg/ml  
• LB agar (Sigma-Aldrich, Gillingham, UK) 17.5g/500ml mQH2O 
autoclaved +amp 50 µg/ml 
• SOC media (Sigma-Aldrich, Gillingham, UK) 
2.7.4.4.2 Method for transformation of E.Coli 
DH5α chemically competent cells (Sigma-Aldrich, Gillingham, UK) were used 
for transformation with plasmid-derived sequences. 100 µl of competent cells 
are defrosted on ice from -80°C, 2 µl of ligated plasmid was added and 
incubated on ice for 30 min. The cells are then transformed by heat shock, 
incubating at 42°C for 30 sec and then immediately transferred to ice for 2 min. 
250 µl of SOC media (Sigma-Aldrich, Gillingham, UK) is added then incubated 
at 37°C at 225 rpm (Innova44, New Brunswick scientific, Enfield, USA). 1/10th 
and 9/10th   of the total volume is then inoculated onto sterile petri dishes of LB 
agar +amp and incubated for 12 hr at 37°C. Individual colonies were picked for 
inoculation of 200 ml of LB broth +amp and grown overnight in conical flasks at 
37°C in an orbital shaker incubator at 225 rpm. 
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2.7.4.4.3 Glycerol stocks of plasmids transformed into competent cells 
500 µl of the inoculated LB broth is aliquoted into 1.5 ml eppendorf with 500 µl 
of sterile glycerol (Sigma-Aldrich, Gillingham, UK) this is stored at -80°C. This 
allows a stock of the transformed E.Coli to be reconstituted rapidly by 
inoculation of fresh LB broth using only a pipette tip scape of the frozen 
glycerol. 
2.7.4.4.4 Purification of plasmid DNA from transformed competent cells 
2.7.4.4.4.1 MIDI prep purification of Plasmid DNA 
The 200 ml of inoculated LB broth is centrifuged 4500 rpm for 30 min at 4°C the 
resulting pellet of cells is purified by plasmid MIDI DNA purification kit (QIAGEN, 
Manchester, UK). 
2.7.4.4.4.2 Phenol Chloroform DNA purification of linearised plasmid 
To improve the yield for low copy number plasmid transformation a 
phenol/chloroform purification of plasmid DNA can be used instead of MIDI prep 
purification. This purification is also used to purify probes synthesised de novo 
after the restriction enzyme digestion prior to RNA probe synthesis (section 
2.7.4.6.): 
• 400 µl of Plasmid DNA combined with 400 µl 
Phenol:chloroform:isoamyalcohol (25:24:1) (Sigma-Aldrich, Gillingham, 
UK) 
• Mix then centrifuge 13,000 rpm for 5 min at room temp 
• To the supernatant add 400 µl Chloroform:isoamyalcohol (24:1) (Sigma) 
• Mix then centrifuge 13,000 rpm for 5 min at room temp 
• To removed supernatant add 40 µl 2 M Sodium acetate and 1 µl ethanol 
and freeze at -80°C for 30 min 
• Centrifuge at 13,000 rpm for 30 min at 4°C 
• Remove supernatant and wash pellet with 70% (v/v) ethanol then air dry 
• Resuspended in RNAse free H2O (Sigma-Aldrich, Gillingham, UK) 
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2.7.4.4.5 Linearisation of plasmid and RNA Probe transcription 
Plasmids were linearised in a restriction enzyme step using specific enzyme 
(see table 2.5) (New England Biosciences, Ipswich, USA) and appropriate 
buffer based on original published method. After confirmation of linearisation of 
the plasmid and quantification by gel electrophoresis, purification using the 
phenol chloroform method (section 2.7.4.4.4.2) was performed to remove any 
residual enzymes and nucleotides. Quantification of linearised plasmid was 
performed by spectrophotometry (Nanodrop ND100 spectrophotometer, 
ThermoFisher Scientific, Paisley, UK) and 1 µg of template DNA was used for 
RNA transcription using a DIG labelled transcription kit (Roche, Wellyn Garden 
City, UK). 
RNA probes were purified after RNAse free DNAse treatment (Roche, Wellyn 
Garden City, UK) by precipitation into 7.5 M Ammonium acetate and 100% 
ethanol at -20°C. All purified digoxygenin labelled RNA probes stored in 70% 
formamide (v/v) (Sigma-Aldrich, Gillingham, UK) at -80°C. The probes were 
used at a final dilution of 1:200 in Hybridisation mix (section 2.7.2) for embryo 
WISH. 
2.8 Synthesis of a novel RNA antisense DIG labelled 
probe  
For confirmation of kaede expression I synthesised a novel RNA DIG-labelled 
antisense probe, using the TOPO TA cloning and transformation kit (Sigma-
Aldrich, Gillingham, UK). This kit allows the insertion of a Taq polymerase PCR 
product to be cloned directly into the TOPO vector for transformation of One-
shot Top10 cells (Sigma-Aldrich, Gillingham, UK). This vector has a number of 
restriction sites and RNA polymerase sites to allow easy determination of insert 
direction and probe synthesis. 
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2.8.1 Synthesis of a kaede PCR product for TOPO TA cloning 
2.8.1.1 Total RNA extraction from kaede positive transgenic 
embryos 
An incross of the Tg(fli1;GFF:UAS;kaede) was used to identify embryos 
expressing kaede based on fluorescence. 20 fluorescence positive embryos 
were pooled and 20 wild type embryos from a LWT incross with no kaede 
expression. Total RNA was extracted into 250 µl of Trizol reagent (Sigma) and 
homogenised by repeat aspiration through a 25 g needle (microlance 3 BD, UK) 
and 1 ml syringe (Plastipak BD, UK). RNA was extracted using 50 µl of 
chloroform after centrifugation (13,000 rpm, 15 min at 4˚C) the supernatant was 
precipitated into 85 µl of Isopropanol (Fisher, UK). A pellet was formed by 
centifugation (13,000 rpm, 15 min at 4˚C) and washed in 75% ethanol (v/v), 
then resuspended in 15 µl of RNAase free H2O and quantified by 
spectrophotometry Nanodrop ND100 spectrophotometer, (ThermoFisher 
Scientific, Paisley, UK).  
2.8.1.2 Reverse transcription to produce cDNA of kaede 
Reverse transcription to synthesise a cDNA library from embryonic total RNA 
including the kaede transgene was performed using the Superscript II kit 
(Invitrogen, Paisley, UK). Effective synthesis was confirmed by gel 
electrophoresis and this cDNA was stored at -20˚C.  
2.8.1.3 PCR to amplify kaede sequence from cDNA library 
The sequence for the kaede mRNA was obtained from the European 
bioinformatics database where it was identified from a BAC clone. 
(http://www.ebi.ac.uk/ena/data/view/BAC20344) Primers were designed using 
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/) 
a primer pair was chosen which gave a 504 bp product from the 678 bp gene. A 
nucleotideBLAST search (http://www.ncbi.nlm.nih.gov/BLAST/) using this kaede 
PCR product against the zebrafish genome showed no alignment with any other 
endogenously expressed genes as would be expected with a transgene. Figure 
2.3 A shows a single PCR product of the expected size by gel electrophoresis. 
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The PCR product was purified and sequenced to confirm that the band 
represented the desired segment of the kaede gene. 
2.8.1.3.1 kaede primer sequences 
Forward 5’ TAAACGGGCACCAGTTTGTT 3’ 
Reverse 5’ ACTTGACACCCTCCTGCCTA  3’ 
2.8.1.3.2 PCR programme for amplification of kaede DNA sequence 
Table 2.6 PCR programme parameters for kaede amplification 
Step  Temp Time 
1 Initial denaturing 94°C 4 min 
2 Denaturing 92°C 1 min 
3 Annealing 54°C 30 sec 
4 Extension 72°C 40 sec 
5 Cycle to step 2 x35  
6 Final elongation 72°C 10 min 
7 Hold 4°C ∞ 
 
Annealing temp taken as 5˚C less than the lowest melting temp of the primer 
pair (59.7˚C). A mastermix was used as per table 2.1 substituting 1 µl of cDNA 
as PCR template for the gDNA.  
2.8.2 TOPO TA cloning vector for insertion of a Taq 
polymerase amplified PCR product  
A feature of the Taq DNA polymerase is that it produces an adenine base 
overhang on the PCR product, the TOPO TA cloning system utilises this 
features and a thymine overhang on the ends of the linearised vector to enable 
accurate insertion of the PCR product for cloning, by the Topoisomerase 
enzyme. 
2.8.2.1 Incorporation of the PCR product into the TOPO TA cloning 
vector 
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1µl of the kaede PCR product was added to 1 µl of the TOPO TA vector, 1 µl of 
salt solution (TOPO TA cloning kit Invitrogen, Paisley, UK) and 3 µl of mQH2O. 
This is incubated for 5 minutes at room temperature then transferred to ice for 
immediate transformation of chemically competent E.Coli. 
2.8.2.2 Transformation of chemically competent cells for cloning 
of PCR product and construct 
2µl of the TOPO cloning reaction is added to a vial of OneShot chemically 
competent E.Coli (Invitrogen, Paisley, UK) and incubate on ice for 30min. The 
cells are then heat shocked for 42˚C for 30 sec in a non circulating water bath 
and transferred to ice where 250 µl of 37˚C SOC media is added then transfer 
to 37˚C rotating incubator at 225 rpm for 1hr. 1/10th and 9/10th of this culture is 
inoculated onto LB agar +amp  petri dishes and incubated at 37˚C overnight. 
2.8.2.3 Selecting colonies for insert confirmation and glycerol 
storage 
10 individual colonies were selected and picked and sub-cloned onto LB agar 
plates +amp, then each of these was re-picked to perform colony PCR and 
sequencing to identify correct insert and the orientation of sense and antisense 
to produce complimentary RNA sense and antisense probes. Each of these 
colonies was grown in 10 ml of LB broth from which glycerol stocks were taken 
500 µl of inoculated LB was mixed with 500 µl of sterile glycerol then frozen at -
80˚C, until sequencing results were available. 
2.8.2.4 Large scale Plasmid DNA purification 
After confirmation by DNA sequencing using M13 forward and reverse priming 
sites confirmation of the correct insert and its orientation in each colony PCR. 
The glycerol stock for the selected colony can be grown in 200ml of LB broth 
overnight in a conical flask at 37˚C in a rotary shaker 225rpm to produce large 
amounts of the plasmid and insert. The cell compartment is isolated from this 
mixture by centrifugation in 50 ml Falcon tubes at 4500rpm for 30min. Plasmid 
DNA is then purified from this bacterial pellet using a MIDIprep kit (Qiagen, 
Manchester, UK) to produce a concentrated solution plasmid DNA, which can 
be used to provide a template for RNA probe synthesis after linearisation. 
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2.8.2.5 Plasmid linearisation for kaede probe synthesis 
Restriction enzyme site was chosen based on pre-existing restriction sites in the 
vector, and the colony PCR sequencing data. This allows for a restriction 
enzyme and RNA polymerase pair to be selected to synthesise a sense and 
antisense RNA probe depending on the orientation that the PCR product is 
inserted into the vector. For synthesis of an antisense RNA probe a NotI 
restriction site was selected and for a sense RNA probe a HindIII restriction site 
was selected. The kaede insert was checked to ensure that there was no 
restriction site within the insert for either of the selected restriction enzymes. 
Restriction enzymes were obtained from New England biosciences USA and 
purified plasmid DNA incubated as per manufacturers recommended 
conditions. Linearised DNA was run on an agarose gel to confirm successful 
linearisation along side uncut purified plasmid DNA. 
2.8.2.6 RNA probe transcription 
For probe synthesis 1 µg equivalent of linearised and purified plasmid is used 
as a DNA template. The restriction site is selected downstream of the PCR 
product insert so that the selected RNA polymerase site initiates synthesis of 
the RNA probe upstream of the PCR insert until the cut site after the insert. For 
the kaede antisense probe Sp6 was the RNA polymerase used and for the 
sense probe T7 RNA polymerase. RNA DIG-labelling kit (Roche, Wellyn 







Figure 2.3 PCR of cDNA from embryos expessing kaede and wild types for 
cloning into TOPO TA cloning system. 
1.5% agrose gel, run at 100V for 30 min, Hyperladder IV in lane 1, PCR product 
using kaede primers with wildtype cDNA in lanes 2 and 3 (wt1 and wt 2). Lanes 
4 & 5 show a single PCR product of ~510bp from cDNA isolated from kaede 
expressing embryos (k1 & k2). EB, extraction blank no tissue in extraction and 




2.8.2.7 RNA probe purification 
After probe synthesis there is a DNAse treatment for 30 min at 37˚C to degrade 
any remaining DNA template. Then the probe is precipitated into Ethanol 
(Fisher, Paisley, UK) with 7.5 M Ammonium acetate and spun down (13,000 
rpm 15 min at 4˚C) to form a pellet which is washed in 70% Ethanol (v/v) then 
resuspended into 30 µl of RNAse free H2O and 70 µl of formamide (Sigma-
Aldrich, Gillingham, UK) and stored at -80˚C. Kaede sense and antisense 
probes were both used at a final dilution of 1:100 in hybridisation mix with 5% 
(w/v) dextran sulphate.  
2.9 Immunohistochemistry 
2.9.1 Phosphorylated Histone H3 antibody 
immunohistochemistry 
Histone H3 is one of the protein constituents of chromatin, during mitosis this 
particular histone H3 is phosphorylated at a specific serine residue. 
Immunohistochemistry of this marker of cell division enables the identification of 
actively dividing cells, which can be co-localised to transgenic cells in the 
developing zebrafish embryo to identify differences in proliferation in specific 
cell groups. I attempted to co-localise PH3 Ab staining to endothelial cells to 
look at differences in endothelial proliferation between the vhl-/- mutant and it’s 
wild type siblings.   
2.9.1.1 Method for PH3 immunohistochemistry 
Embryos were fixed as for WISH (see section 2.7.1) in groups of 20 embryos of 
matched developmental stage. The embryos were rehydrated back into PBS 
through reducing percentage of methanol (75%, 50% and 25%). They were 
washed in PBS to remove any residual solvent then incubated in 100% acetone 
(Fisher, UK) for 7 min at -20˚C then washed in PBS. The embryos were then 
permeablised as per WISH (table 2.4) with proteinase K (10 µg/ml) then fixed in 
PFA 4% (w/v) for 20 min at RT. After washing in Maleic acid buffer with tween 
20 0.1% (MABTw) and blocking buffer for 2 hours the embryos were incubated 
with the PH3 primary antibody (1:200) overnight at 4˚C.  After repeated MABTw 
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washes to remove any unbound primary antibody the secondary antibody 
sheep anti-rabbit antibody conjugated to Alexa 546 fluorophore (1:500) was 
incubated with the embryos in 2% blocking buffer (w/v) (Roche, Wellyn Garden 
City, UK) overnight at 4˚C. Embryos washed in PBS then gradually equilibrated 
in gycerol 75% (v/v) and stored at 4˚C until imaging, see section 2.3.2 and 
2.3.3. 
2.10 Pharmacological manipulation of the zebrafish 
embryo 
2.10.1 Pharmacological manipulation of the nitric oxide 
pathway 
2.10.1.1 Inhibition of nitric oxide synthase 
l-nitro arginine methyl ester (l-NAME) is a non-specific inhibitor of the nitric 
oxide (NO) synthase enzyme. l-NAME (Sigma-Aldrich, Gillingham, UK) was 
made up in E3 media with 1% DMSO as solvent then diluted to a final 
concentration of 1mM as per the method previously published (North et al. 
2009). Although L-NAME has good solubility published data using small 
molecule drug screens and local methods for drug exposure using embryonic 
zebrafish use DMSO as an initial solvent with subsequent dilution into E3. This 
working solution was added to embryos from 24hr post fertilisation and 
exchanged with freshly made L-NAME every 24hr due to the short half-life of 
the drug. All imaging was performed in 1% (w/v) low melting point agarose 
made with the L-NAME dosed E3 media. 
2.10.1.2 Pharmacological addition of nitric oxide 
Sodium nitroprusside acts as a NO donor to increase the available NO in vivo. 
This compound has been used by a previous PhD student in our lab and has 
been shown to produce reproducible vascular effects in the developing 
zebrafish embryo at the time points I was interested in observing, with existing 
methods. Sodium nitroprusside (Sigma-Aldrich, Gillingham, UK) was made up 
in 1% DMSO (Sigma) and diluted in E3 to a final concentration of 100 µM. 
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Media with the active compound was made up fresh and exchanged every 24 
hrs. 
2.10.1.3 Detection of NO signalling in the developing zebrafish 
embryo 
The diaminofluorophore 4-amino-5-methylamino-2-7-difluorofluorescein-
diacetate (DAF-FM-DA) (Molecular probes, Invitrogen, Paisley, UK) fluoresces 
in the presence of NO. This fluorescence, which can be detected using laser 
excitation at a wavelength of 488 nm and detected at 530 nm has been used to 
identify alterations in NO production in the developing zebrafish embryo in vivo 
(Lepiller et al. 2007). Data from this paper shows this fluorophore to be a 
specific reporter of NO levels in the developing zebrafish embryo, reduction in 
fluorescence was seen after incubation with the NOS inhibitor N-monomethyl-L-
arginine monoacetate (L-NMMA) and a specific NO scavenger carboxy-2-
phenyl-4,4,5,5- tetramethylimidazolinone-3-oxide-1-oxyl (c-PTIO). Levels of the 
reporter were also increased in the zebrafish embryo by SNP exposure a NO 
donor. Embryos incubated in 5 µM final concentration of DAFF-FM for 2 hours 
at 28°C protected form light. The embryos are then mounted as per previous 
methods for in vivo fluorescence imaging (section 2.3.2)  
2.10.2 Pharmacological manipulation of the Notch signalling 
pathway 
2.10.2.1 Inhibition of notch signalling with DAPT 
N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) is 
a gamma secretase inhibitor which inhibits the enzymatic cleavage of the Notch 
ligand receptor complex at the cell membrane. This leads to reduction of Notch 
receptor, which activates transcription of Notch target genes in the signalled 
cell. DAPT stored at 50 mM stock in DMSO was used for zebrafish experiments 
diluted into E3 media at final concentrations of 100 µM and 0.2% (v/v) DMSO. 
The DAPT was added to the embryo media at 48 hpf until imaging and 
quantification at 72hpf. 
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2.11 Real time reverse transcription quantitative 
polymerase chain reaction 
Real time reverse transcription quantitative polymerase chain reaction (RT-
qPCR) allows for the quantitative assessment of mRNA expression in differing 
environmental conditions. The expression of a gene of interest is normalised to 
expression levels of a known housekeeping or control gene, the expression 
level of which should remain constant between the conditions. Using a PCR 
reaction the amplification rates of the gene of interest in the different conditions 
can be compared to derive differences in gene expression or mRNA/cDNA copy 
number after normalisation for housekeeping gene expression differences. This 
technique allows us to quantify the effect of different conditions on even very 
lowly expressed genes by virtue of the PCR amplification phase of the RT-
qPCR reaction. We used SYBR-green for quantification for our RT-qPCR 
reactions; this fluorophore incorporates into double stranded DNA and causes 
fluorescence. This fluorescence allows the detection and quantification of 
double stranded DNA amplification by PCR reaction after each amplification 
cycle. 
2.11.1 Isolation of zebrafish embryonic total RNA 
2.11.1.1 Tissue preparation for RNA extraction 
For total RNA isolation I chose to use the trunk tissue from the embryonic 
zebrafish to look at expression differences in the vascular tissue and 
surrounding peri-vascular tissue. As we were interested in the changes in gene 
expression related to different flow conditions we were unable to isolate 
endothelial tissue from the other tissues of the trunk as the time taken to isolate 
it was felt would alter the expression levels. 
The trunk and tail of the Tricaine anaesthetised zebrafish was isolated from the 
head using a scalpel blade #6 (Swann-Morton, Sheffield, UK) and forceps 
Dumont #5 tweezers, the trunk and tail tissue was then immediately transferred 
to 250 µl TRIzol (Sigma-Aldrich, Gillingham, UK) on ice. For 48 hpf embryos 30 
sectioned embryo trunks were pooled together, for 72 hpf embryo 20 trunks 
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were pooled to ensure adequate yields of total RNA. The pooled tail sections in 
TRIzol were then snap frozen in liquid nitrogen and transferred directly to the -
80˚C freezer until total RNA extraction. The rapid processing and snap freezing 
is performed to minimise the possibility of RNA degradation after tissue 
sectioning and allows multiple groups of total RNA to be extracted together 
without any time delays or differences in processing time which may influence 
subtle expression changes in the tissue. 
2.11.1.2 RNA extraction 
Pooled tail sections were transferred from -80˚C freezer directly on to ice and as 
the TRIzol reagent melted the tissue was homogenised using an eppendorf 
pestle (Carl Roth, Karlsrhue, Germany) and then aspirated through a 1 ml 
syringe (plastipak BD, New Jersey, USA) and 25 gauge needle (Microlance 3 
BD, New Jersey, USA) to fully homogenise the tissue for RNA extraction. 50 µl 
of chloroform is added to the homogenate and TRIzol reagent, inverted and left 
at room Temperature (RT) for 3 min then centrifuged at 13,000 rpm for 15 min 
at 4˚C. The aqueous supernatant containing the RNA is removed and is then 
precipitated into 85 µl of isopropanol and pelleted by centrifugation (13,000rpm, 
15 min at 4˚C). This is resuspended in 15 µl of RNAse free H2O and stored at -
80˚C until required for reverse transcription to form cDNA. Prior to storage RNA 
is quantified by spectrophotometry Nanodrop ND100 spectrophotometer, 
(ThermoFisher Scientific, Paisley, UK). 
2.11.2 Reverse transcription of extracted total RNA 
cDNA synthesis is performed using the Verso reverse transcriptase kit (Thermo 
scientific, Paisley, UK). 1 µg equivalent of RNA template is initially heated to 
70˚C for 5 min to remove any secondary structure incubated with a synthesis 
buffer, reverse transcriptase enhancer, verso enzyme and primer mixture. A 
primer mixture of 3:1 (v:v) of random hexamers:oligo-dT was used for all cDNA 
synthesis of zebrafish total RNA. The reaction was incubated at 42˚C for 30 
min, then cDNA quantified by Nanodrop spectrophotometer and stored at -
20˚C. 
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2.11.3 Identification and optimisation of primers for real time 
RT-qPCR 
2.11.3.1 Genes anaysed and primers for RT-qPCR analysis 






Primer Seq  






vegfab NM_001044855.2 CAGTGTGAGCCTTGCTGTTC 
CCATAGGCCTCCTGTCATTT 
102.7 230 













flt4 NM_130945 TCTCGTTAGTGCCGTATCCA 
GATGATGTGTGCTGGCTGTT 
98.6 164 
ephrinB2 NM_131023 ACCACGTTGTCACTCAGCAC 
AGATGTTTGCTGGGCTCTGT 
93.3 205 























cxcr4a NM_131882 TTGTGCTCACTCTGCCATTC 
ACCGGTCCAAACTGATGAAG 
90 144 




Primers were designed using Genscript RT-qPCR primer design software 
(http://www.genescript.com/) to produce a PCR product of between 70 and 
250bp.  
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2.11.3.2 Primer optimisation for RT-qPCR 
2.11.3.2.1 Primer specificity 
Primers were then run on a gradient PCR program with wildtype cDNA as a 
template, the gradient provides a range of annealing temperatures in 1˚C 
increments across the thermal cycler. This enables the optimum annealing 
temperature to be identified and when the product is then run on an agrose gel 
confirmation of a single and thus specific PCR product can be determined. If a 
primer pair, produce multiple bands across the annealing temperature gradient 
then new primers are designed for the gene of interest, as specificity is 
inadequate. Confirmation of the specificity of the PCR product is done by DNA 
sequencing (Core facility University of Sheffield Medical school, UK) of the 
purified PCR product then in silico analysis of sequence similarities using 
BLASTn (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to search against the zebrafish 
genome. 
2.11.3.2.2 Primer efficiency 
Primer pairs were then run using the IQ SYBR-green mastermix (Bio-Rad, 
Hemmel-Hempstead, UK) with a standard curve of wildtype cDNA serial 
dilutions from 10 pg-1 µg. Accepted primer efficiency for RT-qPCR is 90-105%, 
the efficiency of our primers is derived by calculating the slope of the line of 
best fit for the cDNA standard curve, slope of 3.32 correlates to a primer 
efficiency of 100% (Graphpad Software, San Deigo, USA). Each standard curve 
was run in duplicate with non-template controls to derive primer efficiency data. 
2.11.4 Analysis of real time RT-qPCR data 
All RT-qPCR was performed on a MyIQ single colour real time PCR detection 
system (Bio-Rad, Hemel-Hempstead, UK) using IQ SYBR-green supermix (Bio-
Rad, Hemel-Hempstead, UK). Each gene of interest and control gene (β-actin2) 
pair was run in duplicate to ensure technical reproducibility of the PCR 
amplification. The analysis was performed on 3 biological replicates of cDNA, 
which was pooled from 20-30 embryos depending on the age of embryos to 




Table 2.8 SYBR-green mastermix for  RT-qPCR 
SYBR-green supermix 10 µl 
F primer (conc as per optimisation) 0.5 µl 
R primer (conc as per optimisation) 0.5 µl 
mQ H2O 5 µl 
cDNA (conc as per optimisation) 1 µl 
total 20 µl 
 
Data analysis was performed on IQ5 optical system software (Bio-Rad, UK) 
which converts the raw Relative Fluorescence Units (RFU) into a mean 
threshold cycle for replicated samples based on plate templates. The cycle 
threshold (Ct) is then used to obtain a ΔΔCt value which adjusts the change in 
expression of the gene of interest to any change in expression of the control 
gene (β-actin2) this can then be converted into a fold change for the gene of 
interest by the equation: 2^-( ΔΔCt). Graphical representation of the 
amplification rates of a number of assayed genes as generated by the analysis 
software can be seen in figure 2.4 A, each individual coloured line represents 
an individual gene with the point it crosses the threshold (horizontal green line) 




Figure 2.4 Fluorescence amplification data and melt curve analysis from 
RT-qPCR for multiple gene targets and biological replicates. 
A. Graph showing the fluorescence amplification (RFU) of individual PCR 
reactions (coloured line) against PCR cycle. B. Melt curve data showing a single 
fluorescence peak for the majority of PCR products indicating single PCR 
product. Light blue line shows multiple peaks that may indicate contamination 
with multiple primers or excess primer dimer product.   
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2.11.4.1 Melt curve 
On completion of the PCR amplification the PCR product is analysed for 
specificity by quantifying the amount of fluorescence during incremental heating 
of the product. In the presence of a single PCR product all the fluorescence will 
be lost in a tight temperature range as the single product has a specific size 
dependent denaturing temperature. If the multiple products are present as a 
result of non-specific priming then multiple melt curve peaks will be seen for a 
single gene product. This provides additional confirmation of specific gene 
amplification for each RT-qPCR analysis (Figure 2.4 B). 
2.12 Statistics 
2.12.1 Statistical analysis and significance 
All statistical analysis and graphical representation was done with GraphPad 
Prism v5.0 Software (GraphPad Software, San Diego USA). Data presented as 
mean ± Standard error of the mean (SEM), n notates the number of embryos in 
the group analysed. The statistical test used to analyse significance is 
annotated in the individual figure along with the post-test analysis where 
appropriate 
2.12.2 Graphical annotation of significance 
Table 2.9 Statistical significance as represented on all graphical results. 





2.12.3 Power calculations 
Post hoc power calculation performed using G*power v3 software 
(http://www.psycho.uni-duesseldorf.de/abteilungen/aap/gpower3/download-and-
register) open source software.  
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Chapter 3 Characterisation of the 
angiogenic phenotype of the Von 





Hypoxic signalling drives angiogenesis in both normal physiology and 
pathology. The vhl homozygous mutant zebrafish has been shown previously to 
undergo angiogenesis as a result of constitutive hypoxic signalling (Van Rooijen 
et al. 2009). In this chapter I have extended these initial descriptions by 
undertaking a detailed assessment of development of the intersegmental and 
dorsal longitudinal vessels of the vhl-/- mutant compared with wildtype, as a 
preliminary to mechanistic studies in later chapters. This characterisation will 
enable me to use this model to test hypotheses regarding the role of regulatory 
pathways in the genesis of these angiogenic vessels. 
3.2 Results 
3.2.1 Characterisation of the vascular phenotype of the vhl-/- 
mutant 
3.2.1.1 Formation of the intersegmental artery in the vhl-/- mutant 
Tg(vhlhu2117-/-;fli1:eGFP) embryos were imaged using spinning disc confocal 
fluorescence microscopy and the vascular pattern compared to that of wildtype 
controls (Figure 3.1). I focused on formation of the ISV, an easily imaged 
vessel. These have been extensively studied and provide an accessible model 
of embryonic vessel formation. The ISV is formed from angiogenic sprouts 
emerging from the aorta and primary cardinal vein. This vessel is one of the 
earliest vessels formed in the developing zebrafish embryo (Isogai 2003; Childs 
et al. 2002), beginning around 21 hpf. 
My observations of vessel patterning in 2 dpf vhl mutants revealed little or no 
differences in vessel patterning, even though the ISVs have already formed by 
this stage. However, at 3 dpf, I found that the diameter of ISVs in vhl mutants 




3.2.1.1.1 Increased diameter of the DLAV in the vhl-/- mutant 
The DLAV forms from the angiogenic sprouts of the ISV which join with 
ipsilateral sprouts from adjacent somites and subsequently branch across the 
midline to form the DLAV plexus which progressively remodels into a single 
vessel from two initially adjacent vessels during development (Zygmunt et al. 
2012) (Figure 3.1 arrowhead). Since this vessel is formed after the ISV is 
established, and by a somewhat different process of fusion and remodelling 
(Armer et al. 2009), I wanted to see if the enlargement in diameter seen in the 
ISV was also seen in the DLAV. Figure 3.2 C shows that the increase in 
diameter of the DLAV at 3 dpf is about 60%, even greater than the increase 




Figure 3.1. Comparison of trunk vessel morphology in the vhl-/- mutant 
and wildtype at 3dpf.  
A. Wild type Tg(fli1:eGFP) imaged at the mid trunk at 3 dpf, * indicates paired 
intersegmental vessel (ISV) and ^ indicates the dorsal longitudinal vessel 
(DLAV) Scale bar 50 µm. B. vhl-/- mutant showing enlargement of the ISV and 
DLAV vessels in addition to increased tortuosity of the DLAV with looping which 
extends above the pigment line. 
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3.2.1.1.2 Increased total trunk vessel length in the vhl-/- mutant  
In addition to the significant change in ISV and DLAV diameter I observed an 
increase in tortuosity of of both the ISV and DLAV at 3 dpf in addition to an 
increased number of angiogenic sprouts of both vessels in the vhl-/- mutant. I 
measured total vessel length in a two-somite region to quantify this. This data 
showed a significant 50% increase in total vessel length in vhl-/- mutants 
compared to controls at 3 dpf (Figure 3.2 B). Any additional loops or vessel 
sprouts are included in this quantification, giving quantification of both the 
increased tortuosity and branching in the trunk vessels in the vhl-/-.    
3.2.1.1.3 Increases in the area of endothelial cytoplasm in the vhl-/- mutant 
Figure 3.2 D, shows the total endothelial area in the same two-somite mid trunk 
region in the vhl-/- mutant and wildtype. This measurement was obtained by 
comparing the same two-somite region of a vhl-/- mutant and control embryo. 
The vhl-/- mutant has a significantly larger area of fluorescence (46.54 ± 3.1% 
than wildtypes 28.97 ± 1.47 µm2), (SEM n=5), indicating around 60% increase 
in the area of endothelium in the vhl-/- mutant. 
3.2.1.2 Is the vessel phenotype of the vhl-/- mutant due to 
accelerated development of the normal phenotype? 
The vascular phenotype of the vhl-/- mutant, particularly the looping of the 
DLAV, can be identified as early as 3 dpf as shown in figure 3.1. The patterned 
trunk vessels develop normally by angiogenesis prior to appearance of this 
abnormal phenotype. It was possible that the phenotype I identified might have 
represented acceleration of normal development. I therefore imaged the same 
region at 4,5 and 7 dpf. The photomicrographs of the same region over this 








Figure 3.2 Quantification of the differences in the vascular phenotype of 
the wt and vhl-/- mutant.  
A. ISV diameter using 3 dpf Tg(vhlhu2117-/-;fli1eGFP) over a 2 somite mid trunk 
region of interest (ROI). The ROI is taken from the level of the clocae, mid trunk 
and contains the 2 adjacent somites with associated vessels (for full method 
see section 2.4.2). The ISV was measured at 2 points in each of the three 
vessels and the mean of this was used for statistical comparison across the 5 




Figure 3.2 (cont) The length of the ISV, DLAV and additional aberrant vessels 
was measured using the segmented line tool in imageJ to give a total vessel 
length within the ROI. C. DLAV diameter at 3dpf in the vhl-/- compared to wt, 
same ROI. 2 measurements of the vessel diameter were taken from the mid 
somite point D. Total area of GFP fluorescence in vhl-/- vs wt. Total area 
obtained by forming a binary image in image J software using the same 
threshold level. This gave a total area of GFP within the ROI, which could be 
used to derive the 2D area of GFP within the ROI when the image is flattened to 




From 4 to 7 dpf there was continued enlargement of the ISV and DLAV. The 
DLAV becomes increasingly tortuous, dilated and forms loops above the 
pigment line as the fusion of the DLAV plexus is abnormal compared to the 
remodelling seen in wildtypes (Zygmunt et al. 2012). However by 7 dpf there is 
extensive angiogenesis in the mutant, which is never seen in the wildtype even 
at later time points (Isogai et al. 2001). This aberrant angiogenesis progresses 
from the distal ISV, with sprouts forming from 3dpf and progresses proximally 
down the ISV towards the aorta and PCV over time. Significantly, in the 
wildtype, patterning of the ISV and DLAV is limited to the somite boundaries 
and follows a characteristic pattern (Childs et al. 2002). The aberrant 
angiogenesis of the mutant initially can only be seen at the distal ISV at 3 dpf, 
but then begins to penetrate the somite boundaries; a feature not observed in 
wildtypes (Childs et al. 2002). By 7 dpf these angiogenic sprouts form 
lumenised communications between pairs of ISV by crossing the somite and 
from the ISVs to the expanded DLAV plexus. 
3.2.1.3 Lymphangiogenesis in the vhl mutant is also abnormal 
Tg(fli1:eGFP) labels endothelium of the developing lymphatic system as well as 
the arterial and venous vessels. In Figure 3.3 this can be seen in the wildtype 
embryo as the emergence of fine sprouts between 3 and 4 dpf at the horizontal 
myoseptum consistent with previous reports (Hogan, Herpers, et al. 2009b). 
Between 4 dpf and 7dpf there is enlargement, increased tortuosity and 
angiogenic sprouting of these developing lymph channels in the vhl-/- mutant 
compared with the tightly regulated patterning seen in the wildtype embryos 





Figure 3.3. Progression of the angiogenic phenotype of the vhl-/- mutant 
from 3dpf to 7dpf. 
Top panel shows a comparison of the mid trunk vessel morphology 
photomicrographs of Tg(fli1:eGFP) of 2 somites showing the ISV and DLAV of 
the wildtype and vhl-/- mutant at 4,5 and 7 dpf. Scale bar 50 µm. Asterisk = ISV; 
arrowhead = DLAV; arrow = lymphatic vessels at the myoseptum. 
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3.2.1.4 Does the cerebral circulation of the vhl-/- mutant show the 
same phenotype as the trunk vessels? 
Since the vhl-/- mutant has constitutive activation of hypoxic signalling the vessel 
changes I identified in trunk vessels would be likely to be present in other 
vascular beds. I next sought to confirm this. 
Previously published data indicated that the central arteries (CtA) of the mid 
and hindbrain project up into the brain from the posterior communicating 
segment and the basilar artery (Isogai et al. 2001). Although these vessels are 
formed by angiogenesis the mechanism by which they sprout and re-model is 
different to that of the trunk vessels (Bussmann et al. 2011). Despite this, I 
found a significant enlargement in diameter of the CtA in vhl-/- mutants, an 
increase of 50% compared to controls (Figure 3.4).  
This difference in diameter of the CtA in the vhl-/- mutant is similar to the 
increases in size seen in both the ISV and DLAV seen in Figure 3.2. This 
suggests that the angiogenic phenotype of the vhl-/- mutant is seen in spatially 








Figure 3.4 Differences in the cerebral vasculature of the vhl-/- mutant using 
the Tg(vhlhu2117-/-;fli1:eGFP) line 
A. Cerebral vasculature at 60 hpf in the top panel shows the Central arteries 
(CtA) of the wt embryo penetrating the mid and hind-brain. In the lower panel 
the same vessels in the vhl-/- mutant are dilated and form multiple sprouts and 
communications. Scale bar, 100 µm. B. Comparison of the diameter of the CtA 
in the wt and vhl-/- (Mean and SEM; ** p<0.01; t test; n=5). 
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3.2.2 Do the increases in endothelium in the vhl-/- mutant result 
in lumenised vessels? 
 The Tg(fli1:eGFP) line labels the cytoplasm of endothelial cells. Although the 
dynamics and morphology of this fluorescent protein have been used by some 
groups to indicate lumenisation of trunk vessels this has only been published in 
established developmental vessels of the zebrafish (Herwig et al. 2011), not in 
angiogenic sprouts stimulated by hypoxic signalling. I wanted to ascertain 
whether the increase in endothelial cytoplasm and vessel sprouting in the vhl-/- 
mutant led to lumenisation and formation of patent vessels. To assess 
lumenisation I injected nanoparticles Qdots (Sigma UK). 
The photomicrographs in the lower panel of Figure 3.4 show angiogenic sprouts 
emerging from the distal ISV in the vhl-/- mutant containing intravascular Qdot 
nanoparticles. This is the region of the vasculature I have imaged using the 
endothelial GFP marker. The intravascular Qdots injected into the circulation 
indicate these sprouts are lumenised and thus are likely to be formed by or 
connected to stalk cells which form the bulk of the developing angiogenic vessel 
behind the tip cell (Potente et al. 2011). Although these primitive sprouts do not 
carry erythrocytes they clearly form a lumen in continuity with the circulation and 
vasculature. This suggests the endothelium of these developing angiogenic 
sprouts, are exposed to haemodynamic forces. 
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Figure 3.5 Angiograms of vhl-/- mutant and wt embryos at 4 dpf. Qdot 205 
nm non-targeted nanoparticle were injected into the circulation of 4 dpf wt and 
vhl-/- embryos. Top two panels shows whole mount wt fli1:eGFP, lower two 
panel shows vhl-/-; fli1:eGFP and Qdot fluorescence overlay. Scale bar, 400 µm. 
Bottom panel shows expanded mid trunk region (lumenised angiogenic sprouts 
containing Qdots, arrowhead). Scale bar 100 µm.  
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3.2.3 Increases in endothelial cell number in the vhl-/- mutant 
Since the vhl mutant has increased endothelial area and vessel size, I 
hypothesised that these changes were likely to be accompanied by increased 
endothelial number. I therefore crossed the Tg(flk1:eGFP-NLS) into the vhl 
mutant background enabling more detailed assessment. This transgenic line 
uses the flk1 zebrafish promoter to drive endothelial expression of GFP tagged 
with a nuclear localising signal that restricts fluorescence to the nuclei. This 
transgenic line enabled me to quantify endothelial cell number. 
To simultaneously examine both membrane behaviour and nuclear dynamics in 
the vhl mutant I then also crossed the Tg(flk1:eGFP-NLS) with the Tg(kdr-
l:HRAS-mCherry) expressing endothelial membrane-tagged RFP. This dual 
transgenic enabled me to examine both endothelial cell number and accurately 
measure the aortic lumen in the wildtype and the vhl-/- mutant, in addition to 
vessel morphology. 
3.2.3.1 Increased endothelial cell number in the aorta of the vhl-/- 
mutant 
In the vhl-/- mutant at 3 dpf I found a significant increase in endothelial cell 
number in the aorta. Within the same two somite mid trunk region examined in 
Figure 3.6 there was a highly significant 50% increase in endothelial cell 




Figure 3.6 Aortic endothelial cell number and aortic diameter in the wt and 
vhl-/- mutant of the mid trunk aorta.  
A. The wt aorta with arterial ISV sprouting from the aorta (arrowhead) with the 
endothelial membrane labelled with red fluorescence, Tg(kdr-l:HRAS-mCherry) 
and the nuclei labelled with GFP Tg(flk1:eGFP-NLS). Scale bar 50 µm. B. Aorta 
of the vhl-/- mutant showing increased number of endothelial nuclei over the 2 





Figure 3.7 Quantification of aortic endothelial cell number and aortic 
diameter in the wt and vhl-/- mutant of the mid trunk aorta.  
A. Luminal diameter of the aorta 20.4 ± 0.9 µm in the wildtype and 27.9 ± 0.6 
µm in the vhl-/- mutant (mean ± SEM; t test; *** = p<0.001; n=12). Measured 
using the Tg(kdr-l:HRAS-mCherry) line. B. Number of aortic endothelial cells in 
a matched 2-somite region in wt and vhl-/- mutants containing; 6.5 ± 0.4 cells in 
the wt and 9.7 ± 0.4 cells in the vhl-/- mutant (mean ± SEM; t test; *** = p<0.001; 
n=5) measured using the dual transgenic line Tg(flk1:eGFP-NLS) Tg(kdr-
l:HRAS-mCherry). 
The two measurements were obtained from different transgenic backgrounds 
less of the dual transgenics were available for repeated observation due to 
smaller numbers of co-segregating reporter constructs. 
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3.2.3.2 Increased aortic diameter in the vhl-/- mutant 
The Tg(kdr-l;HRAS-mCherry) line allows accurate membrane localisation at 
higher magnification and enabled me to accurately measure luminal size of this 
vessel. Figure 3.6 shows that the aorta of vhl mutants was of significantly larger 
diameter, an increase of 35% when compared to controls. This is consistent 
with the increases seen in ISV and DLAV diameter, using the Tg(fli1:EGFP) 
line. 
3.2.3.3 Increased endothelial cell number in trunk vessels of the 
vhl-/- mutant 
To obtain accurate quantification of the number of endothelial nuclei in the trunk 
vasculature I used the Tg(flk1:eGFP-NLS) line. Spinning disc confocal 
microscopy provided 2µm Z-stack fluorescence images through the trunk of the 
developing embryo. The spinning disc microscopy due to its rapid stage 
movement and Z-stack acquisition allows multiple imaging of embryos of the 
same developmental stage to be performed. Due to the low numbers of 
homozygous mutants, (25% from a heterozygous incross) it is important to 
obtain adequate biological replicates of the mutant group to provide statistical 
significance. This imaging system provides the fastest, high quality in vivo 
imaging to make the comparisons required.  These sequential images enabled 
accurate manual quantification of individual endothelial nuclei and confirmation 
of separate but overlapping nuclei through the trunk and over three ISV and 
communicating DLAV. Figure 3.8 shows the significantly increased number of 
endothelial cells in the vessels of the vhl-/- mutant compared to the wild type, 
reflecting an increase of 50% in the number of endothelial cells in vhl-/- mutants 
compared to controls. These data indicates that the enlargement of these 
vessels and angiogenesis seen in the mutant vasculature is associated with an 






Figure 3.8 Assessment of the endothelial cell number in the vasculature of 
the wt and vhl-/- mutant at 3dpf.  
A. Tg(flk1:eGFP-NLS) and bright field image overlay of mid trunk in a 3 dpf wt 
and vhl-/- mutant (*=ISV, ^=aorta). Scale bar, 100 µm. B. Endothelial nuclei 






3.2.4 Endothelial tip cell differentiation in the vhl-/- mutant 
3.2.4.1 Increased number of endothelial cells producing filopodia 
in the   vhl-/- mutant 
Tip cell and filopodia generation are features of the endothelial tip cell identity 
driven by local gradients in VEGF-A (Gerhardt 2003). Given the increases in 
endothelial cell number and vessels in the vhl-/- mutant, I expected to see 
concurrent increases in tip cell population in vhl mutants. 
To identify tip cells I examined the labelled endothelium for filopodia formation 
in the ISV of vhl-/- mutants using Tg(kdr-l:H-ras;mCherry)s916 transgenics 
(Hogan, Bos, et al. 2009a). Given the increased number and size of vessels 
that I had identified I expected to see increased numbers of tip cells along this 
vessel. Figure 3.9A shows the labelled membrane of the ISV shown as a grey 
scale image to enhance membrane contrast and demonstrate tip cell and 
filopodia morphology. To quantify the difference in the number of tip cells 
between the wildtype and the vhl-/- ISV I looked for membrane projections from 
the surface of the ISV and the presence of filopodia which confirm active tip cell 
phenotype. In figure 3.9A there is an increase in angiogenic sprouts from the 
membrane, there is an associated increase in filopodia seen in the enlarged 
segment of the ISV (expanded white box in figure 3.9B) seen in the mutant. 
These angiogenic sprouts with active filopodia were very rare in wildtypes, 





Figure 3.9 Increased filopodia of the endothelial membrane of the ISV in 
the vhl-/- mutant at 3 dpf.  
A. ISV Endothelial morphology and tip cell formation, Tg(kdrl:HRAS-
mCherry)s916 to localise endothelial fluorescence to membrane, scale bar 50µm. 
In the wt ISV no sprouts are seen, the vhl-/- shows endothelial sprouts with 
filopodia labelled with the membrane tagged fluorescent mCherry.  
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Figure 3.9 (cont) B. Shows the region of the vhl-/- ISV with sprouts and 
filopodia magnified in 3.9A to show fluorescence of filopodia (arrowheads) in 
the vhl-/- mutant to indicate active angiogenic sprouts possessing tip cells. C. 
Quantification of the number of angiogenic sprouts with filopodia, (labelled on 
the graph as tip cell) along the ISV, adjusted for total length in the wt and vhl-/- 
mutant (vhl-/- 0.025 ± 0.001 wt 0.0056 ± 0.001, mean number of angiogenic 
sprouts / µm of ISV ± SEM; n=7; t test; *** p<0.001). 
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3.2.5 Is the increase in number of endothelial cells in the vhl-/- 
mutant due to proliferation? 
One possible explanation for the difference in endothelial number vhl-/- mutants 
is an increase in endothelial proliferation. This would be consistent with the 
expansion in endothelial cytoplasm, vessel growth and angiogenic tip cell 
phenotype seen in the vhl-/- mutant (Ellertsdottir et al. 2010). 
To assess endothelial cell proliferation I used immunohistochemistry for 
phosphorylated histone H3 (PH3) to co-localise mitotic cells with endothelial 
nuclear GFP in the Tg(flk1:eGFP-NLS) reporter in the vhl-/- and wt backgrounds. 
Given the increased nuclear number seen in the vhl-/- mutant I expected to see 
increased numbers of endothelial nuclei in the vhl-/- mutant co-localise with the 
PH3 Antibody, indicating actively mitotic cells and thus proliferation.  
Despite good tissue penetration with the antibody, resulting in labelled cells in 
the neural tube, co-localisation with GFP and the fluorescently labelled PH3 
antibody (alexa 546) was very rare with only single cells co-localising in the 
whole trunks of embryos (Figure 3.10). The vhl-/- mutant shows continued 
expansion in the number of endothelial cells over time so we repeated this 
experiment in vhl-/- mutants at 5dpf to see if the greater total number of 
endothelial cells might enable us to co-localise more endothelial nuclei. 
Unfortunately I was unable to identify any more than single co-localised nuclei, 




Figure 3.10 Immunohistochemistry of the proliferation marker 
phosphorylated histone H3 and fluorescent endothelial nuclei in 4dpf vhl-/- 
mutant and wt embryos. 
PH3 staining using Alexa 546 nm secondary (red) with endogenous 
Tg(flk1:eGFP-NLS) (green) and nuclear stained with 4',6-diamidino-2-
phenylindole (DAPI) (blue) there are no co-localised red and green endothelial 




The vhl-/- mutant displays hypoxic signalling-driven angiogenesis during early 
embryonic development. This overlaps with normal developmental 
angiogenesis and vascular patterning. As the zebrafish has numerous 
advantages for the study of vascular development I wished to characterise in 
detail the angiogenesis in the vhl mutant so it could be used to examine 
signalling pathways involved in the regulation of angiogenesis. 
There is an extensive literature on the features of angiogenesis which has been 
reviewed extensively (Potente et al. 2011). Angiogenesis is characterised by 
the differentiation of endothelial cells into tip and stalk cell in the presence of 
local VEGF gradients. Tip cells produce membrane projections, filopodia which 
enable path finding to connect with other tip cells to form new vascular 
connections (De Smet et al. 2009; Gerhardt 2003; Phng & Gerhardt 2009). In 
addition to the migratory phenotype of the tip cell, stalk cells undergo 
proliferation and re-organisation to form the stable endothelium of the 
developing vessels and lumenise via complex processes to form an effective 
vessel to enable flow of blood (Blum et al. 2008; Herwig et al. 2011; Carmeliet 
2000).  
In this chapter I have attempted to demonstrate that the aberrant angiogenesis 
seen in the vhl-/- mutant behaves in the same stereotyped way both at a cellular 
and morphological way as a result of constitutive hypoxic signalling. Previous 
work has described the angiogenesis seen in the mutant line with particular 
emphasis on the retinal vasculature and its similarities to human retinal 
pathology (Van Rooijen et al. 2010). I chose to examine the trunk vessels for 
this study due to their accessibility and also since these have been used 
extensively for the study of developmental angiogenesis and endothelial cell 
behaviour in the zebrafish. This provides comparative data on all aspects of 
these vessels in the developmental setting. 
The vhl-/- mutant demonstrated a consistent pattern of aberrant angiogenesis, 
which was not seen, even at later time points, in the wild type embryo. This 
additional vessel development was first seen at 3 dpf after the ISV and initial 
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DLAV connection seemed to form normally. It is not clear why there is a delay in 
onset of the abnormal angiogenesis. This may represent the time required for 
accumulation of the HIF transcriptional complex and subsequent protein 
synthesis in the developing organism. Alternatively there may be an initial 
contribution from maternal RNA prior to the expression of the zygotic mutant vhl 
transcript (Schier 2007).  
I have shown that the abnormal angiogenesis seen in the vhl-/- mutant is 
progressive from 3 dpf until 7 dpf shortly before the embryos die due to high 
output cardiac failure at 9 dpf (Van Rooijen et al. 2009). There is an expansion 
in the endothelial cytoplasm and the total area of vessel, in addition to the 
increased diameter of both the ISV and DLAV from as early as 3 dpf. A 
potential limitation of this study of the angiogenic morphology is that it is based 
on vessel morphology, using the endothelial promoter fli1. The fli1 promoter is 
expressed in both arterial and venous vessels and the differences in vessel 
morphology do not take into account potentially different vessel responses 
between the two vessel types. There are differences in the response to VEGF 
ligands and receptors in arterial and venous angiogenic sprouts (Hogan, 
Herpers, et al. 2009b) and this could result in differences in an angiogenic 
response to HIF-1α signalling. Despite the potential signalling difference I did 
not see any variation in angiogenesis depending on the arterial or venous origin 
of the ISV sprout. Also, previous data has also shown an up regulation in all 
VEGF ligands and receptors as a result of the vhl-/- mutation in the developing 
zebrafish embryo (van Royen et al. 2009). 
Tip cells are differentiated endothelial cells stimulated by local VEGF gradient 
which act in a similar manner to axonal growth cones, for emerging vessels 
(Potente et al. 2011). Currently there is no single marker of a differentiated tip 
cell (Phng & Gerhardt 2009). I used an endothelial membrane reporter to show 
that in the vhl-/- mutant there is significantly increased filopodia formation along 
the length of the ISV. This suggests increases in tip cell population fate in the 
vhl-/- mutant. However, the additional vessels seen in the vhl-/- mutant and the 
increases in filopodia and tip cells suggest the additional vessels are formed by 
a process of classical tip and stalk cell driven sprouting angiogenesis. 
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Tip cell formation and angiogenic sprouting is only one of the earliest features 
of endothelial angiogenesis. The ability of these sprouts to form a vascular 
lumen from modifications of the stalk cell morphology and expand the 
endothelial cell number to support this new vessel formation is critical to 
formation of effective mature vessels. I have shown that the angiogenic sprouts 
of the vhl-/- mutant lumenise early in their formation and there is a concurrent 
expansion in the number of endothelial cells in the mutant vasculature.   
I hypothesised that the increased number of endothelial cells seen in the mutant 
was due to increased endothelial proliferation. Given the established position of 
VEGF as a growth factor and endothelial mitogen and the increases 
demonstrated in the vhl-/- mutant. Unfortunately I was unable to demonstrate 
any differences in active mitosis in the endothelial cells of the mutant using the 
PH3 antibody. This is likely to be due to technical reasons and I have not 
confirmed or refuted the presence of increased endothelial proliferation in vhl 
mutants. Two alternative techniques may address this question:  One would 
have been to use the synthetic nucleoside bromodeoxyuridine. This is 
incorporated into dividing cells and can be identified by immunohistochemistry 
and co-localised to the endothelium. This would give an indication of the 
number of endothelial divisions over a period time rather than at single time 
point, which is a limitation of PH3 immunostaining. The second would be to use 
time-lapse imaging of endothelial nuclei in the mutant and wildtype 
backgrounds and use either manual or automated tracking of the nuclei over 
several hours to quantify number of divisions during time-lapse acquisition. This 
would also provide information about the origins of these proliferating cells and 
the sites of active division. It has been shown that the origin of the cells which 
form the DLAV in the developing embryo emerge from the aorta (Blum et al. 
2008), it is possible that the increases in cells seen in this vessels is as a result 
of aortic proliferation and then migration into the ISV and DLAV as opposed to 
proliferation in situ. 
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3.3.1 Is the abnormal vascular phenotype endothelial cell 
autonomous? (Appendix 1) 
In the vhl-/- mutant line there is up regulation of hypoxic signalling in all cells. In 
characterising the angiogenic vessel phenotype of the vhl-/- mutant, I was 
interested to see if increases in hypoxic signalling in only endothelial cells, was 
sufficient to induce an angiogenic vessel phenotype. Imaging of a double 
transgenic expressing a dominant active hif-1αb protein expressed in the 
endothelium showed no angiogenic phenotype during the time period observed. 
WISH experiments to confirm the expression of the transgenes and the GAL4-
UAS system indicated that the fli1GFF-UAS system was resulting in effective 
endothelial expression of kaede mRNA and protein.  
Although there was some global increase in expression mainly in the head of 
the PHD3 mRNA, (used here as a reporter of HIF signalling) in this endothelial 
driven hypoxia transgenic, there was not a clear vascular distribution of PHD3 
mRNA using WISH. A possible explanation for the lack of clear endothelial 
UAS-da-hif-1αb expression and angiogenic phenotype, may be due to 
methylation and silencing of multiple copy insertion of the UAS residue, or 
potentially its proximity to the modified GAL4 promoter (Akitake et al. 2011). As 
it is difficult to make strong conclusions from the data (Appendix 1) and I cannot 
be certain that there is up-regulated endothelial HIF expression it is difficult to 
comment further on the role of cell autonomous HIF over expression in 
endothelium and the initiation and production of angiogenesis.   
Unfortunately there was insufficient time, within this project, for me to produce 
the same constitutively active HIF construct with a 4x UAS promoter for the 
production of a stable transgenic line. This technique may have reduced the 
effects of any UAS silencing by methylation (Akitake et al. 2011). This area may 
be of interest for future research as the site of autochrine and paracrine vegfaa 
secretion in the vhl-/- mutant or the timing of its onset may begin to explain why 





I have shown that pathological angiogenesis in the vhl-/- mutant zebrafish 
demonstrates phenotypic features consistent with published descriptions of 
angiogenesis in other models. These models include hypoxia driven 
angiogenesis in different vessel territories in the zebrafish and developmental 
models of angiogenesis in both the mouse and zebrafish (Van Rooijen et al. 
2010; Potente et al. 2011). Previous work had identified the up regulation of 
important angiogenic growth factors in the zebrafish mutant line (vegfa, flt1, fli1, 
kdr and kdr-l) which have been shown to be critical in the genesis of new blood 
vessels in a number of models (Phng & Gerhardt 2009; van Royen et al. 2009). 
The presence of these factors in the vhl-/- mutant with the cellular and 
morphological features of angiogenesis described in this chapter indicate the 
vessel phenotype of the zebrafish vhl-/- mutant trunk is a reliable in vivo model 
of hypoxia driven angiogenesis (Ellertsdottir et al. 2010). These observations 
enabled me to use this model to investigate cell-signalling pathways regulating 






Chapter 4 The role of flow in the 





Angiogenesis has been shown to require flow dependent signals in the 
developing zebrafish vasculature (Nicoli et al. 2010). In addition flow has been 
shown to regulate formation and the remodelling of the DLAV plexus in concert 
with VEGF-A signalling (Zygmunt et al. 2012). Despite this understanding of the 
effect of flow on endothelial behaviour and the regulation of new vessels, there 
is little information on the role of haemodynamic flow on angiogenesis driven by 
constitutively active hypoxic signalling or pathological angiogenesis. It has been 
shown in previous work using the vhl-/- mutant zebrafish that the cardiac output 
and velocity of blood in the aorta is elevated compared with wildtype siblings 
(Van Rooijen et al. 2009). I hypothesised that this alteration in circulatory force 
might be permissive to the aberrant angiogenesis described in the previous 
chapter. In this chapter I therefore examined the effect of altering blood flow on 
the developing vasculature in vhl mutants. 
4.2 Results 
4.2.1 The effect of absent blood flow on vascular development 
in vhl mutants 
4.2.1.1 Genetic manipulation of circulation in the developing vhl-/- 
zebrafish  
Using a morpholino antisense oligonucleotide against the sarcomeric protein 
troponin t2, I was able to block the construction of effective contractile apparatus 
in the developing embryonic heart to prevent cardiac contraction (Sehnert et al. 
2002). I injected this morpholino (MO) into the Tg(vhlhu2117;fli1:eGFP) transgenic 
to examine the effect of absent blood flow on the mutant angiogenic phenotype 
described in the previous chapter. This targeted morpholino blocks the 
formation of the contractile apparatus of the cardiac myocyte during 
development. Although the gross anatomy of the heart is preserved, due to the 
block to transcription of this essential protein cardiac contraction cannot be 
initiated. Successful knockdown can be identified using simple optical 
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microscopy where cardiac contraction is identified at about 20-24 hpf and 
circulating erythrocytes can be observed in real time in the embryos, this is lost 
in the morpholino injected embryos.   
Figure 4.1 shows the stereotyped formation of the ISV and DLAV in the wild 
type embryo injected with control MO.  The vessels are restricted to the somite 
boundaries and follow a stereotyped pattern (Childs et al. 2002). This pattern is 
preserved in embryos injected with troponin t2 MO, which have never been 
exposed to circulatory flow. This indicates that these patterned vessels, which 
emerge from the aorta at a similar time to the onset of circulation, are not 
dependent on flow for formation. However the additional vessel changes which 
are seen in the vhl-/- mutant, enlargement of the patterned vessels and 
sprouting of new vessels, are not present in the vhl-/- mutant injected with 
troponin t2 MO, which is never exposed to circulation and flow.  
In the vhl-/- mutant which has endothelium exposed to flow there is about a 50% 
increase in the diameter of this vessel compared to control, in the vhl-/- mutant 
with absent circulatory flow this is reduced to control levels. The same pattern is 
seen in the DLAV diameter, which is increased by around 60% in the vhl-/- 
mutant with flow but this highly significant increase is reduced back to control 
levels in the absence of flow (Figure 4.2 A & B). In both of these 
measurements, ISV & DLAV diameter, there is no significant change in vessel 
size in the control group, which is injected with the troponin t2 MO thus not 
exposed to flow. 
The total vessel length of a two-somite region and total area of endothelium 
showed similar patterns to ISV and DLAV diameter in the vhl-/- mutant, injected 
with troponin t2 and no flow. The highly significant increases in the vhl-/- mutant 
for vessel length and area of GFP fluorescence are reduced to control levels by 
the absence of flow. There is no significant difference between the wild type 
embryos with no flow and the vhl-/- with no flow in any of the groups studied. 
There is a reduction seen in the wildtype embryo with absent flow in the total 
vessel length and area of endothelial GFP expression, compared to the wild 
type with normal flow, although a smaller difference than observed in the 
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mutant. This difference may reflect the smaller size of the somites in the 3 dpf 
embryo injected with troponin t2 MO resulting in the length in vessel and area 





Figure 4.1 The effect of removing circulatory flow from the endothelium of 
the wild type and vhl-/- mutant at 3 dpf. 
4dpf Tg(fli1:eGFP) embryos injected with control or troponin t2 morpholino, 
essential vascular patterning is preserved with the ISV and DLAV forming 
despite the absence of circulatory flow in the wt and vhl-/-. However the aberrant 
angiogenesis seen in the vhl-/- Control MO embryo is lost in the vhl-/- without 




Figure 4.2 Quantification of absent circulatory flow on the hypoxia driven 
angiogenesis in the vhl-/- mutant. 
A. ISV diameter in 4dpf wt & vhl-/- Tg(fli1:eGFP) embryo injected with troponin t2 
or Control MO. B. DLAV diameter in wt & vhl-/- injected with troponin t2 or 
Control MO. C. Total vessel length in wt & vhl-/- injected with troponin t2 or 
Control MO. D. Vessel area (% area GFP) in wt & vhl-/- injected with troponin t2 





Figure 4.3 Time course of the vhl-/- mutant angiogenic phenotype 
compared with aged matched vhl-/- mutants injected with trop t2 MO. 
The angiogenic features previously described in the vhl-/- mutant show 
progression over time (left column photomicrographs). The vhl-/- mutant injected 
with Trop t2 MO shows none on these features even at later time points (right 
column). Tg(vhlhu2117;fli1:eGFP). Scale bar, 50 µm. 
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4.2.1.1.1 Does absence of blood flow block the increase in endothelial cell 
number in vhl-/- mutants? 
I have previously shown that the vhl-/- mutant has an expansion in the number 
of endothelial cells in its vessels, which corresponds with the morphological 
changes of angiogenesis. Given the loss of angiogenic changes in the vhl-/- 
mutant in the absence of circulatory flow I expected to see a reduction in the 
number of endothelial cells in vhl-/- mutant injected with troponin t2 MO. Figure 
4.4 confirmed a significant reduction in endothelial cell number in the ISV and 
DLAV of the vhl-/- mutant injected with the troponin t2 MO (Figure 4.5). There 
was also a reduction in endothelial cell number in the ISVs in wild type embryos 
in the absence of flow. There was no difference in the endothelial cell number 
between wild type embryo injected with troponin t2 MO and vhl-/- mutant 
embryos injected with troponin t2 (Figure 4.5). 
The reduction of endothelial cells in the normal patterned vessel in the absence 
of flow may reflect the shorter length and reduced total area of endothelial 
tissue induced by the lack of circulation. Alternatively there maybe a reduction 
in either cell division in situ or migration into these vessels from the aorta, where 
these cells originate (Fouquet et al. 1997; Childs et al. 2002). A limitation of the 
Tg(vhlhu2117;flk1:eGFP-NLS) is the lack of concurrent information about vessel 
morphology. Each individual nucleus is seen in isolation, making accurate 
assessment about the exact location of individual nuclei difficult, particularly at 
the junction of vessels and where nuclei are overlaid in close proximity. To 
overcome this limitation I used the Tg(vhlhu2117;kdrl;HRAS-mCherry;flk1:eGFP-








Figure 4.4 Reduction in the endothelial cell number seen in the vhl-/- 
mutant in the absence of circulatory flow. 
4 dpf Tg(vhlhu2117;flk1:eGFP-NLS) injected with either troponin t2 MO or control 
MO and imaged at 4 dpf, photomicrograph of a two somite region of ISV and 
DLAV at the mid trunk adjacent to the cloaca. vhl-/- mutant shows increased 
endothelial cells in the control injected embryo with a reduction to control levels 







Figure 4.5 Endothelial nuclei counts vhl-/- and wild type embryos in the 
presence of circulatory flow or absence of flow. 
Endothelial cell nuclei counts in a two somite region of ISV and DLAV in wt and 
vhl-/- mutant embryos at 4 dpf Tg(vhlhu2117;flk1:eGFP-NLS). The significant 
increase in endothelial cells in the vhl-/- is significantly reduced in the vhl-/- 






4.2.2 Pharmacological circulatory arrest in the vhl-/- mutant  
I next sought to determine whether cessation of cardiac contraction by another 
method similarly reduced angiogenesis in vhl mutants. I therefore used the 
myosin ATPase inhibitor 2,3-butanedione 2-monoxime (BDM) to block cardiac 
contraction (Jou et al. 2010). This compound was added to the developing 
embryo at 36 hpf. This agent act to uncouple excitation-contraction of the 
cardiac myocyte, this is achieved by inhibition of calcium influx into the myocyte 
resulting in absence of cardiac contraction after treatment (Jou et al. 2010). 
Since blood flow starts 12 h earlier, this also enabled me to determine if initial 
exposure to circulation is sufficient to rescue the loss of phenotype induced by 
troponin t2 knockdown.  
Circulatory arrest at 36 hpf by application of the BDM compound to the 
developing embryos blocked the formation of the vhl-/- angiogenesis (Figure 
4.6). This effect is the same as that of the troponin t2 MO injection resulting in 
normalisation of the ISV and DLAV diameter to that of the wildtype vessel size. 
The inhibition of cardiac contraction with BDM also reduced the vessel length of 
the vhl-/- mutant (40% longer over a 2 somite region) to the length of wildtype 
vessels. BDM treatment did not change the diameter or total vessel length in 
wild type embryos compared with control media treatment as seen in Figure 4.6 




Figure 4.6 Pharmacological inhibition of circulatory flow results in the 
attenuation of the vhl-/- angiogenic phenotype. 
3 dpf Tg(vhlhu2117;kdrl;HRAS-mCherry;flk1:eGFP-NLS) imaged over two somites 
at the level of the cloaca. Endothelial membrane labelled with red fluorescence 
and nuclei labelled with green fluorescence. BDM is an inhibitor of cardiac 
contraction embryos incubated in BDM from 24 hpf until imaging at 72 hpf. 
Despite the normal developmental angiogenesis in embryos treated with BDM 
the angiogenesis of the vhl-/- mutant is attenuated. Scale bar, 50 µm. 
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Figure 4.7 Effect of BDM, an inhibitor of cardiac contraction on the 
quantification of the vhl-/- angiogenic phenotype.  
A. ISV diameter in the vhl-/- and wt treated with BDM 15mM or control from 
24hpf until imaging at 72hpf. Treatment with the BDM results in inhibition of 
cardiac contraction shortly after contraction to enable us to study the effect of 
cessation of circulation after its onset. B. DLAV diameter in vhl-/- and wt. C. 
Total vessel length of ISV and DLAV over a 2 somite ROI in vhl-/- and wt 
embryos. All groups mean ± SEM, 2-way ANOVA; Bonferroni post test; *** 
p<0.001; n=11.   
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DLAV diameter was increased by about 50% in the vhl-/- mutants with 
circulation compared with wildtypes; this increase is blocked in the vhl-/- treated 
with BDM (Figure 4.7 B) by the removal of flow. There is no significant 
difference in the DLAV diameter in either wild type or mutant embryos treated 
with control or BDM. 
Figure 4.7 C shows the 50% increase in total vessel length in vhl-/- mutants was 
reduced to wild type levels when treated with BDM. The reduction in total vessel 
length observed in wild type embryos treated with troponin t2 (Figure 4.2 C) was 
not seen in the BDM treated wild type group (figure 4.7 C), which may relate to 
the period of circulation prior to circulatory arrest. 
Treatment of the vhl-/- mutant to remove circulatory flow during vessel 
development blocks the formation of the hypoxic signalling-induced angiogenic 
response. This appears to be blood flow dependent and occurs despite initial 
exposure of endothelium to a flow signal in the vhl-/- mutant. 
The increase in endothelial nuclei in the ISV and DLAV of the trunk vessels of 
the vhl-/- mutant is normalised to control levels in vhl-/- mutant treated with BDM 
from 36hpf (Figure 4.8). In these experiments there was no statistically 
significant difference in the number of endothelial nuclei in the wild type control, 
wild type BDM and vhl-/- BDM groups. This is at odds with the data on 
endothelial cell number after injection of troponin t2 in the wild type to block 
circulation (shown in Figure 4.5). With the troponin t2 MO knockdown there was 
a significant decrease in the number of endothelial cells in wild type embryos 
injected with the MO, a decrease of 27%. It is possible that loss of circulation at 
a later stage in development in the BDM experiment may account for this 
difference. It is also possible this is due to a flow-dependent effect on 
endothelial proliferation during this early period of circulation, prior to circulatory 
arrest in the BDM treatment group.  
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Figure 4.8 Effect of pharmacological inhibition of cardiac contraction on 
endothelial number in the vhl-/- aorta (A) and trunk vessels (B). 
A. Number of endothelial nuclei in the ISV and DLAV of a 2 somite ROI 
adjacent to the cloaca in vhl-/- and wt 3 dpf embryos treated with BDM 15 mM or 
control media. B. Endothelial nuclei in the aorta of 2 somites in vhl-/- and wt 3 
dpf embryos treated with BDM 15 mM or control media. All groups: Mean ± 
SEM; 2-way ANOVA; Bonferroni post test; *** p<0.001; n=11.   
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4.2.3 Are the increases in the number of erythrocytes in the 
vhl mutant required for development of the angiogenic 
phenotype? 
The vhl-/- mutant has increased red cell production as a result of increased in 
hypoxic signalling (Van Rooijen et al. 2009). Since this increase precedes the 
changes in the vasculature I was interested to study the effects of this 
erythrocytosis on angiogenesis. Previous work in our laboratory has shown that 
the vhl-/- mutant has increased red cell velocity and cardiac output which 
precede the angiogenesis. In addition to these increases, I have previously 
shown that there is early lumenisation of the angiogenic sprouts of the vhl-/- 
mutant (Figure 3.6). Therefore increased force exerted on the endothelium from 
increased numbers of red cells may play a role in the angiogenic phenotype. To 
examine red cells prior to the initiation of the angiogenic phenotype I used 
Tg(fli1:eGFP;gata1a:dsRed) embryos with dsRed-labelled erythrocytes The 
dense columns of red fluorescence seen within the green endothelium in the 
vhl-/- mutant (Figure 4.9) suggest more erythrocytes passing through these 
vessels at the same developmental stage in the mutant angiogenic phenotype 
compared to the vessels of the wild type. 
4.2.3.1 Does early venesection reduce red cell density in the vhl-/- 
mutant?  
I developed a technique for venesecting the developing embryo at 48hpf using 
a micropipette and micromanipulator, which uses the embryo’s heartbeat to 
drive erythrocytes and plasma from the circulation into the surrounding agarose. 
Then by imaging the aorta I was able to quantify the number of erythrocytes in a 
fixed volume of aorta, based on measurements of aortic length and diameter 
and an assumption of a cylindrical tube for the aorta, enabling me to calculate a 
red cell density. Figure 4.10A shows that although red cell density is reduced in 
vhl-/- mutants after the procedure, by 5 dpf the density of red cells has 




4.2.3.2 Does venesection alter red cell velocity in the vessels of 
the vhl-/- mutant? 
Despite the recovery in the density of red cells back to non-venesected levels in 
the vhl-/- mutant by 5 dpf there is still a measurable effect on aortic velocity seen 
in figure 4.10B. This shows that at 5 dpf the velocity in the aorta as a result of 
venesection is reduced, compared to the sham procedure. As this reduction of 
aortic velocity may represent a difference in the flow in the developmental 
vessels and angiogenic vessels I wanted to see if this change led to an 
alteration in the vhl-/- mutant vessel phenotype.  
4.2.3.3 Does venesection in the vhl-/- mutant block the angiogenic 
phenotype? 
I performed venesection on 2 dpf mutant and wildtype embryos. Figure 4.11 
shows that venesection had no effect on the angiogenic phenotype of the vhl-/- 
mutant as previously described in this chapter. Due to the technical difficulties 
in performing this procedure on a 48 hpf embryo and the individual mounting 
and manipulation it is difficult to perform this procedure in large numbers.  
Post-hoc power calculations for the vhl-/- mutant groups were performed based 
on a significant difference between groups of p ≤ 0.05, the power calculation for 
ISV diameter calculates that the power is 0.309. This indicates that the number 
of observations in this experiment is inadequate to conclude that reducing aortic 
velocity by venesection has no effect on the mutant phenotype. To achieve 
power of > 0.8 would require an n > 12 for the expected effect size. For DLAV 
and vessel length the power is even lower and would require group sizes of > 
40 embryos to achieve a power of > 0.8. Given I have only demonstrated a 
modest reduction in aortic velocity after venesection in the mutant and no 
change in erythrocyte density at 5 dpf, such large experiments were not feasible 




Figure 4.9 Polycythaemia of vhl-/- mutants and the resulting increased 
erythrocyte flow in the developing and constitutive hypoxia driven 
angiogenic vessels. 
Tg(vhlhu2117;fli1:eGFP;gata1a:dsRed) 3dpf embryos were imaged using spinning 
disc confocal microscopy endothelium is labelled with green fluorescence and 
the red fluorescence shows the path of labelled red cells. The intensity of the 
red fluorescence is dependent on the number of red cells passing through the 
vessel during Z-stack acquisition. (asterisks=ISV, arrowhead=DLAV). Expanded 
image shows the increased red fluorescence seen in the ISV and DLAV in the 
vhl-/-and wt. Scale bar, 50 µm. 
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Figure 4.10 Effect of venesection on the erythrocyte density and its effect 
on the aortic erythrocyte velocity in the vhl-/- mutant. 
A. Venesection of vhl-/- mutants by injury with a micropipette at the duct of 
Cuvier at 2 dpf reduces the erythrocyte density under circulatory force, but this 
density is back to the same levels as control vhl-/- mutants by 5 dpf. B. The 
venesection reduces the aortic velocity to wild type levels in the vhl-/- mutant by 
5 dpf. All groups: Mean ± SEM; 2-way ANOVA; Bonferroni post test; * p<0.05, 




Figure 4.11 Venesection at 2 dpf to reduce aortic velocity in the vhl-/- 
mutant does not change the angiogenic phenotype at 5dpf. 
A. Effect of venesection at 2 dpf on vhl-/- and wt embryos with quantification of 
ISV diameter in Tg(fli1:eGFP) in a 2 somite ROI at the level of the cloaca. B. 
Effect of venesection on the DLAV diameter in vhl-/- and wt at 5 dpf. C. Effect of 
venesection at 2 dpf on vhl-/- and wt embryos with quantification of total vessel 
length of ISV and DLAV in Tg(fli1:eGFP) in a 2 somite ROI at the level of the 
cloaca. D. Effect of venesection on the total area of GFP expressing 
endothelium in the same ROI in vhl-/- and wt at 5 dpf. All groups mean ± SEM; 




































































































































































Extensive research has shown that the differentiation, behaviour and 
morphology of endothelial cells is altered in different types of circulatory flow, in 
particular shear stress (Boon & Horrevoets 2009; Davies 2008). In addition 
recent work in the zebrafish has identified a mechanism for flow dependent 
regulation of developmental angiogenesis (Nicoli et al. 2010). I wanted to use 
the zebrafish model of constitutively active, HIF-driven angiogenesis to address 
the question of whether altering flow in the presence of increased hypoxic 
signalling alters angiogenic behaviour in vivo. 
I have shown that removing flow in the developing vhl-/- mutant leads to 
attenuation in all of the features of the angiogenic phenotype described in the 
previous chapter. Of particular interest is that the phenotype is returned to 
control levels by the injection of the troponin t2 MO, as opposed to a partial 
reduction. This suggests that flow is a requirement for development and may lie 
downstream of the increases in VEGF-A signalling present in the mutant (Van 
Rooijen et al. 2009). To confirm this it would be necessary to look at the 
different levels of zebrafish vegf isoforms and their expression by WISH in the 
vhl-/- and wildtype embryos in the presence and absence of flow.   
In the developmental setting the absence of flow results in the loss of the 
accessory 5th aortic arch in the zebrafish. There are similarities with the 
observation that the aberrant angiogenesis of the vhl-/- mutant is lost in the 
absence of flow. Given that the developmental regulation of this flow dependent 
angiogenesis is regulated by mirRNA-126 and alteration of endothelial vegf 
sensitivity, it would be interesting to look at expression levels of mirRNA-126 in 
the endothelium of the aberrant mutant vessels and how its expression 
responds to the loss of flow. The technique of WISH for microRNAs is becoming 
increasingly available in the zebrafish model (Lagendijk et al. 2012), 
assessment of the role of this and other microRNAs in the vhl mutant 
phenotype would clearly be of great interest. 
An additional striking feature of the experiments in the vhl-/- mutant with and 
without circulatory flow is the differential response of vessels to flow. In the vhl-/- 
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mutant there is complete attenuation of the angiogenic phenotype in the 
absence of flow. However the early developing vessels which form by sprouting 
angiogenesis, (ISV and DLAV) are preserved and pattern normally in both the 
wild type and the vhl-/- mutant despite the removal of flow. This indicates that 
early developmental angiogenesis is independent of endothelial flow sensing 
but that hypoxia signalled angiogenesis requires flow. Also the on going 
detection of flow is essential for the continued development of the vhl-/- 
phenotype, as indicated by the BDM experiments, in which flow was removed 
only after 12 hrs. The differential regulation of angiogenesis based on sensitivity 
of the endothelium to flow signals and the mechanism by which the 
angiogenesis is stimulated (developmental or hypoxia signalling) has not been 
previously reported. 
Although apparently novel, this differential regulation may not be so surprising 
given that the early formation of developmental vessels occurs before, or at the 
onset of circulation. These primitive vessels are required to form the 
stereotyped trunk vessels often before flow has been established outside the 
aortic loop. Hypoxia-driven angiogenesis however is a physiological adaptation 
to reduced oxygenation and thus intuitively may require the presence of flow, as 
there is little value in the production of novel vessels to overcome hypoxia, if 
there is no flow of oxygenated erythrocytes in these vessels. However, this 
remains only a hypothesis. 
Although antisense oligonucleotide morpholinos are an effective tool for the 
temporary knockdown of zebrafish genes in development they have been 
shown to cause off target effects (Nasevicius & Ekker 2000) potentially via p53 
activity (Bill et al. 2009). Despite the simple readout of gene knockdown (visual 
confirmation of lack of circulation) of troponin t2 knockdown in my experiments 
there remains the possibility that this MO has off-target effects leading to loss of 
the vhl-/- angiogenic phenotype. I used the chemical BDM which uncouples 
excitation and contraction in the contractile apparatus (Jou et al. 2010), 
resulting in the arrest of cardiac contraction in the developing zebrafish. Despite 
the different mechanism of arresting flow in the developing embryo, the effect 
on the vhl-/- angiogenic phenotype was the same as when induced by troponin 
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t2 MO injection. This probably confirms that the development of the angiogenic 
vessel morphology in the vhl-/- mutant is flow-dependent. 
The increase in the number of endothelial cells in the vhl-/- mutant was blocked 
by both genetic knockdown of troponin t2 and BDM treatment. However even in 
wildtypes, troponin t2 injected embryos showed lower numbers of endothelial 
nuclei than controls. This difference in endothelium was not seen in the group 
treated with BDM. This may suggest that the difference is due to the short 
period of flow, which occurs between 24 and 36 hpf in the BDM treatment 
group. Unfortunately I do not have data to look at the number of endothelial 
cells in the aorta prior to formation of the ISV and DLAV. This data would 
correspond to the period of aortic flow in the BDM group but not in the troponin 
t2 MO group. This may enable us to explain the difference in cell number in the 
endothelium never exposed to flow compared to endothelium initially exposed 
to flow prior to its arrest.  
It is possible that changes in the number of endothelial cells in the aorta, prior to 
their migration into the ISV and DLAV, may subsequently affect the population 
of cells available to migrate from the aorta to form these vessels (Childs et al. 
2002; Blum et al. 2008). This may explain the lower numbers of cells seen in 
the ISV and DLAV in embryos never exposed to flow, as migration from the 
aorta drives normal patterning preceding any significant in situ proliferation in 
these vessels (Zygmunt et al. 2012).  
Alternatively it has been previously established that there is a flow dependent 
population of haematopoietic stem cells in the ventral wall of the aorta from 
30hpf which migrate and proliferate in response to flow (North et al. 2009). 
These cells would express endothelial markers at this stage in development 
and the number of this subset of endothelial cells would be reduced in the 
absence of flow (North et al. 2009). A similar mechanism may influence aortic 
endothelium and permit normal migration and proliferation in preparation for ISV 
and DLAV formation at the point of aortic flow, in a similar manner to the 
haematopoietic stem cell (HSC) population. To address this experimentally it 
would be interesting to look at the endothelial cells of the aorta and their 
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migration patterns after troponin t2 knockdown or BDM treatment over a series 
of time points. It would be possible to track the migration and also image 
proliferation of these cells from the aorta to the ISV and DLAV in a similar 
manner to the demonstrated by (Blum et al. 2008), This tracking of individual 
endothelium could be achieved using transgenic kaede (photo-convertible) 
endothelial cells and time-lapse imaging to track individual endothelial cells 
from there origin to sites of mitosis in both the wild type and the vhl-/- mutant. 
4.3.1 Summary 
 I have shown that circulatory flow is required for the initiation and maintenance 
of the vhl-/- angiogenic phenotype. This attenuation of the vhl-/- mutant 
phenotype is established as a result of cessation of flow even after its onset and 
not merely the absence of flow throughout development. Changes in endothelial 
cell number are consistent with those seen in vessel morphology in response to 
absent flow in the mutant vessels. These changes in response to a flow signal 
of endothelial angiogenic behaviour have not been previously described.  
The possibility that alteration in the circulation of soluble angiogenic growth 
factors like VEGF-A and NO which have been shown to be modified by up-
regulated HIF signalling may mediate flow and thus the aberrant angiogenesis I 
have described. I have undertaken a detailed study of the role of the vascular 
growth factors and cell signalling molecules, which have been shown to alter 




Chapter 5 Examination of the 
interactions between blood flow, 
Notch and nitric oxide signalling in 




In the previous chapter I described my discovery that blood flow is required for 
aberrant angiogenesis seen in the trunk vessels of homozygous vhl mutants. In 
this chapter I summarise my attempts to identify mechanisms that underlie this 
flow-dependent angiogenesis. Specifically, I aimed to examine whether 
alterations in Notch and / or NO signalling might contribute to this phenomenon. 
5.2 Results 
5.2.1 Identification of changes in endothelial Notch signalling 
in response to flow using a novel Notch reporter 
transgenic 
As discussed in Chapter 1, Notch signalling plays a central and complex role in 
the initiation and co-ordination of angiogenesis. Given that reduction of Notch 
signalling has been shown to block angiogenesis I wanted to see if alterations 
in endothelial Notch signalling regulated the response to flow seen in the vhl-/- 
mutant without haemodynamic flow. It (notch signalling) therefore appeared a 
good candidate pathway to examine in this model. 
To identify changes in Notch signalling I used a novel transgenic zebrafish 
Tg(CSL:venus) kindly provided by Martin Gering (University of Nottingham, UK). 
All canonical Notch signalling occurs by activation of the CSL transcriptional 
binding complex in the presence of the NICD. This transgenic line uses a 
multiple repeat of the CSL binding domain to activate expression of the 
modified green fluorescent protein (GFP) molecule, venus. In this transgenic the 
fluorescent protein expression is a result of activation of canonical Notch 
signalling pathway and can be observed in cells with increased Notch activity as 
fluorescence. The modified GFP (venus) used for this transgenic has been 
shown to have more rapid protein synthesis, folding and improved stability, 
improving real time visualisation of Notch-dependent cellular signals (Nagai et 
al. 2002).  
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5.2.1.1 Morpholino knockdown of troponin t2 increases endothelial 
Notch signalling in the developing aorta 
To examine whether prevention of blood flow altered vascular Notch signalling, 
I knocked down troponin t2 (in the same manner as in the previous chapter) in 
Tg(CSL:venus) embryos and visualised reporter expression. 
Figure 5.1 shows the trunk region of representative 48 hpf control and troponin 
t2 morphants.  I found that troponin t2 knockdown increased fluorescence in the 
aorta and a number of ISVs at 48 hpf and 72 hpf. There is greater fluorescence 
of the aorta in the 72 hpf troponin t2 morphant embryos compared with 48 hpf 
troponin t2 morphants. I quantified aortic fluorescence in groups of embryos 
(Figure 5.2). This showed troponin t2 knockdown increased aortic fluorescence 
by about 40% at 48hpf and around 300% at 72hpf. The increase in 
fluorescence seen in some of the ISV was not seen in all intersegmental 
vessels and the level of intensity in these vessels varied in the embryos. This 
variation may reflect the smaller numbers of endothelial cells in these vessels or 
that they overlie the neural tube which demonstrates high levels of Notch 
signalling in the Tg(CSL:venus) line. These limitations make further 
fluorescence analysis of this particular vascular tissue difficult. As a result 
analysis of notch reporter expression was focused on the aortic endothelium, 








Figure 5.1 Flow dependent changes in aortic endothelial Notch signalling 
as a result of troponin t2 MO knockdown at 48 hpf and 72 hpf.  
Troponin t2 and Control MO injection of Tg(CSL-venus)qmc61 embryos, 
fluorescence shows areas of Notch signalling mediated by the CSL transcription 
factor. Top panels show the increased Notch-dependent fluorescence in the 
aorta (arrowhead) and ISV (asterisk) in the mid-trunk of 48 hpf embryos injected 
with troponin t2 MO not exposed to circulatory flow (see Fig 5.9 for expanded 
detail of the aorta reporter expression). This Notch reporter line is not restricted 
to endothelial tissue so Notch mediated fluorescence can be seen in neural 
tube, yolk sac and the developing fin edge. In the top panels the aortic tissue 
(arrowhead) contains more green fluorescence in the embryo without circulatory 
flow. Lower panels show increased CSL signal in the aorta in the absence of 
flow compared to the earlier time point. There is also an increase in neural tube 
signal at 72 hpf compared to 48 hpf. Scale bar, 200 µm. 
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Figure 5.2 Quantification of endothelial notch signal at 48hpf (A) and 
72hpf (B) in the presence of flow or absence (Trop T2), due to injection 
with troponin t2 MO. 
The overall aortic fluorescence was measured by obtaining the mean aortic 
fluorescence along the dorsal aortic wall using a line tool in imageJ drawn 
through the dorsal aorta endothelium in the Tg(CSL-venus)qmc61 notch reporter 
line injected with control or troponin t2 MO. This technique overcomes the 
cellular variability in CSL expression by averaging the fluorescence through the 
tissue. There is a significant increase in aortic endothelial fluorescence in the 
endothelium of embryos not exposed to flow (troponin t2 MO) at 48hpf (A) By 
72hpf (B) this the difference in fluorescence is increased. All groups, mean ± 





















































5.2.1.2 Pharmacological induced circulatory arrest leads to 
increases in endothelial notch expression 
The previous experiments showed that complete prevention of cardiac output 
by troponin t2 knockdown led to increases in Notch signalling in the developing 
vasculature. Although troponin t2 is not expressed outside the heart (Sehnert et 
al. 2002), it is possible these observed effects were not caused by the absence 
of blood flow. I therefore treated Tg(CSL:venus)  embryos with the myosin 
ATPase inhibitor BDM as in the previous chapter. Developing embryos were 
treated with BDM from 36hpf (after onset of cardiac contraction) until imaging at 
72hpf. Cessation of cardiac contraction and circulatory flow was confirmed by 
microscopy at several stages throughout drug incubation and before imaging. 
Figure 5.3A shows representative photomicrographs demonstrating that BDM 
treatment increased reporter expression in the aorta and ISVs; mean aortic 
fluorescence was increased by 45% in BDM-treated embryos (Figure 5.3B). 
Therefore, complete prevention of cardiac output (by troponin t2 knockdown) or 
pharmacologic cessation of blood flow after onset of circulation (by BDM 





Figure 5.3 Effect of pharmacological induced circulatory arrest with BDM 
(15mM) at 36hpf on endothelial Notch signalling imaged at 72 hpf. 
Aortic fluorescence in the Tg(CSL-venus)qmc61 Notch reporter line treated with 
BDM 15 mM or control E3 media from 36 hpf until 72 hpf. There is a clear 
increase in aortic endothelial notch signal in the embryos not exposed to flow 
(BDM 15 mM) at 72 hpf aorta (arrowhead) and ISV (asterisk) (A). This 
difference in aortic fluorescence is significantly increased in the BDM group 
compared to control embryos (B). All groups: Mean ± SEM; unpaired two-tailed 
t test; ** = p<0.01; n=8. 
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5.2.1.3 Confirmation that increased endothelial Notch signalling is 
mediated by a classical Notch ligand-receptor interaction 
Notch signalling is mediated by expression of a ligand on the surface of the 
signalling cell, which binds to a receptor on an adjacent cell. This receptor-
ligand complex is then cleaved at the cell membrane of the transducing cell and 
then the ligand-receptor complex is internalised to activate signalling in the 
receiving cell by direct promotion of numerous gene targets. 
To examine whether the increase in aortic Notch signalling seen in response to 
absent blood flow shown above results from this classical or canonical Notch 
signalling, I treated Tg(CSL:venus) embryos injected with the troponin t2 
morpholino with the γ-secretase inhibitor DAPT. This blocks cleavage of the 
ligand-receptor complex at the cell membrane before internalisation and 
activation of Notch signalling targets in the nucleus by NICD binding to the CSL 
complex. 
Control troponin t2 morphant Tg(CSL:venus) embryos treated with DAPT (see 
methods section 2.10.2.1) showed no difference in aortic reporter expression, 
consistent with the generally low level of reporter expression in these embryos 
(Figure 5.4 and 5.5). It is possible that the fluorescent protein that is clearly 
seen in the endothelium, but at lower levels may still be present in the tissue 
due to expression at an earlier time point, prior to DAPT exposure, a 
phenomenon known as perdurance. Perdurance is the persistence of a reporter 
fluorophore, due to the stability of the reporter in the cytoplasm, after the 
expression of the driving transcription factor or gene has ceased. This 
phenomenon results in the appearance of continuing gene expression with in 
vivo imaging. This is a well described limitation of single time point observation 
of transgenic lines and a well described issue with stable fluorophores like GFP 
(Wells et al. 2011; Vitorino et al. 2009). However, the increases in reporter 
expression induced by troponin t2 knockdown, was completely abolished by 
DAPT treatment. This indicates that the increase in Notch signalling induced by 
absence of blood flow is dependent on NICD formation from the extracellular 
Notch receptor.  If this is due to canonical Notch signalling, this may be due to 
the effect of blood flow on Notch at a ligand / receptor level. However, the 
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possibility remains that the effect is via a non-canonical pathway resulting in 





Figure 5.4 Effect of a pharmacological Notch signalling inhibitor on the 
flow dependent increase in CSL-venus fluorescent signal. 
Troponin t2 and Control MO injection of Tg(CSL-venus)qmc61 embryos, right 
panels incubated with the Notch inhibitor DAPT in E3 media, left panels 
incubated in control media. The increased aortic (arrowhead) fluorescence 
induced by troponin t2 MO injection is reduced to control levels by Notch 




Figure 5.5 Quantification of the mean aortic CSL-venus fluorescence in 
embryos injected with troponin t2 MO and the effect of DAPT. 
 Quantification of the mean aortic fluorescence in troponin t2 and Control MO 
injected Tg(CSL-venus)qmc61 embryos either treated with control E3 media or 
incubated in DAPT 100 µM (Notch inhibitor) from 48-72 hpf. The significant 
increase in CSL fluorescence in troponin t2 MO injected embryos can be 
blocked by incubation with DAPT. All groups: Mean ± SEM; two way ANOVA; 
*** = p<0.001; n=10.  
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5.2.2 Identification of Notch signalling components 
differentially expressed in endothelial cells in the 
absence of circulatory flow 
Since the above studies suggested that blood flow regulates endothelial Notch 
signalling via ligand/receptor interactions, I examined whether blood flow alters 
expression of these molecules. 
I therefore used RT-qPCR to quantify expression of a range of Notch ligands, 
receptors and downstream targets (vegfab, vegfc, kdr/flk1, kdr-l/flt1, flt4, 
ephrinB2, her6, her12, notch3, nrarpa, dll4, cxcr4a, β-actin2) in RNA extracted 
from the trunk of developing embryos with and without blood flow (due to 
troponin t2 knockdown), at 48 hpf and 72 hpf. Differential expression was 
normalised to expression of β–actin. 
Figure 5.6 shows expression of each of these genes in 48 hpf control or 
troponin t2 morphant embryos. Our group previously showed that cxcr4a 
expression increases in troponin t2 morphants (Packham et al. 2009), and this 
was confirmed in my experiments, thus acting as a positive control.  From the 
genes I examined, only the notch ligand dll4 was significantly differentially 
regulated in trunk tissue in response to flow. dll4 expression was increased 2.5-
fold in the absence of flow (induced by troponin t2 knockdown). There was no 
significant differential expression of the vegf ab and vegf c ligands or of kdr and 
flt4 (vegf) receptors. There was also no significant alteration in the expression of 
the notch receptor notch3 or the downstream Notch targets her12 and ephrin-
b2a (figure 5.6). 
At 72 hpf the only significantly differentially expressed gene in the absence of 
flow was cxcr4a (Figure 5.7), which was increased 3-fold compared to the 
control MO injected group. There was increased expression of dll4 at this time 



















Figure 5.6 RT-qPCR of trunk tissue from 48 hpf embryos comparing the 
relative expression of known angiogenic genes, Notch ligands, receptors 
and notch signalling targets in troponin t2 MO injected embryos. 
Graphs show the fold change of mRNA transcripts in the troponin t2 MO treated 






Figure 5.6 (cont) 
All experiments performed in triplicate with 3 biological replicates (3 separate 
pools of 30 embryos). Mean ± SD; * = p<0.05; t test; n=3. 
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Figure 5.7 RT-qPCR of trunk tissue from 72 hpf embryos comparing the 
relative expression of known angiogenic genes, notch ligands, receptors 
and notch signalling targets in troponin t2 MO injected embryos. 
Graphs show the fold change of mRNA transcripts in the troponin t2 MO treated 
group (n=20 embryos) normalised to the expression of β-actin as housekeeper 
gene in troponin t2 injected embryos. 
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Figure 5.7 (cont) 
All genes run in triplicate with 3 biological replicates (3 separate pools of 20 
embryos). The only significant differential regulation is the up regulation of 




5.2.2.1 Confirmation that differential expression of dll4 in 
response to flow is an endothelial specific change in 
expression 
RT-qPCR enables quantification of differential expression of RNA transcripts in 
the tissue of embryos in response to flow but does not provide information 
about spatial restriction of expression. I therefore next performed whole mount 
in situ hybridisation for dll4 in control and troponin t2 morphants.  
In control morphants, I demonstrated vascular dll4 expression at 36 hpf, which 
appeared to diminish by 48 hpf and was not detectible at 72 hpf (Figure 5.8). 
However, in troponin t2 morphants, dll4 expression was more strongly detected 
at 36hpf and persisted even at 72 hpf (Figure 5.8). 
5.2.2.2 Knockdown of dll4 blocks the endothelial increase in notch 
expression seen in response to absent flow 
Data from the qPCR analysis and the transgenic notch reporter lines suggested 
that the notch ligand dll4 may mediate the flow dependent up regulation of 
notch signalling in the endothelium of the developing zebrafish. To confirm the 
role of dll4 I used a MO against the ATG site of dll4 (Geudens et al. 2010) in the 
Tg(CSL-venus) line and measured the aortic fluorescence as a measure of 
endothelial notch signalling. 
Figure 5.9A shows the increase in aortic endothelial notch signal in the absence 
of flow after injection of troponin t2 MO. This is an increase in venus aortic 
expression of around 65%, due to the absence of flow after troponin t2 MO 
injection. Co-injection of a dll4 MO in the presence of flow does not alter the 
levels of venus expression but in the absence of flow dll4 knockdown blocks the 





Figure 5.8 Whole mount in situ hybridisation of dll4 mRNA expression in 
embryos exposed to circulatory flow and without (troponin t2 MO 
injection) 
Top panels show the expression of dll4 in the aorta (arrowhead) and ISV of the 
36 hpf embryo with increased expression in these vessels in the embryos 
without flow. There is increased expression of dll4 in the embryo injected with 
troponin t2 at 48 hpf and 72 hpf although the overall expression declines over 





Figure 5.9 Effect of dll4 MO knockdown on the flow dependent increase in 
notch signalling in the CSL:venus transgenic reporter. 
A: dll4 MO knockdown on notch reporter expression in 72hpf Tg(CSL-
venus)qmc61 embryos with and without blood flow by troponin t2 MO injection. B: 
Mean aortic fluorescence in control (n=18) and dll4 morphant (n=19) 72hpf 
Tg(CSL-venus)qmc61 embryos with and without blood flow due to troponin t2 




5.2.3 Effect of manipulating NO signalling on the development 
of the vhl-/- mutant vessel phenotype 
5.2.3.1 The effect of NOS inhibition on angiogenesis in the vhl-/- 
mutant  
NO regulates many processes in vessel biology. I therefore attempted to 
determine if NO production contributed to the aberrant angiogenesis in the vhl-/- 
mutant. L-NAME is a non-specific inhibitor of all isoforms of NO synthase and 
has been shown in other mammalian models to effectively inhibit eNOS. I 
incubated vhl-/- embryos (in a Fli1:eGFP transgenic) background in [1mM]  L-
NAME from 24 hpf until 96 hpf and examined the effect on vascular 
development. 
Figure 5.10 shows the trunk vessels of wild type and vhl-/- mutants at 4 dpf 
treated with or without L-NAME. The characteristic angiogenic phenotype 
previously described in vhl mutants is apparent. I found no effect of L-NAME on 
the formation or appearance of the aorta, ISVs or DLAV in either wildtype or vhl 
mutants. Figure 5.11 shows quantification of the total vessel area, ISV 
diameter, DLAV diameter and total vessel length, incubation with L-NAME at 1 
mM has no effect on any of these measurements in either vhl-/- or wildtype 




Figure 5.10 Effect of NO inhibition by L-NAME on the vhl-/- mutant 
angiogenic phenotype. 
4 dpf wild type and vhl-/- mutants in the Tg(fli1:eGFP) background treated with 
control media or L-NAME a NO synthase inhibitor from the onset of cardiac 
contraction until imaging at 4 dpf. Photomicrographs of the mid trunk region. 
There is no change in the vhl-/- angiogenic phenotype after incubation with this 













Figure 5.11 Quantification of vessel diameter, endothelial area and vessel 
length in wt and the vhl-/- mutant treated with L-NAME NO synthase 
inhibitor. 
4dpf wild type and vhl-/- mutants in the Tg(fli1:eGFP) background treated with 
control media or L-NAME a NO synthase inhibitor from the onset of cardiac 
contraction until imaging at 4dpf. Measurement of the ISV and DLAV diameter 
show no differences in the L-NAME and control treated groups. There is no 
difference in the total vessel length and area of endothelium. All graphs mean ± 




5.2.3.2 Effect of manipulation of NO on the aortic size in the vhl-/- 
and wild type embryo 
L-NAME has previously been shown to alter vascular tone and vessel diameter 
in the developing zebrafish at similar times to the experiments I performed in 
the vhl-/- and wildtype embryos. I had hypothesised that changes in vessel 
diameter and tone may alter endothelial force which may lead to attenuation of 
the vhl-/- angiogenic phenotype which shows increased vessel size in the trunk 
and has previously been shown to have increases in cardiac output (Van 
Rooijen et al. 2009). Differences in the aorta diameter in response to L-NAME 
have been shown in vessel physiology experiments (Fritsche et al. 2012) and in 
experiments on flow dependent migration of haematopoietic stem cells (North et 
al. 2009). 
 To confirm the results of my earlier experiments looking at the effect of NO 
synthase inhibition on the vhl-/- mutant phenotype, I looked to see if L-NAME 
was effective in altering aortic diameter. Identification of a change in vascular 
reactivity would show that L-NAME at this dose has vasoactive effects in the 
zebrafish embryo as previously published, confirming that the compound is able 
to penetrate into the vascular tissue. This would lend further support to my 
conclusion that inhibition of NO signalling does not alter the vhl-/- mutant vessel 
phenotype, confirming the negative result in figures 5.10 and 5.11.  
Figure 5.12 shows that the size of the aorta in the age matched vhl-/- mutants 
compared to wild types. The diameter of the aorta was not altered by L-NAME 
(1mM) treatment or by exposure to the NO donor SNP (100 µM). Although the 
SNP treatment suggests an increased diameter, which was the effect seen in 



















Figure 5.12 Effect of L-NAME and SNP on the aortic diameter in the vhl-/- 
mutant and wt embryo at 4dpf. 
Measurement of the aortic diameter in the Tg(fli1:eGFP) background in both the 
vhl-/- mutant and wildtype embryo. L-NAME (1mM) and SNP (100mM) incubated 
in embryo media from 24hpf until imaging at 4dpf. The vhl-/- mutant shows 
enlarged aortic diameter at the same embryonic stage however inhibition or 
donation of NO does not alter the aortic diameter significantly. All graphs mean 
± SEM; 2-way ANOVA; all groups ns; n=7.  
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5.2.3.3 Total embryo NO signalling using the fluorophore DAFF-
FM 
In addition to the effects of NO signalling on vessel size, quantification of NO 
signalling directly has been previously demonstrated directly using a 
fluorophore activated by the presence of NO (Lepiller et al. 2007). Given my 
difficulty in replicating published effects of NO manipulation in the developing 
zebrafish I wanted to see if either L-NAME or SNP were able to alter embryo 
levels of NO. I compared the total level of NO signalling in the vhl-/- mutant and 
wild type, and looked at the effect of L-NAME and SNP on the total NO signal in 
both of these genotypes. Figure 5.13 shows a whole mount photomicrograph of 
overlaid bright field and fluorescence images of DAFF-FM, which labels NO 
signalling and its distribution in the embryo in both the wild type and vhl-/- 
mutant and in both cases incubated in the NO synthase inhibitor L-NAME or the 
NO donor SNP. 
The levels and distribution of fluorescent signal in the embryos in fig 5.13 shows 
little difference in the amount or distribution of the NO signal in wild type and 
vhl-/- mutant embryos. The tissue distribution of the NO signal at this 
developmental stage is consistent with published data (Lepiller et al. 2007), 
indicating high levels of signal in the bulbus arteriosus, notochord and caudal fin 
edge. Figure 5.14 shows there is no change in the DAFF-FM signal in the L-
NAME treated embryos, either wild type or vhl-/- mutant. The NO donor SNP 
incubation resulted in a significant increase in NO derived DAFF-FM fluorescent 
signal of about 2-fold in the wild type and of about 1.6 fold in the vhl-/- mutants. 
Interestingly there was a smaller increase in the level of NO in the vhl-/- mutants 
compared with the wild type embryos, however there was no difference 
between these groups when treated with L-NAME.  
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Figure 5.13 DAFF-FM fluorescence in 4 dpf wildtype and vhl-/- mutant 
embryos incubated with L-NAME or SNP.  
Fluorescence and bright field overlay images of DAFF-FM, which fluoresces on 
contact with NO.  There is increased fluorescence in the embryos treated with 
SNP (100 mM) but no reduction in the embryos treated with L-NAME (1 mM) 
compared to controls. There is no difference in wt and vhl-/- DAFF-FM signal. 
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Figure 5.14 Quantification of whole mount DAFF-FM fluorescence at 4 dpf 
in wt and vhl-/- mutant embryos treated with SNP or L-NAME.  
Whole mount fluorescence in 4 dpf wt or vhl-/- embryos adjusted to wt control 
levels. There is no effect on the NO fluorescent reporter after treatment with L-
NAME (1 mM) however there is increased fluorescence in the groups treated 
with SNP (100 µM) in both wt and vhl-/- background. All graphs mean ± SEM; 2-







In this chapter I investigated two signalling pathways of particular relevance to 
endothelial behaviour; Notch signalling and NO signalling. Both have been 
shown to regulate angiogenesis, vasculogenesis and in the case of NO, 
endothelial responses to flow (Phng & Gerhardt 2009; Fritsche et al. 2012; 
Sessa 2009). 
To study the effects of flow on the notch signalling pathway I used a zebrafish 
transgenic reporter line of notch activity Tg(CSL:venus). This allowed me to use 
genetic knockdown and pharmacological manipulation of the heart to regulate 
blood flow. Blocking onset of circulation in the developing zebrafish by 
knockdown of troponin t2 resulted in clear up regulation of notch signalling in the 
aortic endothelium. The same increase was seen when the circulation was 
stopped at 36hpf, using BDM. This indicates that the increases in notch 
observed in the endothelium of the transgenic are as a direct result of changes 
in flow resulting in increased expression of the CSL transcriptional apparatus. 
The observation of suppression of notch signalling in endothelial cells by the 
absence of blood flow has not been previously described.  
The transgenic used for these experiments acts as a notch-signalling reporter 
producing fluorescent venus expression as a direct result of activation of the 
DNA binding site of the notch transcriptional apparatus CSL. I wanted to confirm 
this increase in notch dependent fluorescence due to changes in endothelial 
notch signalling not via an indirect mechanism altering binding of CSL. 
Clarification of this was important as a number of notch receptor and CSL-
independent signalling pathways have now been described in the literature 
(Bray 2006; Martinez Arias et al. 2002). The increases in CSL seen in the 
transgenic were blocked by incubation with the DAPT indicating that the 
increase in the notch transcriptional activator CSL is as a result of increased 
intracellular NICD signalling which may be derived from changes in ligand-
receptor interactions although the possibility of an indirect activation of CSL 
transcriptional activity has not been entirely excluded. 
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Having established the increase in notch signalling in endothelium in response 
to flow I wanted to look at the individual signalling components to identify the 
component or components of the pathway which were differentially regulated by 
changes in endothelial detection of circulatory flow. I looked at the expression of 
mRNA in the trunk of the developing embryo using RT-qPCR. One limitation of 
this technique is that I was unable to isolate only endothelial cells from the 
zebrafish to assess changes in transcription. I used trunk tissue which has the 
advantage of removing brain tissue transcripts from the assay, as this is known 
to contain large amounts of active notch signalling during development (Cau & 
Blader 2009). Also by isolating only the trunk tissue we are only looking at the 
tissue specific regulation of angiogenesis in the vessels studied. This also 
minimised the effect of other vascular tissues already shown to regulate 
angiogenesis in response to haemodynamic signals in particular the cerebral 
vessels (Bussmann et al. 2011).  
Despite the use of this mixed tissue in the RNA extraction process I was able to 
show that dll4, a notch ligand which has been previously shown to influence 
endothelial angiogenesis in the developmental setting (Siekmann & Lawson 
2007b; Leslie et al. 2007), is differentially regulated at a transcriptional level by 
flow. RT-qPCR showed a significant up regulation of the dll4 transcript in the 
absence of circulatory flow by troponin t2 genetic knockdown. Subsequently I 
demonstrated that this differential regulation seen in trunk tissue is restricted to 
the endothelium between 48 hpf and 72 hpf. The levels of expression change in 
dll4 are consistent with the changes in cxcr4a which has been previously shown 
to differentially regulated in the absence of circulatory flow (Packham et al. 
2009). 
Many of the target genes used for my RT-qPCR did not demonstrate any 
differential expression at either 48 hpf or 72 hpf, which would have provided 
additional evidence that the notch pathway is strongly implicated in the 
regulation of flow dependent endothelial regulation. This may be due to the 
selection of qPCR genes of interest. This was based on previously published 
notch receptors, ligands and transcriptional targets and the validation of suitable 
primer probes. This process is time consuming and inherently biased, thus the 
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lack of notch target hits may just reflect the fact I have not selected the correct 
gene targets for assay. One possible technique with which to address this 
experimental difficulty may be to use a microarray technique on isolated 
endothelium, which would provide an unbiased approach to this problem. 
However, isolation of endothelium form the in vivo model is likely to alter 
transcriptional profiles and cultured endothelium may not demonstrate the in 
vivo sensitivity to notch signalling I have described.  
Notch signalling has been shown to be regulated on various levels and is very 
dependent on the signalling context, timing and cell type in the production of its 
signalling output (Andersson et al. 2011; Bray 2006). This in combination with 
the large number of notch signalling ligands, receptors, co-factors and target 
genes makes this a difficult and time consuming undertaking. However there 
are some genes on which any future study would need to focus. The notch 
ligand jagged1 has been shown to have opposing effects on angiogenesis to 
dll4 (Benedito et al. 2009). Unfortunately I was unable to optimise this particular 
primer set for adequate amplification of mRNA transcripts in my extracted RNA. 
Another potential notch target gene is Enhancer of split. This may be 
differentially regulated by flow, which would add to the evidence for the role of 
dll4 in activation of the canonical notch-signalling pathway in response to flow. 
The increase in dll4 expression in response to loss of flow is attractive as a 
mechanism for the regulation of hypoxic signalling dependent angiogenesis in 
the vhl-/- mutant. dll4 is known to act as a repressor of angiogenesis in the 
vascular development of the zebrafish (Leslie et al. 2007). Clearly if this is up 
regulated in response to reduced flow this may be a potential mechanism by 
which vhl-/- mutant angiogenesis is repressed in the absence of flow.  
Despite extensive testing I have been unable to rescue the vhl-/- mutant 
phenotype by down regulation of notch signalling in the absence of flow. To 
approach this I have used either troponin gene knockdown or BDM circulatory 
arrest by which to block flow in the mutant. In combination with either DAPT or 
dll4 gene knockdown by morpholino to block endothelial Notch signalling. 
Despite altering the timing and doses of co-injection of morpholino and the 
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exposure to BDM I have failed to show rescue of the vhl-/- mutant vessel 
phenotype. Isolated knockdown of dll4 or troponin t2 does not result in the same 
level of toxicity that was seen in the co-injection group or dual treatment group 
suggesting that the combination of knockdown results in excessive mortality, 
which requires further investigation. 
One experimental system which may be able to address this difficulty would be 
a Cre/lox transgenic which by using tamoxifen induction of Cre recombination 
would allow for a endothelial restricted knockdown of the dll4 transcript and 
control over the timing of this knockdown, tools for the production of such a 
transgenic are now established (Mosimann & Zon 2011). This would minimise 
any off target toxicity on the other developmental processes in my zebrafish 
developmental model, which may be the cause for the high mortality I have 
experienced in my rescue experiments to date. This technique has been 
effectively used in the mouse retinal model of angiogenesis to elucidate the 
balance of dll4 and jagged1 on angiogenesis (Benedito et al. 2009). 
Unfortunately such a complex transgenic system was outside the scope and 
timescale of this project. 
The experiments performed to identify a role for NO signalling in the production 
of the flow sensitive angiogenesis in the vhl-/- mutant were negative. I was not 
able to demonstrate any change in the angiogenic phenotype of the vhl-/-mutant 
after inhibition of the NO synthase enzyme. However it is difficult to be certain of 
this as a true negative experimental result due to the absence of physiological 
effect of the compound L-NAME at similar doses and exposures to previously 
published positive studies into manipulation of NO in the developing zebrafish 
embryo. These studies showed aortic constriction and reduction in erythrocyte 
flow after treatment with L-NAME and reduced migration of haematopoietic 
stem cells (North et al. 2009; Fritsche et al. 2012). 
Given the large body of published literature on the effects of NO synthase 
inhibition on blood vessels in the zebrafish model it would seem likely that the 
lack of effect of L-NAME in my experiments is due to a problem with the 
experimental system. The most likely explanation is a problem with the 
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compound or its preparation however attempts to resolve this by using new 
preparations resulted in the same negative results. It is also possible that 
differences in the E3 media used in my experimental setup led to the 
precipitation or inhibition of the L-NAME causing the discrepancy in my results 
and those published by other groups. Alternative NO synthase inhibitors exist 
however these are thought to have more specific effects on the various NOS 
subtypes which would be expected to reduce the effect of these compounds 
e.g. L-NMMA compared to L-NAME (Alderton et al. 2001). I was unable during 
this project to assess the reasons for these negative results. Further 
experiments looking at NO synthase inhibition and the effect on hypoxia-
stimulated angiogenesis would focus on the lack of activity of L-NAME in our 
experimental setup. Simple controls like assessment of the pH of the media, 
rate of degradation of the compound and penetration of the embryo by the 
compound would all have to be assessed before the negative result could be 
confirmed that blocking NO does not inhibit the formation of vhl-/- dependent 
angiogenesis. 
In addition a more thorough study of the role of NO signalling in hypoxia 
signalled angiogenesis would need to look at the expression patterns and 
activity of the NOS orthologues in the zebrafish and there overlapping effects 
(Lepiller et al. 2009) in comparison with the established effects of mammalian 
eNOS, iNOS and nNOS. This would also need to be assessed in the vessels of 
the vhl-/- mutant. Established MO have been published against nNOS have 
been described and the developing technique of TALEN mutagenesis may 
allow stable mutants in the NOS family with which to further study this 
interaction of flow and vhl-/- dependent angiogenesis. 
5.3.1 Summary 
I have identified a flow dependent suppression of endothelial dll4 expression, 
which in the absence of blood flow leads to increased endothelial notch 
signalling. This observation suggests that endothelial cells require a flow signal 
which is permissive to angiogenesis mediated by suppression of notch 
signalling in the presence of a local VEGF gradient, stimulated by hypoxic 
signalling. This may be expected to affect the angiogenic phenotype of the vhl-/- 
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mutant, which I have previously demonstrated is flow dependent. Unfortunately 
I have been unable to show that by blocking dll4 dependent notch signalling I 
can rescue the loss of vhI-/- vessel phenotype seen in the absence of flow. 
However the presence of an endothelial flow stimulus, which is capable of 
modulating endothelial behaviour via notch signalling, is a novel observation 
and may lead to a better understanding of angiogenic regulation. 
If angiogenesis driven by hypoxia has sensitivity to flow, mediated by notch 
signalling this presents novel mechanisms which could manipulate pathological 
angiogenesis. In the field of oncology the regulation of angiogenesis is a key 
target for therapeutics to arrest the metastatic spread of cancers. The success 
of the VEGF inhibitors in oncology has not been as successful as initially 
hoped. If it were possible to locally regulate flow at the site of malignancy either 
pharmacologically or physically with surgical intervention this would be a 
potential adjunct to established anti-angiogenic therapies, without the prolonged 
process of novel drug discovery. The additional target of notch signalling for 
regulation of pathological angiogenesis is another potentially attractive 
translational finding as the gamma-secretase inhibitors have already been used 
in clinical trials, (Purow 2012) providing established tools to take these findings 







Chapter 6 General discussion 
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The vhl-/- mutant zebrafish has the unique advantage of enabling the study of 
both developmental and hypoxic signalling driven angiogenesis concurrently, in 
vivo. I have characterised in detail the aberrant vessel development in the trunk 
of the mutant in the early part of this study. The angiogenesis stimulated by the 
vhl-/- mutation demonstrates conserved features of endothelial behaviour and 
signalling, which have been described in both cell culture and other higher 
mammalian models. My observations indicate that the vessel growth I have 
described acts as a reliable model of angiogenesis with which to investigate the 
role of flow and its endothelial signalling effects. Establishing this conservation 
of behaviour and signalling is important to the translation of any potential 
therapeutic observations into other models and potentially man. 
During the characterisation of the vhl-/- induced angiogenesis I observed that 
aberrant angiogenesis follows a stereotyped pattern, despite the apparent 
chaotic vessel appearance compared with the controls. The earliest changes 
are seen in the dorsum of the embryo, then over time additional vessels and 
sprouts emerge more proximally closer to the aorta. Although I have described 
endothelial cell number changes in the aorta it is noteworthy that no additional 
angiogenic sprouts were seen, suggesting that the factors determining 
development of the paired intersegmental vessels that run between each 
somite are not affected by increased hypoxic signalling. It is possible that the 
process of vasculogenesis and the other roles of the aorta in development (e.g. 
haematopoietic stem cell production) may protect it from additional angiogenic 
sprouting driven by hypoxic signalling. Alternatively the early resistance of this 
vessel to sprouting behaviour may be due to changes in timing of as yet 
unknown endothelial signals, or a contribution of maternal RNA that prevents 
hypoxic signalling from occurring until after these vessel sprouts are specified. 
To speculate on the mechanism for this stereotyped sprouting pattern and its 
distribution, it is possible that there is overlap of the initial developmental 
signals, which pattern the vasculature into its stereotyped form, including 
potentially the plexins-semaphorins family and their downstream targets 
(Torres-Vázquez et al. 2004; Zygmunt et al. 2011). These molecules may be at 
higher concentrations in proximity to the aorta in order to tightly limit the 
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angiogenic sprouts to the somite borders. Or it is possible these signals are at a 
lower concentration along the dorsum of the embryo or that the timing of 
expression declines as the levels of hypoxic signals accumulate. Further study 
into how the up-regulated hypoxic signals are able to overcome these 
developmental pathways and produce the extensive angiogenic networks seen 
in the mutant would be necessary to understand the differential regulation of 
these processes. The ability to target angiogenesis to a particular vascular bed 
or site would have particular relevance in overcoming the occlusive vascular 
diseases like stroke and heart disease. 
During this study I was unable to spend sufficient time to fully address the role 
of endothelial specific hypoxic signalling in initiation of angiogenesis in the vhl 
mutant. Clearly this would be of great interest in terms of the initiation and 
maintenance of the angiogenesis seen in the vhl-/- mutant. The mutant has clear 
upregulation of hypoxic signalling (Van Rooijen et al. 2009) throughout its 
tissues, one consequences of this being the aberrant vessel development which 
I have described. The transgenic that I generated using the modified GAL4:UAS 
construct to increase HIF1 signalling in only endothelial cells 
Tg(fli1:GFF;UAS:kaede, UAS; da-hif-1ab-IRES-GFP)i218 showed no increase in 
endothelial angiogenic behaviour (Appendix 1). This would be consistent with 
the established literature; the autocrine expression and secretion of VEGF is felt 
to maintain endothelium in a state of quiescence (Warren & Iruela-Arispe 2010). 
Only when local gradients of this growth factor (VEGF) are established in the 
surrounding tissues is there adequate stimulus for angiogenesis. Unfortunately 
my experiments were inadequate to make categorical conclusions about the 
effect of endothelial up regulation of hypoxic signalling and angiogenesis. 
However this system of targeted expression of angiogenic ligands using the 
modified yeast GAL4:UAS system in the zebrafish would be an powerful tool 
with which to study this in the future. 
An additional question arising from the characterisation of the vhl-/- mutant 
vasculature relates to the site of endothelial migration, proliferation and 
potentially apoptosis. Previous literature has shown the dynamic reorganisation 
of the ISV and DLAV in terms of the individual endothelial cells (Blum et al. 
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2008) and the role of arterial specified cells in the formation of the DLAV 
(Zygmunt et al. 2012). It is possible that this particular vessel bed in the 
developing embryo has a particular sensitivity to the accumulation of hypoxic 
signals resulting in the earliest vessel changes appearing in this region of 
vasculature before more proximal vessels. Using a nuclear-labelled vascular 
reporter in conjunction with a different endothelial membrane reporter in the 
same transgenic line would enable detailed time-lapse imaging to track the 
migration and nuclear division in vivo. The transgenic line Tg(flk1:eGFP-
NLS;kdr-l;HRAS-mCherry)  is already established in our laboratory but due to 
the amount of time required to develop and perform these experiments I have 
not been able to address these questions in this study. Clearly the differential 
regulation of the developmental and pathological angiogenesis seen in this 
zebrafish mutant embryo is an important to understanding how to target 
angiogenic vessels with a view to therapeutic manipulation. 
The identification of flow sensitivity in the aberrant angiogenesis of the vhl-/- 
mutant is potentially the most exciting observation from this project. I have 
demonstrated that removing flow in the developing vhl-/- mutant embryo, prior to 
and shortly after the onset of circulation blocks the formation of new vessels 
and the expansion in endothelial cell number. These experiments demonstrated 
a differential sensitivity to flow of developmental angiogenesis required for 
formation of the ISV and DLAV when compared to hypoxic signalling-stimulated 
angiogenesis. I limited my study to the early development of these vessels 
however it is not clear if the aberrant angiogenesis seen in the mutant 
demonstrates flow sensitivities at a later stage, or if this process inhibits only the 
initiation of new vessel sprouts. It is possible that removal of flow at a later 
developmental stage may lead to regression of vhl-/- induced angiogenesis. 
Recent developments in morpholino technology mean that there are now 
photosensitive morpholino oligonucleotides, which could be used to knockdown 
en essential cardiac protein like troponin, but at a later time point to enable the 
study of the timing effects of removal of flow on hypoxic signalling induced 
angiogenesis. 
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One particular area not addressed in this study is the mechanism by which the 
endothelium is able to transduce the flow signal. There is no consensus on the 
mechanism for flow transduction in the endothelial cell in the literature, however 
transcription factors like klf2a have been shown to be differentially regulated by 
alterations in haemodynamic flow (Lee et al. 2006), which result in alterations in 
vegfaa sensitivity in limited endothelial territories in the developing zebrafish 
(Nicoli et al. 2010). A detailed study of the mechanism of endothelial flow 
transduction was outside the scope of this study. Given the data available on 
developmental flow sensitivity (Nicoli et al. 2010) in the zebrafish it would be 
interesting to look at the effects of knockdown of klf2a and miRNA-126 in the 
vhl-/- mutant. It is not necessarily the case that this regulatory pathway is 
preserved in the aberrant angiogenic endothelium particularly given the 
differential sensitivity to flow of developmental and pathological angiogenesis 
that I have demonstrated.  
Further study is also required to address the issue of what threshold of flow is 
required for hypoxic signalling mediated angiogenesis. In vessels of the size 
studied in the vhl-/- mutant the lumen of the ISV and DLAV is only the size of a 
single red cell; as a result much of the physical force on the endothelium at this 
developmental stage is derived from physical deformation of the endothelium. 
This is of particular interest in the vhl-/- mutant due to its increased red cell mass 
as a consequence of increased epo expression (Van Rooijen et al. 2009). It is 
notable that the onset of angiogenesis in the mutant is delayed until 2-3dpf, the 
time when expression levels of both vegf and epo are increased.  If additional 
studies were to implicate a role for erythrocyte density in the response of 
endothelium to flow this would be of significant translational interest. As 
established clinical tools are established to manipulate red cell number within 
modern haematology practice; including venesection and drugs like 
hydroxyurea to reduce red cell number and also medications to activate bone 
marrow production of red cells. It is tempting to suggest that such therapies 
might be useful as potential adjunctive therapies to influence angiogenic 
behaviour in diseases dependent on angiogenesis like cancer and macular 
degeneration 
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There remain questions about how manipulation of dll4 and subsequently notch 
signalling in the endothelial cell alters angiogenic behaviour in response to flow. 
My experiments have shown that the notch ligand dll4 is regulated by flow in the 
endothelium of the developing zebrafish (summarised in Figure 6.1), it is not 
clear from my experiments how the alteration in this ligand is transduced by the 
endothelial cell. There is data indicating that the microRNA-30 family are 
involved in the post-transcriptional regulation of dll4 in zebrafish (Bridge et al. 
2012). Clearly examination of the expression of these regulatory RNAs and the 
response to flow would be future experiments to clarify the signalling pathway 
activated by changes in flow sensing by endothelial cells. Alternatively 
screening a number of mirRNAs may identify novel regulators of endothelial 
response to flow in these cells, given the increasing literature indicating there 
role in endothelial flow transduction and response (Nicoli et al. 2010; Bridge et 
al. 2012). 
I was unable to show that manipulation of dll4 in the vhl-/- mutant without flow is 
able to rescue the loss of angiogenic vessels despite various approaches.. This 
finding would link the flow sensitive aberrant angiogenesis seen in the mutant 
with the alteration of dll4 in endothelial cells in response to flow. An alternative 
approach to this important question would be the use of a system where 
expression of dll4 could be regulated, for example a Cre/Lox system. Using 
such a system, where the levels of dll4 expression could be manipulated in only 
endothelial cells and at a specific time point, minimising any off target toxicity 
from notch signalling alterations in the presence of the background vhl mutation 
may be a solution to the experimental difficulties to date. Alternatively these 
experiments could be performed in established mouse retinal models of 
angiogenesis, where the molecular machinery and assays are already 






Figure 6.1. Summary of the role of Notch signalling and dll4 on the 
angiogenic phenotype in the presence of endothelial activation. 
Summary diagram indicating the potential role of Notch signalling and the ligand 
dll4 on established angiogenic growth factors like vegfaa / ab and the receptor 
population. In the vhl-/- mutant the endothelial activation is a result of up-
regulated HIF-1α signalling which increase levels of vegfaa / ab despite the 
increased expression of these vascular growth factors the absence of 




A potential limitation of my study is that all of the experiments have been 
performed in zebrafish. Although the advantages of this model have enabled 
the detailed assessment of the angiogenic process in vivo and in addition to the 
ease of manipulation of genes of interest, translating the experiments to other 
models would indicate that the regulation of notch signalling by endothelial dll4 
expression in response to flow is a conserved signalling pathway. This could be 
achieved using the mouse retinal model or using cultured human umbilical vein 
cells (HUVECS) which could be exposed to varying levels of flow in the 
presence of up regulated HIF1 signalling to look at the effect on notch signalling 
assayed by RT-qPCR. 
Angiogenesis is a critical process in both the development of a complex 
organism and the initiation and maintenance of disease. There are common 
signaling processes involved in both pathology and development; in this study I 
have used an embryonic zebrafish model, which enables the study of both 
processes. Pathological angiogenesis driven by hypoxia plays a critical role in 
the development of cancer and understanding the behaviour of endothelial cells 
in this process may enhance our ability to influence this process therapeutically. 
Initial attempts to regulate tumour growth by halting angiogenesis have yielded 
somewhat disappointing results clinically (Potente et al. 2011), any additional 
mechanisms, which may enhance the effects of established clinical anti-VEGF 
agents could have significant therapeutic impact. Also any novel insights into 
the regulation of angiogenesis may also have additional benefits outside the 
cancer field. The ability to target vessel growth might enable initiation of new 
vessels to circumnavigate occlusion or to perfuse hypoxic tissue. This is of 
particular relevance in a number of human diseases like stroke and heart 
disease, pathological consequences of vessel blockage and damage. 
To conclude, I have discovered novel interactions between blood flow, hypoxic-
signalling regulated angiogenesis, and Notch signalling. Further work is likely to 
reveal much more about the complex regulation of blood vessel formation in 
development and disease. 
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7.1 Endothelial cell constitutive hypoxic signalling and 
the initiation of an angiogenic phenotype 
The Tg(UAS:da-hif-1αb-IRES-GFP)i218 line was crossed with the 
Tg(fli1:GFF;UAS:kaede), positive double transgenics were identified by 
endothelial KAEDE expression and expression of GFP in the eye to identify 
carriers of the da-hif construct. These embryos were compared to GFP negative 
fish, which lack the dominant active HIF construct. In three separate crosses no 
angiogenic phenotype was identified in the double transgenic by 4 dpf (Figure 
7.1). We considered that endothelial hypoxia may not give as dramatic a 
phenotype as that seen with the vhl-/- mutant line but further observations at 
7dpf revealed no morphological changes in the endothelium. 
To confirm that there was up regulated hypoxia signalling in the endothelium of 
the double mutants we looked at expression patterns in the double transgenics 
of a validated hypoxia signalling transcriptional target propyl-hydroxylase 3 
(PHD3) and KAEDE fluorescent protein expression. It was hoped that a clear 
vascular expression pattern of both of these by whole mount in situ 
hybridisation would confirm that the expression of the endothelial promoter and 
effective GAL4 and UAS expression in the double transgenics. Figure 7.2 
shows the clear expression of the kaede mRNA in a classical vascular 
distribution both in the head and trunk of the selected double transgenic 
embryo. However there is no vascular distribution to the PHD3 mRNA 
expression, although there is some expression in the head but this does not 
appear to be clear endothelial distribution expected.     
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Figure 7.1. Effect of up regulated HIF-1α signalling in the endothelium of 3 
dpf embryo labelled with Tg(fli:GFF;UAS:kaede) 
Top panel shows the normal vascular pattern seen at 72 hpf with paired ISV 
and the DLAV remodelling into a single longitudinal vessel. Lower panel shows 
representative photomicrograph of embryo selected for endothelial kaede 
expression and a constitutively active mutated HIF construct both driven by the 






Figure 7.2. WISH expression of kaede and phd3 genes in double 
transgenics and controls to confirm expression of the fli1:GFF promoter 
and the downstream UAS:kaede and UAS:da-hif-1ab-IRES-GFP constructs 
A.  Expression of kaede detected by WISH antisense probe at 72 hpf in 
Tg(fli1:GFF;UAS: da-hif-1ab-IRES-GFP)i218 embryos, there is no expression as 
this a promoted transgene with no endogenous expression B. Expression of 
kaede in double fluorescence selected Tg(fli1:GFF;UAS:kaede, UAS; da-hif-
1ab-IRES-GFP) showing staining in an endothelial distribution C. Expression of 
PHD3 by WISH in 72 hpf embryos selected for Tg(fli1:GFF;UAS:kaede) 
showing some endogenous expression in the head D. Expression of PHD3 in 
double transgenic fluorescence selected Tg(fli1:GFF;UAS:kaede,UAS; da-hif-
1ab-IRES-GFP) with increased expression in the head above the endogenous 
levels and in the somites but with no endothelial expression pattern seen in the 
trunk. Scale bar, 400µm. Although there is increased staining in the head in D. 
this is likely to be due to trapping of the stain and a result of over exposure. To 
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ensure that no endothelial stain is seen in the trunk vessels the development 
time is left longer, as the tissue of the head is better permeabilised by the 
process then increased variability in head staining can be seen despite the 
same process of treatment in both C & D. Despite the differences in stain the 
distribution suggests that there is no specific endothelial increase in phd3 
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